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ABSTRACT 
Background Basal cell carcinoma is the most common cancer in the world. The 
incidence of superficial basal cell carcinoma, a subtype of basal cell carcinoma, is 
rising at a far steeper rate than the other subtypes, and as a non-aggressive subtype, 
it can be treated non-invasively. Aggressive subtypes of basal cell carcinoma are 
often ill-defined, which poses a clinical problem in preoperative margin assessment. 
Another ill-defined skin cancer type is lentigo maligna. Lentigo maligna is an in situ 
melanoma, and a precursor of lentigo maligna melanoma. These two forms are 
clinically challenging to distinguish from each other, which is crucial as melanoma 
has the worst prognosis of all skin cancers. Non-invasive imaging is an option for 
increasing the accuracy of preoperative diagnosis and the assessment. 
Hyperspectral imaging is a novel, fast, and computer-aided imaging modality with a 
wide field of view. In non-invasive treatment of non-aggressive basal cell 
carcinomas, photodynamic therapy has many advantages: an excellent cosmetic 
outcome as well as a shorter application time and recovery period. 
Notwithstanding these advantages, the efficacy of photodynamic therapy is lower 
when compared to topical pharmacological options such as imiquimod and 5-
fluorouracil.  
Objectives This dissertation focuses on non-invasive imaging and non-invasive 
treatment. In non-invasive imaging, the aim is to study the performance of a 
hyperspectral imaging system in separating lentigo maligna melanoma from lentigo 
maligna and assessing the preoperative margins of ill-defined basal cell carcinomas 
compared to clinical delineation assessments performed with a dermoscope. In 
non-invasive treatment, the aim is to compare the efficacy of three different 
photosensitisers in photodynamic therapy of non-aggressive basal cell carcinomas. 
Methods There are two pilot studies with hyperspectral imaging: one on lentigo 
maligna and lentigo maligna melanoma, and another one on ill-defined basal cell 
carcinoma. Tumours were preoperatively visually inspected utilising a dermoscope, 
and thereafter imaged with the hyperspectral imaging system. Next, surgical 
excision was performed. Hyperspectral images were created with computer-aided 
mathematical models. Additional mathematical models were subsequently 
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developed. In the results analysis, the findings of the hyperspectral imaging and 
clinically assessed margins were compared to the histopathology results, where 
assessment was performed blind to the hyperspectral imaging findings.  
A non-sponsored, prospective, randomised, controlled and double-blinded trial 
focused on non-invasive treatment. In this trial, two novel photosensitisers, 5-
aminolevulinic acid nanoemulsion and low-concentration hexylaminolevulinate, 
were compared to the commonly used methylaminolevulinate in photodynamic 
therapy of non-aggressive basal cell carcinomas, i.e. thin nodular or superficial 
subtypes. The primary outcome was histological clearance at three months. 
Secondary outcomes included adverse events such as pain associated with the 
treatment while using a long-lasting local anaesthetic as pain management, post-
treatment reaction, as well as cosmetic outcome, and fluorescence and 
photobleaching during the illumination. We used an experimental fluorescence 
imaging system. Punch biopsies were performed prior to treatment and during 
follow-up. Both patient and observers of outcomes were blind to the 
photosensitiser that was used. 
Results Hyperspectral imaging exhibited a unique hyperspectral graph for 
lentigo maligna melanoma, lentigo maligna, and healthy skin. Based on these 
results, hyperspectral images were created where hyperspectral data was 
represented in several abundance maps. The maps showed differing abundances 
for lentigo maligna melanoma and lentigo maligna, and it was possible to localise 
the invasion site inside the lesion. For ill-defined basal cell carcinoma, the margins 
of the tumour were delineated more accurately than by clinical assessment, and the 
results were confirmed with histopathology. 
The results of the clinical trial in photodynamic therapy showed that the 
histological clearance of hexylaminolevulinate was similar compared to 5-
aminolevulinic acid nanoemulsion and methylaminolevulinate, with no differences 
in cosmetic outcome, pain or post-treatment reaction between the arms. In our 
fluorescence and photobleaching analyses the results were widely spread. 
Conclusions In conclusion, hyperspectral imaging seems to be a promising and 
useful new imaging modality with a wide field of view: it is fast, easy to use and it 
seems to be capable of visualising subclinical findings. In non-invasive treatment, 
hexylaminolevulinate is an interesting option for photodynamic therapy of non-
aggressive basal cell carcinomas. Hexylaminolevulinate at low concentrations 
achieves a comparable efficacy to 5-aminolevulinic acid nanoemulsion and 
methylaminolevulinate at higher concentrations. No differences were observed in 
adverse events or cosmetic outcome between the arms.  
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TIIVISTELMÄ 
Tausta Tyvisolusyöpä on maailman yleisin syöpä. Tyvisolusyövällä on eri 
alatyyppejä, joista pinnallinen tyvisolusyöpä ja ohut nodulaarinen tyvisolusyöpä 
ovat vähäisen riskin tyyppejä, jotka on mahdollista hoitaa muutoin kuin 
leikkaamalla. Pinnallinen tyvisolusyöpä on lisääntynyt muita alatyyppejä 
nopeammin, ja näin ollen myös ei-kirurgisten hoitovaihtoehtojen käyttö 
todennäköisesti lisääntyy. Valoaktivaatiohoito ja voidehoidot, joita ovat imikimodi 
ja 5-fluorourasiili, ovat vaihtoehtoja kirurgialle. Valoaktivaatiohoidon etuja ovat 
erinomainen kosmeettinen lopputulos sekä lyhytkestoisempi hoitoaika ja 
paikallisreaktion kesto verrattuna voidehoitoihin. Imikimodin teho on kuitenkin 
parempi kuin valoaktivaatiohoidon. Suuren riskin tyvisolusyöpiä ovat aggressiiviset 
alatyypit, joille tyypillisiä ovat kasvaimen epätarkkarajaisuus ja kliinisesti 
näkymättömät kasvainalueet. Lentigo maligna -melanooma on ihomelanooman 
alamuoto, jolle tyypillisiä ovat myös nämä piirteet. Lentigo maligna on lentigo 
maligna -melanooman esiastemuoto. Näitä kahta on vaikea erottaa toisistaan silmin 
ja dermatoskoopilla arvioiden. Epätarkkarajaiset ihosyövät ovat siis kliininen haaste. 
Kajoamattomilla kuvantamismenetelmillä on mahdollista parantaa ihokasvainten 
diagnostiikkaa ja arviota. Hyperspektrikuvantaminen on uusi, nopea ja 
tietokoneavusteinen kuvantamismenetelmä, jolla on laaja kuvausalue. 
Tavoitteet Väitöskirjassa tutkitaan hyperspektrikuvantamista ja vähäisen riskin 
tyvisolusyövän valoaktivaatiohoitoa kliinisessä lääketutkimuksessa. Tavoitteena on 
tutkia hyperspektrikameran kykyä erottaa lentigo maligna -melanooma ja lentigo 
maligna toisistaan, sekä arvioida hyperspektrikameran kykyä määrittää 
epätarkkarajaisen tyvisolusyövän rajat ennen leikkausta verrattuna kliiniseen 
arvioon dermatoskoopin kanssa. Kliinisen lääketutkimuksen tavoitteena on verrata 
kolmen eri valoherkistäjävoiteen tehoa vähäisen riskin tyvisolusyövän 
valoaktivaatiohoidossa.  
Menetelmät Hyperspektrikuvantamista tutkittiin kahdessa pilottitutkimuksessa. 
Näistä toisessa kuvattiin lentigo malignaa/lentigo maligna –melanoomaa, ja toisessa 
epätarkkarajaista tyvisolusyöpää. Molemmissa tutkimuksissa kasvaimet arvioitiin 
ennen kuvantamista kliinisesti dermatoskoopin avulla. Lopuksi kasvaimet leikattiin. 
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Hyperspektrikuvat tuotettiin matemaattisen mallinnuksen avulla 
tietokoneavusteisesti. Patologi, joka arvioi leikkeet, ei tiennyt, mitä 
hyperspektrilöydökset olivat. Kameran löydöksiä verrattiin histopatologiaan, ja 
epätarkkarajaisen tyvisolusyövän tapauksessa myös kliinisesti määritettyihin 
kasvaimen rajoihin.  
Kliininen lääketutkimus oli tutkijalähtöinen, prospektiivinen, kontrolloitu, 
satunnaistettu ja kaksoissokkoutettu. Tutkimuksessa verrattiin kahden uudehkon 
valoherkistäjävoiteen eli 5-aminolevuliinihapon nanoemulsion ja matalapitoisen 
heksyyliaminolevulinaatin tehoa laajasti käytettyyn metyyliaminolevulinaattiin. 
Päätulos oli histologinen paraneminen kolme kuukautta valoaktivaatiohoidon 
jälkeen. Toissijaisia tuloksia olivat kosmeettinen lopputulos sekä hoidon 
haittavaikutukset eli kipu ja hoidonjälkeinen paikallisreaktio. Kivunhoitona 
käytettiin pitkävaikutteista paikallispuudutetta ennen kasvainten käsittelyä 
valoaktivaatiohoitoa varten. Tutkimuksessa arvioitiin myös valoherkistäjävoiteen 
fluoresenssia ja kulumista valotuksen aikana (ns. photobleaching) kokeellisella 
laitteistolla. Diagnoosi ja hoitotulos varmistettiin koepaloin. Tutkimuksessa potilaat 
ja tulosten arvioijat eivät tienneet, mitä valoherkistäjää oli käytetty. 
Tulokset Lentigo maligna -melanooman, lentigo malignan ja terveen ihon 
hyperspektrikäyrät ovat erilaisia. Näin ollen lentigo maligna -melanooma ja lentigo 
maligna on mahdollista erottaa toisistaan hyperspektrikuvantamisen avulla. 
Hyperspektrikuvien perusteella oli myös mahdollista paikallistaa invaasioalue. 
Hyperspektrikamera määritti epätarkkarajaisen tyvisolusyövän rajat tarkemmin kuin 
kliinisesti oli määritetty, ja histopatologia tuki tätä löydöstä.  
Valoaktivaatiohoidossa tyvisolusyöpä parani lähes yhtä hyvin matalapitoisella 
heksyyliaminolevulinaatilla kuin korkeapitoisemmilla 5-aminolevuliinihapon 
nanoemulsiolla ja metyyliaminolevulinaatilla. Valoherkistäjävoiteiden välillä ei ollut 
eroja haittavaikutuksissa tai kosmeettisessa lopputuloksessa. Fluoresenssin ja 
valoherkistäjän kulumisen tuloksissa oli laaja hajonta. 
Johtopäätökset Hyperspektrikuvantaminen vaikuttaa lupaavalta uudelta 
menetelmältä, jolla on laaja kuvausalue, ja joka on nopea ja helppokäyttöinen. 
Lisäksi hyperspektrikamera näyttää pystyvän visualisoimaan silmälle näkymättömiä 
muutoksia. Heksyyliaminolevulinaatti on mielenkiintoinen uusi vaihtoehto vähäisen 
riskin tyvisolusyövän valoaktivaatiohoitoon, sillä jo matalalla pitoisuudella 
saavutetaan vastaava hoitotulos kuin korkeammilla pitoisuuksilla 5-
aminolevuliinihapon nanoemulsiota tai metyyliaminolevulinaattia. Kuitenkaan 
hoidon kosmeettisessa lopputuloksessa tai haittavaikutuksissa ei ole eroja 
valoherkistäjien välillä.  
ix 
TABLE OF CONTENTS 
1 Introduction ........................................................................................................................ 17 
2 Review of the literature ...................................................................................................... 20 
2.1 Skin cancers ........................................................................................................ 20 
2.1.1 Classification ..................................................................................... 20 
2.1.2 Epidemiology .................................................................................... 20 
2.1.3 Basal cell carcinoma.......................................................................... 22 
2.1.3.1 Basal cell carcinoma subtypes .......................................... 22 
2.1.3.2 Epidemiology of basal cell carcinoma in detail .............. 26 
2.1.3.3 Basal cell carcinoma: burden of disease and economical 
impact .............................................................................. 31 
2.1.3.4 Risk factors of basal cell carcinoma ................................ 33 
2.1.3.5 Tumour cell origin and pathophysiology of basal cell 
carcinoma ........................................................................ 35 
2.1.4 Lentigo maligna and lentigo maligna melanoma ............................ 35 
2.1.4.1 Cutaneous melanoma subtypes ....................................... 35 
2.1.4.2 Epidemiology of lentigo maligna and lentigo maligna 
melanoma in detail .......................................................... 41 
2.1.4.3 Risk factors for melanoma, lentigo maligna and lentigo 
maligna melanoma .......................................................... 46 
2.1.4.4 Tumour cell origin and pathophysiology of melanoma, 
lentigo maligna and lentigo maligna melanoma ........... 48 
2.2 Sectioning of the tissue specimens and tumour margin assessment .............. 50 
2.3 Non-invasive optical imaging ............................................................................ 52 
2.3.1 Dermoscopy in basal cell carcinoma ............................................... 55 
2.3.2 Reflectance confocal microscopy in basal cell carcinoma ............. 57 
2.3.3 Optical coherence tomography in basal cell carcinoma ................ 58 
2.3.4 Impact of non-invasive technologies on delineation of 
basal cell carcinoma .......................................................................... 59 
2.3.5 Wood’s light in lentigo maligna and lentigo maligna 
melanoma .......................................................................................... 60 
2.3.6 Dermoscopy in lentigo maligna and lentigo maligna 
melanoma .......................................................................................... 60 
2.3.7 Reflectance confocal microscopy in melanoma, lentigo 
maligna and lentigo maligna melanoma .......................................... 62 
2.3.8 Optical coherence tomography in melanoma, lentigo 
maligna and lentigo maligna melanoma .......................................... 63 
x 
2.3.9 Hyperspectral imaging in melanoma, lentigo maligna and 
lentigo maligna melanoma ................................................................64 
2.3.10 Comparison of non-invasive technologies in recognizing 
cutaneous malignant melanoma .......................................................65 
2.4 Treatment with surgery .......................................................................................67 
2.4.1 Surgery of basal cell carcinoma ........................................................67 
2.4.2 Surgery of lentigo maligna and lentigo maligna melanoma ...........68 
2.5 Topical and non-surgical treatment of basal cell carcinoma and 
lentigo maligna .....................................................................................................69 
2.5.1 Cryosurgery ........................................................................................69 
2.5.2 Imiquimod ..........................................................................................69 
2.5.3 5-fluorouracil......................................................................................71 
2.5.4 Photodynamic therapy ......................................................................71 
2.5.4.1 Mode of action and photobleaching ................................71 
2.5.4.2 Photosensitisers and light sources ...................................72 
2.5.4.3 Pretreatment and enhancing of photosensitiser’s 
penetration........................................................................75 
2.5.4.4 Tolerability .........................................................................76 
2.5.4.5 Pain management ..............................................................78 
2.5.4.6 Efficacy and cosmetic outcome in basal cell carcinoma 79 
2.5.4.7 Photodynamic therapy of lentigo maligna .......................80 
2.5.5 Patients’ preferences and patient selection in treatment of 
basal cell carcinoma ...........................................................................81 
3 Aims of the study .................................................................................................................82 
4 Materials and methods ........................................................................................................83 
4.1 Study design .........................................................................................................83 
4.1.1 Study I and II: Pilot studies ..............................................................83 
4.1.2 Study III: Clinical trial .......................................................................83 
4.1.3 Sample size of the studies .................................................................84 
4.1.4 Ethical aspects and approvals by authorities ...................................86 
4.2 Patients .................................................................................................................86 
4.2.1 Inclusion and exclusion criteria ........................................................87 
4.3 Hyperspectral imaging ........................................................................................88 
4.3.1 Mathematical models used and their interpretation .......................93 
4.3.2 Linear mixture ....................................................................................93 
4.3.3 Linear mixture with single scattering albedo ...................................93 
4.3.4 Chromophore-specific with single-scattering albedo .....................94 
4.3.5 Standard variate .................................................................................94 
4.4 Dermoscopy ........................................................................................................94 
4.5 Photographing and fluorescence imaging .........................................................94 
4.5.1 Digital photographing .......................................................................94 
4.5.2 Fluorescence imaging and Photobleaching .....................................95 
xi 
4.6 Photodynamic therapy and outcome assessments of photodynamic 
therapy ................................................................................................................. 95 
4.7 Tissue sampling for histopathology .................................................................. 97 
4.8 Statistical analyses and calculations on accuracy .............................................. 98 
5 Summary of results ............................................................................................................. 99 
5.1 Study I ................................................................................................................. 99 
5.2 Study II .............................................................................................................. 100 
5.3 Study III ............................................................................................................ 101 
6 Discussion ......................................................................................................................... 102 
6.1 Advantages and disadvantages of the hyperspectral imaging system .......... 102 
6.2 Separating in situ melanoma versus invasive melanoma, and 
localising the site of invasion ........................................................................... 104 
6.3 Detecting subclinical extensions in ill-defined basal cell carcinomas 
and recognising the true borders of the lesion .............................................. 106 
6.4 Advantages and disadvantages of non-invasive treatments of non-
aggressive basal cell carcinoma ........................................................................ 107 
6.5 Possible advantages of hexylaminolevulinate................................................. 108 
6.6 Usefulness of local infiltration anesthesia ...................................................... 109 
6.7 Strengths and limitations of the study ............................................................ 110 
6.8 Clinical implications ......................................................................................... 111 
6.9 Future prospects ............................................................................................... 112 
7 Conclusions ....................................................................................................................... 113 
 
  
xii 
List of Figures 
Figure 1: Risk areas in BCC 
Figure 2: Anatomic distribution of BCC by subtype 
Figure 3: BCC subtypes by age group, borrowed from Raach et al. 2006, courtesy 
of British Journal of Dermatology 
Figure 4: Lentigo maligna incidence by body area 
Figure 5: Serial sectioning of the elliptical excision specimen and the possible error 
in the method 
Figure 6: Non-invasive imaging devices 
Figure 7: Flowcharts of the studies 
Figure 8: A) Structure of the camera B) Clinical imaging C) Function of the 
camera, courtesy of Ilkka Pölönen 
Figure 9: A) Recording of diffuse reflectance, courtesy of Ilkka Pölönen B) Data 
processing, courtesy of Ilkka Pölönen 
Figure 10: Treatment protocol for PDT I and II sessions 
Figure 11: Unique hyperspectral graph of lentigo maligna melanoma, lentigo 
maligna, and healthy skin, courtesy of Ilkka pölönen 
 
 
  
xiii 
List of Tables 
Table 1: Worldwide number of skin cancers during the year 2000 
Table 2: Number of skin cancers in Finland during the year 2017 
Table 3: BCC classification by architectural growth pattern and risk for recurrence 
Table 4: Risk factors for BCC 
Table 5: Subtypes of primary cutaneous melanomas 
Table 6: Factors defining the TNM categories 
Table 7: Potential biomarkers in melanoma 
Table 8: Increasing incidence of LM/LMM in the USA and Europe 
Table 9: Risk factors for melanoma 
Table 10: Comparing risk factors for LMM and SSM 
Table 11: Comparison of features of dermoscopy, reflectance confocal 
microscopy, optical coherence tomography and hyperspectral 
imaging 
Table 12: Dermoscopic findings in BCC subtypes by architectural pattern 
Table 13: Dermoscopic criteria in distinction of facial solar lentigo/thin seborrheic 
keratoses versus LM/LMM 
Table 14: Detecting MM with different non-invasive technologies 
Table 15: Patient and lesion characteristics 
 
 
   
xiv 
ABBREVIATIONS 
AJCC   American Joint Committee for Cancer 
AK   Actinic keratosis 
5-ALA   5-aminolevulinic acid  
BCC   Basal cell carcinoma 
nBCC   Nodular basal cell carcinoma 
sBCC   Superficial basal cell carcinoma 
BF-200 ALA  5-aminolevulinic acid nanoemulsion 
CMOS   Complementary metal-oxide semiconductor 
FOV   Field of view 
5-FU   5-Fluorouracil 
FPI   Fabry-Perot interferometer 
ENVI Environment for visualising images (i.e. image processing 
software) 
HAL   Hexylaminolevulinate 
HIS   Hyperspectral imaging system 
HSI   Hyperspectral imaging   
KC   Keratinocyte carcinoma 
LDH   Serum lactate dehydrogenase 
LM   Lentigo maligna 
LMM   Lentigo maligna melanoma 
MAL   Methylaminolevulinate 
MAPK   Mitogen-activated protein kinase 
MM   Cutaneous malignant melanoma 
MMS   Mohs micrographic surgery 
NMSC   Non-melanoma skin cancer 
NSAID  Non-steroidal anti-inflammatory drug 
OCT   Optical coherence tomography 
PDT   Photodynamic therapy 
PUVA   Psoralens and ultraviolet A 
xv 
PpIX   Protoporphyrin IX 
RCM   Reflectance confocal microscopy 
RGB   Red-Green-Blue 
SCC   Squamous cell carcinoma 
SLN   Sentinel lymph node 
SSM   Superficial spreading melanoma 
TNM   Tumour-Nodules-Metastasis 
USB   Unified S-band 
UVA   Ultraviolet radiation of relatively long wavelengths 
UVB   Ultraviolet radiation of relatively short wavelengths  
UVR   Ultraviolet radiation 
VAS   Visual analogue scale 
WHO   World Health Organization 
  
xvi 
ORIGINAL PUBLICATIONS 
Publication I Neittaanmäki N, Salmivuori M, Pölönen I, Jeskanen L, Ranki A, 
Saksela O, Snellman E, Grönroos M: Hyperspectral imaging in 
detecting dermal invasion in lentigo maligna melanoma. Br J 
Dermatol. 177(6):1742-1744, 2017 Dec. 
Publication II Salmivuori M, Neittaanmäki N, Pölönen I, Jeskanen L, Snellman E, 
Grönroos M. Hyperspectral Imaging System in the Delineation of 
Ill-defined Basal Cell Carcinomas: a pilot study. J Eur Acad 
Dermatol Venereol. 33(1):71-78, 2019 Jan. 
Publication III Salmivuori M, Grönroos M, Tani T, Pölönen I, Räsänen J, Annala 
L, Snellman E, Neittaanmäki N. Hexyl aminolevulinate, 5-
aminolevulinic acid nanoemulsion, and methyl aminolevulinate in 
photodynamic therapy of non-aggressive basal cell carcinomas: A 
non-sponsored, randomized, prospective and double-blinded trial. 
ACCEPTED MANUSCRIPT: doi:10.1111/jdv.16357 
 
 
 
 
 17 
1 INTRODUCTION 
This dissertation consists of three original communications, which are concerned 
with the diagnosis and treatment of skin cancer. With an aging population and a 
consistently increasing incidence of skin cancers, there is a pressing need for new 
technologies and treatments to improve the use of available resources. 
Skin cancers are divided into three main groups: the melanocytic cancers, i.e. 
cutaneous malignant melanoma (MM), keratinocyte skin cancers (KC), which are 
further divided into squamous cell carcinoma (SCC) and basal cell carcinoma 
(BCC), and other skin cancers such as Merkel cell carcinoma and adnexal tumours. 
80% of KCs are BCCs, and KCs are the most common cancers in the world. Thus, 
BCC is the most common cancer of all. 
BCC is not regarded as a lethal cancer. It is extremely rare that BCC 
metastasises or advances locally, but it is a versatile cancer with different subtypes, 
each with a different level of aggressiveness. It is also common that one individual 
has several BCCs: multiple primaries and sometimes multiple recurrences. Thus, 
BCC causes remarkable costs in diagnosis and care, and significant morbidity, 
especially among individuals with multiple lesions (Chen, Bertenthal et al. 2007, 
Chren, Sahay et al. 2007, Holm, Nissen et al. 2016). The gold standard for the 
treatment of BCC is surgery, but for patients with high morbidity or low-risk BCC, 
an alternate, non-surgical option could be the best choice for treatment. 
Clinically, BCCs are classified into morpheaphorm, i.e. ill-delineated, and well-
delineated by the visualisation of the lesion border.  
The well-delineated BCCs are often indolent and thus low-risk tumours when 
located at low-risk sites. The indolent subtypes of BCC are nodular (nBCC) and 
superficial (sBCC) BCC. sBCC, which typically is not a thick, but is a potentially 
wide tumour, is a particular subtype that can be treated with non-surgical options, 
of which there are several. One elegant, tumour-selective topical treatment is 
photodynamic therapy (PDT). The components involved in the mode of action for 
PDT include a photosensitiser acting as the source and precursor of photoactive 
protophorphyrin IX (PpIX), a light-source, and the oxygen level of the target 
tissue. In the PDT reaction, radical oxygen species are created, which leads to cell 
apoptosis and necrosis. Due to differences in the permeability of the stratum 
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corneum, and in the metabolic activity and cell proliferation rate of healthy and 
malignant cells, the photosensitiser accumulates in the tumour tissue. Thus, 
malignant tissue is destroyed, and healthy skin is preserved. The disadvantages of 
PDT are its varying effectiveness, and intensive pain that often occurs during 
illumination. The main advantages of PDT are an excellent cosmetic outcome, and 
a short application time. Healthcare professionals deliver the treatment. The 
treatment outcome may vary due to differing treatment protocols that use different 
photosensitisers. Therefore, to enhance the effectiveness of PDT, it is crucial to 
search for new and more efficient photosensitisers in PDT of sBCC. 
Ill-defined BCCs are often of the aggressive subtypes; morpheaphorm, 
infiltrative and micronodular, which are often located in the head and neck area 
and can instigate a perineural invasion. Ill-defined BCCs challenge the surgeon, as 
preserving the function and cosmetic appearance is essential in this area. The 
aggressive subtypes of BCCs often lead to re-excisions, because the margins appear 
insufficient post-surgery. The need to re-excise increases the treatment costs. 
Additionally, repeated treatment is overtly stressful for patients. Thus, ill-defined 
BCCs are a true clinical challenge, and often it is these subtypes that are the most 
aggressive. 
Lentigo maligna melanoma (LMM) is one subtype of melanoma, and lentigo 
maligna (LM) is graded as a melanoma in situ, i.e. a precursor to LMM. LMM is a 
tumour that has already invaded through the basal membrane of the skin. Both LM 
and LMM are also clinical challenges, since the tumour is often located in the head 
and neck area. Approximately 50% of invasive head and neck melanomas are 
LMM in subtype. In addition, the margins may be ill-defined with subclinical 
extensions, the lesions can be wide, and the invasion may not be recognisable. In 
distinguishing LM and LMM the correct diagnosis is crucial, as LMM requires 
wider margins and regular follow-up of the patient compared to LM.  
There are special operation techniques, such as Mohs micrographic surgery 
(MMS), which is designed to preserve a maximal amount of healthy tissue while 
minimising the risk of recurrence. MMS is often used and recommended in the 
treatment of challenging and high-risk tumours. MMS is time-consuming and 
requires a highly trained team, but it can be cost-effective when tumour selection is 
performed correctly (Mosterd, Krekels et al. 2008, Tolkachjov, Brodland et al. 
2017).  
Non-invasive imaging diagnostic methods are increasingly under investigation. 
Bio-optical imaging systems could provide one solution to improve and speed up 
the pre-operative diagnosis and assessment of skin cancers (Tkaczyk 2017). When 
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the diagnosis is achieved non-invasively, precisely and quickly, it is possible to 
properly plan the treatment and accomplish it in one session. Bio-optical diagnosis 
and imaging provide several advantages: the possibility to make a bedside diagnosis 
non-invasively, to select for optimal sample sites for histopathology, and to make a 
more precise tumour dimension assessment compared to current methods in 
tumour delineation. Non-invasive imaging is not intended to replace the 
histopathological examination of the excised tumours. Optimally, it would speed 
up and improve the preoperative diagnosis and assessment of skin cancers.  
Hyperspectral imaging is another novel, non-invasive bio-optical imaging 
method in the diagnosis of skin cancer. The advantages of hyperspectral imaging 
are a wide imaging area, a rapid imaging process and the possibility of obtaining 
spectral data from digital images, thus possibly obtaining information that is 
invisible to the human eye.  
In this dissertation, two original communications focus on studying the 
feasibility of hyperspectral imaging in clinically challenging situations, such as in 
recognising the invasion in LMM and in the delineation of ill-defined BCCs. The 
third communication, a prospective, randomised, double-blinded and non-
sponsored clinical trial focuses on the effectiveness and adverse events of PDT, 
and also assesses the photobleaching effect of three photosensitisers during the 
treatment of non-aggressive BCCs.  
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2 REVIEW OF THE LITERATURE 
2.1 Skin cancers 
2.1.1 Classification 
Epidermal skin cancers are divided into keratinocyte, melanocyte and Merkel cell 
carcinoma. KC, which is often referred to as non-melanoma skin cancer (NMSC), 
is further divided into BCC and SCC. The embryological origins of both BCC and 
SCC are in ectodermal cells (Lai, Cranwell et al. 2018). Melanocyte carcinoma, i.e. 
malignant melanoma, and Merkel cell carcinoma are their own entities, and both 
are derived from the neural crest mesenchymal cells (Lai 2018). KCs and MM share 
common aetiological factors, such as ultraviolet (UV) radiation (Armstrong, 
Kricker 2001). 
2.1.2 Epidemiology 
A report from the World Health Organization (WHO) on the global burden of 
ultraviolet radiation (UVR) (Lucas, McMichael et al. 2006) presents worldwide 
epidemiological data and estimates from the year 2000. Table 1 summarises 
epidemiological data on the incidence and mortality from a one-year time period to 
emphasise the impact of skin cancers. 
 
Table 1.  Worldwide number of skin cancers during the year 2000, information acquired and 
modified from the WHO report on Global burden of disease from solar UVR (Lucas, 
McMichael et al. 2006) 
Skin cancer  Incidence  Mortality  
Mortality/ 
Incidence 
Burden of disease 
in DALYs 
MM 211 921 65 161 0.30 690.248 
SCC 2 883 037 13 534 0.06 161.892 
BCC 10 532 711 3245 0.0003 57.983 
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According to the 2004 update on the Global burden of disease report by WHO, 
melanoma and other skin cancers are the 12th leading cause of death worldwide for 
males and 15th for females during the year 2004 (World Health Organization 2008).  
The disability-adjusted life year (DALY) is a measurement used by the WHO to 
assess the burden of disease. One DALY is equal to the loss of one year of life 
spent in full health. The DALY also takes into account premature death caused by 
the disease and life lived disabled by the disease (World Health Organization 2008). 
In Finland, the latest report from the Finnish Cancer Registry is from the year 
2017. According to this report, SCC is the 6th and MM the 7th most common 
cancer in Finland for males. The situation is reversed for females: MM is the 6th 
and SCC the 7th most common cancer (Finnish Cancer Registry 2017).  Regarding 
the mortality of cancer deaths, MM ranks 11th for males and 9th for females 
(Finnish Cancer Registry 2017). The Finnish Cancer Registry excludes BCC in the 
statistics mentioned before. Regarding LM, the statistics are not published in the 
yearly cancer report, as they are considered unreliable. LM is reported to the 
Finnish Cancer Registry in the class of benign tumours, as it is only a local 
pathological change in in situ form, and thus the reliability of reporting is 
questionable. Table 2 presents the incidence and mortality rates in Finland from 
the year 2017 including BCC. Regarding the BCC data from the Finnish Cancer 
Registry, it should be mentioned that only one BCC per person is registered yearly, 
and only one BCC per anatomic area per person per lifetime is registered. 
Table 2.  Number of skin cancers during the year 2017 in Finland, information acquired and 
modified from the Cancer 2017 report (Finnish Cancer Registry 2017) 
Skin cancer 
  
Incidence 
 
MALE FEMALE 
Mortality 
 
MALE FEMALE 
Mortality/ 
Incidence 
MALE FEMALE 
MM 917 802 150 71 0.16 0.09 
SCC 944 734 25 16 0.03 0.02 
BCC 4194 4573 0 0 0 0 
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2.1.3 Basal cell carcinoma 
2.1.3.1 Basal cell carcinoma subtypes 
BCC can be classified clinically and histopathologically, with a partial overlap in the 
two classification methods (Trakatelli, Morton et al. 2014). Clinically, BCCs are 
divided into nodular, superficial and morpheaform, where nBCCs have well-
defined borders, morpheaform BCC is ill-defined, and sBCCs can be either, but 
usually this is not a problem in the case of sBCC (Trakatelli, Morton et al. 2014). 
Sometimes fibroepithelioma of Pinkus is classified as a rare form of BCC, but it is 
distinct in both anatomical and clinical form (Trakatelli, Morton et al. 2014). 
In histopathology, BCCs have previously been classified in relation to structures 
of the skin, for example apocrine, eccrine and sebaceous, as well as differentiated 
BCC versus solid, i.e. undifferentiated BCC (Crowson 2006). However, the most 
useful histopathological classification is the architectural growth pattern, which has 
been proven to correlate with prognosis (Crowson 2006) (Table 3). The risk of 
recurrence is not only influenced by the BCC subtype, but also the location, which 
is crucial (Figure 1). 
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Figure 1.  Risk areas in BCC, information for illustration acquired and modified from (NCCN Clinical 
Practice Guidelines In Oncology, NCCN Guidelines
®
) (H-zone= high risk areas, M-zone= 
intermediate risk areas, L-zone= low risk areas). 
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2.1.3.2 Epidemiology of basal cell carcinoma in detail 
BCC is the most common cancer in the world, though it should be noted that it 
mainly affects populations of Caucasian ancestry (Lucas, McMichael et al. 2006). A 
rough estimation based on the WHO report on the global burden of UVR and 
non-communicable diseases (Lucas, McMichael et al. 2006, World Health 
Organization 2008) approximated that 40% of all cancers in the world are KCs. A 
similar estimate was also found by Cakir et al. (Cakir, Adamson et al. 2012). Based 
on calculations from the data presented in Table 5, about 80% of new KCs are 
BCCs.  
BCC is the most common skin cancer of the fair, Caucasian skin phototype, and 
it is also the most common skin cancer of the intermediately dark skin phototypes. 
Accordingly, BCC is also the most common skin cancer in Hispanic, Chinese Asian 
and Japanese populations with a predominance of the pigmented subtype (Gloster, 
Neal 2006). For Blacks and Asian Indians, BCC is the second most common skin 
cancer after SCC (Gloster, Neal 2006). In dark skin, skin cancer tends to have 
greater morbidity and mortality when compared to fair skin types (Gloster, Neal 
2006). A Singaporean register study from 1968 to 1997 showed a trend of 
increasing incidence for BCC, and the degree of increase was higher for lighter skin 
types compared to darker ones (Koh, Wang et al. 2003). 
Regarding reported numbers of BCC, the registration of KCs varies and this 
applies especially for BCC (Verkouteren, Ramdas et al. 2017). Vries et al. estimated 
that the stated number of BCCs in registries should be multiplied by 1.3 to 
correspond to the actual number of BCCs in four European territories, including 
Finland (de Vries, Micallef et al. 2012). In low-risk cases, BCCs are often treated 
without histological confirmation. For example, in four European territories 
including Finland, up to 24.1% of the BCCs were treated without histological 
confirmation in a given time frame (Flohil, Proby et al. 2012). Thus, when the 
multiplicity and treatment based on clinical and/or dermoscopic diagnosis is 
acknowledged, the actual number of BCCs is even higher than reported in national 
cancer or hospital pathology registries (de Vries, Micallef et al. 2012, Flohil, Proby 
et al. 2012).  
Worldwide, the incidence of BCC is constantly increasing, but the rate of 
increase is also affected by latitude and the skin type of the population (Lomas, 
Leonardi-Bee et al. 2012). KC incidence varies in such a way that in lower latitudes, 
where the daily ambient UVR dose is higher, the incidence of KCs is higher. 
However, personal sun exposure habits can also have an effect (Xiang, Lucas et al. 
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2014). This applies to both SCC and BCC, but more strongly to SCC (Xiang, Lucas 
et al. 2014). Traditionally an outdoor profession, like farming, has been a risk factor 
for BCCs (Apalla, Lallas et al. 2016, Szewczyk, Pazdrowski et al. 2016), but recently 
a shift has been observed in the BCC risk for indoor workers. This could be due to 
outdoor activities during leisure time and on vacations (Deady, Sharp et al. 2014, 
Lindelof, Lapins et al. 2017). In Europe, an annual increase of 5.5% in the 
incidence of BCC has taken place during the past decades, and in the USA the 
annual increase rate is 2%. In Australia, the increase seems to have reached a 
plateau, yet Australia still has the highest incidence of BCC in the world at 884/100 
000 person-years for both genders, based on a 2002 estimation (Lomas, Leonardi-
Bee et al. 2012).  
The average age of BCC onset is around 65 to 69 years (Betti, Radaelli et al. 
2010, Scrivener, Grosshans et al. 2002). In some subgroups, such as younger adults 
under 40 years of age, females, individuals of high socio-economic status and urban 
populations, the increase in incidence has been even sharper during recent decades 
(Deady, Sharp et al. 2014, Raasch, Buettner et al. 2006). Furthermore, there has 
been a proportional shift towards the superficial subtype of BCC (Arits, A H M M., 
Schlangen et al. 2011). In young females, the solid superficial subtype is more 
common than a mixed-type histology on the trunk or extremities (Pyne, Myint et 
al. 2017). Therefore, with a shift towards an ever greater proportion of sBCC, non-
surgical options could be the treatment of choice more often (Arits, A H M M., 
Schlangen et al. 2011). BCC is 1.5 times more common in males than in females 
(Xiang, Lucas et al. 2014), but in some countries, this ratio has reversed in younger 
populations (Verkouteren, Ramdas et al. 2017). Additionally, the incidence of BCC 
is still high and increasing in the very elderly (over 80 years), with the most 
common subtype for this group being nBCC in the head and neck region (Lubeek, 
van Vugt et al. 2017). In this age group, it is especially important to weigh the pros 
and cons of treatment (Lubeek, van Vugt et al. 2017). The risk of recurrence 
compared to the burden and adverse events of the treatment should be carefully 
considered. 
The most common subtype of BCC is the nodular type, and thereafter the 
superficial and aggressive types (Raasch, Buettner et al. 2006, Scrivener, Grosshans 
et al. 2002). It is possible that the aggressive types are more common in countries 
with high daily UVR doses (Scrivener, Grosshans et al. 2002, Raasch, Buettner et 
al. 2006, Burdon-Jones, Thomas 2006). Nodular and aggressive subtypes are most 
commonly seen in the head and neck area, and sBCC on the trunk (Scrivener, 
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Grosshans et al. 2002, Raasch, Buettner et al. 2006, Betti, Radaelli et al. 2010) 
(Figure 2). 
 
 
Figure 2.  Anatomic distribution of BCC by subtype. Information for illustrations acquired and 
modified from (Scrivener, Grosshans et al. 2002) A) Distribution of different subtypes on 
different body areas (percentages are calculated in each subtype) B) Distribution of 
different subtypes on the head (percentages in colours are proportionate to each site) 
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Most BCCs are located in the head and neck area, which poses a challenge for 
treatment as preserving the function and cosmetic outcome in this delicate location 
is essential. There is also a difference seen by age group with regard to the 
prevalence of certain subtypes (Betti, Radaelli et al. 2010, Raasch, Buettner et al. 
2006) (Figure 3). In a study where tumour density was calculated by the site-
specific body surface area, the highest BCC densities were found in the following 
order: nose, cheeks/perioral area, eyes, forehead/temples, ears, chin/jaw, neck, 
back, upper arm (including shoulder), lower arm, chest/abdomen), lower leg, 
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hands, scalp, and lastly feet and hip/upper leg which had the same body-surface-
standardized incidence. Unfortunately, the density was not reported by subtypes 
(Richmond-Sinclair, Pandeya et al. 2009).  
 
 
Figure 3.  BCC subtypes by age group. Figure borrowed from (Raasch, Buettner et al. 2006), 
courtesy of the British Journal of Dermatology. 
Some studies have speculated that the rise in global temperature might enhance the 
effective UVR dose. Thus, climate change could also play a role in the increasing 
incidence of KC (van der Leun, Jan C., Piacentini et al. 2008, Piacentini, Della Ceca 
et al. 2018). More commonly postulated reasons for the increasing incidence 
include improved registration, aging populations, increased awareness, better 
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availability of surgery and changed UVR exposure habits (Verkouteren, Ramdas et 
al. 2017, Deady, Sharp et al. 2014).  
The use of sunscreens in the prevention of KCs is widespread and often 
recommended based on the idea of UVR as an aetiological factor. However, good 
quality evidence is sparse. There is more evidence for actinic keratosis (AK) and 
SCC, but it is more unclear for BCC (Sanchez, Nova et al. 2016, Waldman, Grant-
Kels 2019). Screening has some impact on KC incidence (Eisemann, Waldmann et 
al. 2014), and some preventive interventions like oral acitretin (Bath-Hextall, 
Leonardi-Bee et al. 2007) or oral nicotinamide (Chen, Martin et al. 2015) in high-
risk groups have shown evidence for the prevention of KCs. Risk factors for 
developing KC or subsequent BCC as well as risk factors in high-risk groups have 
been studied, and clinical tools and predictors based on these have been developed 
(Lowenstein, Garrett et al. 2017, Whiteman, Thompson et al. 2016, Verkouteren, 
Smedinga et al. 2015). 
2.1.3.3 Basal cell carcinoma: burden of disease and economical impact 
In BCC, it is typical that a single patient can have multiple BCCs, either at the same 
time or as multiple primaries, or at the time passing as new primaries or 
recurrences. In Australia, during a ten-year follow-up 46% of patients with BCC 
were diagnosed with multiple lesions, and 54% with a single lesion (Richmond-
Sinclair, Pandeya et al. 2009), thus roughly half of the patients with BCC will 
develop multiple lesions. From those patients who have multiple BCCs, 56% will 
have over three lesions, 26% over four and 17% over five (Richmond-Sinclair, 
Pandeya et al. 2009). The incidence for patients with a single BCC was 935/100 
000 person-years, whereas for patients with multiple BCCs it was 705/100 000 
person-years (Richmond-Sinclair, Pandeya et al. 2009). The risk of lesion 
multiplicity is greater for older individuals (Flohil, van der Leest, Robert J T et al. 
2013).  
In a systematic review and meta-analysis from patients with BCC, 29% will 
develop a subsequent BCC, 4.3% a SCC and 0.5% a MM, and correspondingly the 
risks were 17.4-fold for BCC, 3.2-fold for SCC and 2.4-fold for MM, when 
compared to the general population (Flohil, van der Leest, Robert J T et al. 2013). 
The risk for subsequent skin cancer was highest in Australia, thereafter in the USA 
and lowest in Europe (Flohil, van der Leest, Robert J T et al. 2013). 
A sharper rise in the incidence of sBCC and of aggressive BCC in general has 
been observed in younger populations (Arits, A H M M., Schlangen et al. 2011). It 
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is possible that there are some undiscovered biological differences between early-
onset BCC, having the first BCC at an average age of 40 years, and late-onset BCC, 
at an average age of about 60 years (Barton, Zens et al. 2016). Early-onset BCC is 
more likely to be an aggressive subtype (Barton, Zens et al. 2016). When looking at 
the proportion of patients with early-onset BCC, 34% of them will develop a 
subsequent skin cancer, and 31% of early-onset BCC patients will develop a new 
BCC with a median development time of 1.1 years for the subsequent skin cancer 
(Berlin, Ferrucci et al. 2015). Thus, a remarkable proportion of early-onset BCC 
patients will develop a new BCC much faster compared to the 36.2% five-year 
cumulative risk generally observed in BCC (Flohil, van der Leest, Robert J T et al. 
2013). 
There seems to be an association between mortality in other cancers and having 
a KC, as the association is stronger for SCC than BCC (Barton, Armeson et al. 
2017). Thus, the idea of KCs being a marker for a cancer-prone phenotype has 
been proposed (Barton, Armeson et al. 2017, Jensen, Bautz et al. 2008). 
In extremely rare cases, BCC can be locally advanced or metastatic. In these 
cases oncological and costly treatments are required (Puig, Berrocal 2015, Mohan, 
Chang 2014). In a Danish registry study, the incidence of metastatic BCC was 
0.0039% among patients with a history of BCC, compared to 0.0001% in the 
general population (Nguyen-Nielsen, Wang et al. 2015).  A registry study from the 
USA found the incidence for locally advanced disease to be 0.8% (Goldenberg, 
Karagiannis et al. 2016). About 1–10% of BCCs are locally advanced (Mohan, 
Chang 2014).  
KCs have a small but remarkable impact on quality of life of affected 
individuals, and this should be noted in the treatment of these patients (Gaulin, 
Sebaratnam et al. 2015). Quality of life should be included more often as an 
outcome in the research of KCs, not least due to the fact that KCs are commonly a 
chronic condition (Gaulin, Sebaratnam et al. 2015). 
BCC diagnosis and treatment costs are generally low for individual cases, but 
due to BCC being so common, the expenses are the fifth highest when taking all 
cancers into account, with only prostate, lung, colon and breast cancers having 
higher costs (Cakir, Adamson et al. 2012). When comparing skin cancers, the total 
cost of illness for BCC in a three-year period was as high as for melanoma, but 
naturally melanoma had a higher cost per case (Bentzen, Kjellberg et al. 2013).  
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2.1.3.4 Risk factors of basal cell carcinoma 
There are several risk factors for developing a BCC, and the relationships between 
them are complex (Verkouteren, Ramdas et al. 2017). There is a predisposing 
genotype as well as several environmental risk factors interacting in the 
development of BCC (Verkouteren, Ramdas et al. 2017) (Table 4). 
Table 4.  Risk factors of BCC, information acquired and modified from (Dessinioti, Antoniou et 
al. 2010, Kraft, Granter 2014, Verkouteren, Ramdas et al. 2017). 
Genotype Phenotype Risks in environment Protective factors 
in environment 
Somatic mutations 
(sporadic PTCH1 and p53) 
Age UVR (solar, therapeutic, 
tanning beds) 
Coffee (caffeine or 
marker of lifestyle 
and life habits??)  
Germline polymorphism 
(MC1R variants, CYP 
family, GST family) 
Male sex Photosensitising agents 
(PUVA) 
Selenium?? 
Germline mutations ** 
(genodermatoses: PTCH1 
and nucleotide excision 
repair genes, some 
unknown genes) 
Personal history of skin 
cancer 
Ionising radiation 
(therapeutic, environmental) 
Carotenoids?? 
? Epigenetic factors, 
something else 
Family history of skin 
cancer 
Chemicals (arsenic) Vitamins?? 
 
Sensitivity to UVR and 
poor ability to tan 
Immunosuppression 
 
 
Fair complexion, light 
hair and eye colour 
  
 
Signs of excessive UVR 
exposure and signs of 
photodamage * 
  
* melanocytic nevi, freckles, solar elastosis, solar lentigines and actinic keratoses  
** PTCH1 mutation in nevoid basal cell carcinoma syndrome, nucleotide excision repair genes in xeroderma 
pigmentosum, unknown gene in Xq24-27 region in Bazex-Dupré-Christol syndrome, unknown mutation in 
Rombo syndrome. 
 
? Possible aetiological factor 
 
?? Inconsistent and insufficient evidence 
The above-presented risk factors often associate with primary BCCs. The risk 
factors that predict a high risk for a second BCC include being 60-75 years of age 
at the moment of the first BCC, male sex, less than three cups of coffee per day, 
the first BCC being of a superficial subtype and more than one BCC at first 
diagnosis (Verkouteren, Smedinga et al. 2015). Additionally, if a patient has more 
than one BCC at first diagnosis the multiple BCCs are more likely to occur on the 
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trunk. Furthermore, multiple BCCs are also more likely to be of the superficial 
subtype (Kuo, Batra et al. 2017).  
There is a strong UVR signature in mutations leading to BCC (Kraft, Granter 
2014, Verkouteren, Ramdas et al. 2017, Armstrong, Kricker 2001, Dessinioti, 
Antoniou et al. 2010), but the relationship of the pattern of exposure to a specific 
subtype, site and the multiplicity of BCC is under discussion (Verkouteren, Ramdas 
et al. 2017).  The association of UVR to BCC is based on epidemiological data, 
such as the linkage of latitude and incidence, and high incidence on sun-exposed 
anatomic locations (Xiang, Lucas et al. 2014, Richmond-Sinclair, Pandeya et al. 
2009, Armstrong, Kricker 2001). It is clear that cumulative UVR dose is a risk for 
SCC and AK, but in BCC, the pattern of exposure and interaction with other 
causative factors play a major role (Xiang, Lucas et al. 2014, Dessinioti, Antoniou 
et al. 2010, Verkouteren, Ramdas et al. 2017, Armstrong, Kricker 2001).  
Intense intermittent UVR exposure, especially in childhood, increases the risk 
for BCC (Verkouteren, Ramdas et al. 2017, Pelucchi, Di Landro et al. 2007). 
Intense intermittent exposure has also been associated with a location on the trunk. 
sBCC is reported to be more common on the trunk (Verkouteren, Ramdas et al. 
2017), but in a study from Australia, a country with high UVR exposure, the 
distribution of all subtypes on different anatomic locations was more equal 
compared to the data from low UVR exposure countries, thus blurring the possible 
association of intense intermittent exposure and superficial subtype (Raasch, 
Buettner et al. 2006). Nodular and aggressive BCCs are more common in the head 
and neck area. For nBCC, the cumulative UVR dose could be an independent risk 
factor in the head and neck area, whereas in sBCC on the trunk, the capability of 
DNA repair or other molecular factors could play a bigger role (Raasch, Buettner 
et al. 2006, Pelucchi, Di Landro et al. 2007). Early-onset BCC associates with an 
aggressive subtype, high solar sensitivity and the number of blistering sunburns 
experienced in childhood (Kuo, Batra et al. 2017). Early-onset BCC is more 
common in women and in the head and neck area (Kuo, Batra et al. 2017). 
Interestingly, solid sBCC with no mixed histology is also more common in women, 
but in young women it is often located on the extremities and trunk (Pyne, Myint 
et al. 2017). The biology of BCC is diverse. 
UVR of relatively short wavelengths (UVB) is capable of causing direct DNA 
damage, via the DNA acting as a chromophore and absorbing the energy of UVB. 
In the case of UVR of relatively long wavelengths (UVA), the effect on DNA is 
indirect, as other structures absorbing UVA create radical oxygen species, which 
can cause DNA damage (Dessinioti, Antoniou et al. 2010). In addition to DNA 
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damage, UVR causes immunosuppression (Dessinioti, Antoniou et al. 2010), and it 
is also being proposed that differences in apoptosis and local immune response 
could affect the type of the tumour and the site-specific incidence of KCs 
(Manestar-Blazic, Batinac et al. 2007). 
2.1.3.5 Tumour cell origin and pathophysiology of basal cell carcinoma 
BCC probably arises from stem cells in hair follicles or in the interfollicular 
epidermis (Wang, Wang et al. 2011, Verkouteren, Ramdas et al. 2017). In the 
pathophysiology of BCC, the Hedgehog signalling pathway is essential (Wang, 
Wang et al. 2011, Kraft, Granter 2014). This pathway controls cell proliferation, 
differentiation and apoptosis (Kraft, Granter 2014). PTCH and SMO are proteins 
in association with the cell membrane and are part of the Hedgehog pathway, and 
when Hedgehog proteins bind to PTCH, the SMO is released and activates the 
pathway (Kraft, Granter 2014). PTCH1 is the gene encoding the PTCH protein, 
and mutations in this gene, such as those found in basal cell nevus syndrome 
patients and often in sporadic BCC, lead to decreased suppression of SMO by 
PTCH (Kraft, Granter 2014). Activating mutations in SMO will also lead to 
activation of the Hedgehog pathway (Kraft, Granter 2014). In sporadic BCC, 67–
90% have mutations in PTCH1 and 10–20% in SMO (Kraft, Granter 2014).  
In sporadic BCC, mutations on the tumour suppressor gene TP53 are also 
common, with some 40-65% carrying these mutations, which lead to the 
overexpression of p53 (Kraft, Granter 2014). A polymorphism of melanocortin 1 
receptor (MC1R) leads to different kinds of photo-protective qualities of 
eumelanin, which lies over keratinocytes’ nuclei (Kraft, Granter 2014). In 
Xeroderma Pigmentosum, a syndrome with multiple BCCs, DNA repair is 
impaired. In sporadic BCC, the role of mutations in DNA repair genes is unclear, 
but they may affect the aggressiveness of different subtypes (Kraft, Granter 2014). 
2.1.4 Lentigo maligna and lentigo maligna melanoma 
2.1.4.1 Cutaneous melanoma subtypes 
Melanoma has four main histopathological subtypes: LMM, acral lentigious 
melanoma, superficial spreading melanoma (SSM) and nodular melanoma (Su 
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1997) (Table 5). Additionally, there are rare variants, which can also be classified by 
their clinicopathological features (Perniciaro 1997) (Table 5).
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Rare forms of melanoma that are also reported include angiotropic, myxoid, 
pedunculated and verrucous variants (Perniciaro 1997), and rare forms of the 
vertical growth phase include minimal deviation melanoma, nevoid melanoma, 
infantile/childhood melanoma, pigment-synthesising melanoma and metastatic 
melanoma (Liu, Mihm 2003). Melanoma can also be discovered based on the 
appearance of tumour metastases on the skin or elsewhere, and in this case the 
primary tumour may be of unknown origin (Perniciaro 1997, Gershenwald, Scolyer 
et al. 2017). In the histopathology of melanoma metastases in the skin, there are 
usually clusters of atypical spindle-shaped or cuboidal melanocytes in the dermis or 
subcutaneous fat, but the histology can vary widely (Perniciaro 1997).  
For prognosis, the tumour-nodules-metastases (TNM) -classification is used, 
where the different categories correlate with survival (Gershenwald, Scolyer et al. 
2017). The latest, 8th edition of melanoma staging with TNM-classes was recently 
released by the American Joint Committee for Cancer (AJCC) (Gershenwald, 
Scolyer et al. 2017) (Table 6).  
Table 6.  Factors defining the TNM-categories, information acquired and modified from 
(Gershenwald, Scolyer et al. 2017). 
T 
Tumour thickness 
Ulceration 
N 
Lymph nodes: clinically occult (SLN positive)/clinically 
detected 
Number of involved lymph nodes 
Presence of in-transit satellites and/or micro-satellite 
metastases 
M 
Evidence of distant metastasis 
Anatomic site of metastasis 
If metastasis present, LDH level elevated or not 
In the AJCC staging, there is only one non-microscopic or non-anatomic 
prognostic factor, which is the serum lactate dehydrogenase (LDH) level. 
However, there are reports of several biomarkers which can already affect the 
treatment of melanoma. These factors may potentially have an impact on the 
staging systems in the future, or even make them obsolete (Gershenwald, Scolyer 
2018) (Table 7). It has been suggested that melanoma could have four genomic 
classes based on the underlying driver mutation: BRAF, RAS, NF1 and triple-wild 
type (Cancer Genome Atlas Network 2015). Classification could also be based on a 
UV-exposure pattern: melanomas of chronically sun-exposed skin (LMM and 
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desmoplastic melanoma) and intermittently exposed sun-protected skin 
(Armstrong, Cust 2017, DeWane, Kelsey et al. 2019). 
When considering the prognosis of a LM/LMM patient, it is crucial that these 
two conditions are distinguished, as the prognosis of LMM is similar to other 
melanoma types of the same Breslow thickness (Gershenwald, Scolyer et al. 2017). 
LM is an in situ melanoma, and has a different prognosis, treatment, and follow-up 
compared to invasive melanoma (Gershenwald, Scolyer et al. 2017, Wright, Souter 
et al. 2019).  
Table 7.  Potential biomarkers in melanoma, information acquired and modified from (Axelrod, 
Johnson et al. 2018) and (Weiss, Hanniford et al. 2015). 
Biomarkers 
Predictive: outcome of therapy Prognostic: 
Targeted 
therapy 
Immune 
checkpoint 
inhibitors  
Diagnostic tools 
Tumour 
genome 
Driver mutations BRAF-
inhibitors/ MEK-
inhibitors 
CTLA-4/ PD-1 - 
response 
Potential tools 
for diagnosis 
and 
prognosis 
  Gene expression: messengerRNA and 
microRNA 
Potential new 
therapies 
Antitumor 
immune 
response/  
Tumour-
infiltrating 
lymphocytes 
  
  
Tumour microenvironment 
Tumour cell signalling 
Mutation burden and neoantigens 
Antigen presentation 
Recognition of antigens by T cell 
receptors 
Cytotoxic T cell response 
Circulating 
blood/ Serum 
markers 
  
Proteins (like LDH) 
microRNA 
tumourDNA 
Clinical signs Immune-related adverse events 
  Site of metastases 
  Tumour burden 
Microbiome Pretreatment microbiome in gut/ 
modification of gut microbiome 
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2.1.4.2 Epidemiology of lentigo maligna and lentigo maligna melanoma in detail 
The overall incidence of melanoma has risen globally for the past few decades, and 
the increase has been from 3–7% to 100% (=2-fold) for every 10–20 years in 
populations with Caucasian ancestry (Nikolaou, Stratigos 2014, Lai, Cranwell et al. 
2018). Interestingly, in younger age groups in Australia, the USA and Europe the 
incidence has begun to stabilise, but the increase has been even more dramatic in 
age groups over 60 years, especially among males.  In the USA, a peak in the 
incidence rate has also been observed in young adults aged 20 to 24 years 
(Nikolaou, Stratigos 2014). In Scandinavia, the increase in melanoma incidence has 
been 10-fold from 1953 to 1997 (Nikolaou, Stratigos 2014). In Europe, there are 
variations in the increase rate in Northern, Southern, Western and Eastern regions, 
perhaps due to different registration systems or shortages in them. The male to 
female ratio and age also vary between the geographic regions (Nikolaou, Stratigos 
2014).  
Melanoma is rare in darker skin phototypes, with 1-8% of skin cancers being 
melanoma in Blacks, 10-15% in Asian Indians, and 19% in Japanese (Gloster, Neal 
2006).  
Even though the incidence of melanoma has increased dramatically, the 
mortality of melanoma has stabilised in Europe, Australia and the USA (Nikolaou, 
Stratigos 2014, Lai, Cranwell et al. 2018). This reflects the early detection of thin 
melanomas at a stage with a better prognosis. However, the increasing mortality 
rate in elderly men over the age of 60 with thick melanomas often of the nodular 
type in the head and area, is an exception (Lai, Cranwell et al. 2018, Nikolaou, 
Stratigos 2014). The increased mortality rate in this age group has been associated 
with a poorer prognosis at the moment of diagnosis, as the melanomas are thick 
and late in stage at the time of detection (Lasithiotakis, Petrakis et al. 2010). The 
survival rate is generally better for females compared to males. The reason for this 
is unknown, and unrelated to sex hormones (Nikolaou, Stratigos 2014). 
The anatomic location of melanoma associates with age, as young patients’ 
melanomas are typically located on the trunk or extremities, and in the elderly they 
are more often located in the head and neck area (Nikolaou, Stratigos 2014). The 
distribution is different in dark skin phototypes, as melanomas in dark skin types 
are often located in non-exposed sites such as the palms, soles and mucosa. 
Accordingly, acral lentiginous melanoma is the most common subtype in Blacks 
(Gloster, Neal 2006).  
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Approximately 50% of invasive head and neck melanomas are LMM, compared 
to only 2% of all melanomas (Cox, Aitchison et al. 1996, Linos, Li et al. 2017). 
Regarding the body distribution in LMM, 18% are reported to be extra-facial (Cox, 
Aitchison et al. 1998). However, it seems that extra-facial LMM is more common 
in low latitudes such as Australia and Hawaii, where extra-facial LMMs make up to 
57% of LMMs (Inskip, Rosendahl 2016). The most common sites for LMM are 
presented in Figure 4. There are differences in location between the sexes, as 
females more commonly have LM on the cheeks, and males more commonly on 
the scalp and cartilaginous area of the ears (Tiodorovic-Zivkovic, Argenziano et al. 
2015).  
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Figure 4.  LM incidence by body area (percentages announced in colours are proportionate to each 
site), information acquired and modified for illustration from (Mirzoyev, Knudson et al. 
2014). 
About 10% of melanomas are LMM (Kraft, Granter 2014), but this proportion 
might be changing, as the incidence of LM/LMM is increasing in studies 
performed in Europe and the USA (Toender, Kjaer et al. 2014, Swetter, Boldrick et 
al. 2005, Greveling, Wakkee et al. 2016, Mirzoyev, Knudson et al. 2014). 
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Additionally, the overall incidence for melanoma in situ has increased in Europe, 
the USA and Australia (Coory, Baade et al. 2006, Toender, Kjaer et al. 2014, 
Helvind, Holmich et al. 2015) (Table 8). This increase is mainly due to LM, as 79–
83% of melanomas in situ are LM (Swetter, Boldrick et al. 2005). A change has also 
been observed in the location of melanomas, as more melanomas and LM are 
located in the head and neck area (Helvind, Holmich et al. 2015, Mirzoyev, 
Knudson et al. 2014). 
Table 8.  Increasing incidence of LM/LMM in the USA and Europe, information acquired and 
modified from (Toender, Kjaer et al. 2014, Swetter, Boldrick et al. 2005, Mirzoyev, 
Knudson et al. 2014, Greveling, Wakkee et al. 2016 and Higgins, Lee et al. 2015). 
  
Incidence per 100 000 person-years  Annual percentage change (timeline) 
  
Female Male Female Male 
Minnesota  
1970-2007 
LM 0.8 -> 10.0 4.0 -> 19.2 - 
LMM - 
 
- 
California  
1990-2000 
LM both sexes 5.4 -> 10.0 * both sexes 4.2% (1999-2000) 
LMM both sexes 1.6 -> 3.2 * both sexes 3.7% (1999-2000) 
Denmark  
LM 1997-2011 
LMM 1985-2011 
LM 0.6 -> 1.5 0.5 -> 1.4 7.53% (1997-2011) 7.17% (1997-2011) 
LMM 0.23 -> 0.54 0.23 -> 0.71 4.7% (1985-2011) 5.2% (1985-2011) 
Netherlands 
1989-2013 
LM 0.76 -> 4.16 0.68 -> 3.76 8.7% (2007-2013)  7.4% (2002-2013)  
LMM 0.22 -> 1.18 0.26 -> 1.25 14.4% (2009-2013)  14.1% (2007-2013) 
* Calculated as an average of the different age groups given in the reference and greater proportion for male was 
reported 
The annual percentage change in incidence for LM/LMM has been greater than 
for any other cancer in the USA (Higgins, Lee et al. 2015). Interestingly, the LM 
and LMM incidence is higher for males in the USA, especially in the 65 years and 
over-age group (Swetter, Boldrick et al. 2005, Mirzoyev, Knudson et al. 2014), 
whereas in Europe it seems that the incidence of LM is higher in females, but the 
incidence of LMM is higher in males (Toender, Kjaer et al. 2014, Greveling, 
Wakkee et al. 2016, Helvind, Holmich et al. 2015). Furthermore, in Europe the 
increasing incidence of melanomas in situ has been sharpest for males over 60 years 
of age (Helvind, Holmich et al. 2015). In the most recent epidemiological study of 
LM/LMM by Grevling et al. from the Netherlands, the differences between 
females and males were slight, and for both sexes the increased incidence did not 
have an impact on mortality or the 5-year survival rate, which was 104% for LM 
and 99% for LMM (Greveling, Wakkee et al. 2016). The risk for developing LMM 
after being diagnosed with LM is 2–3% (Greveling, Wakkee et al. 2016), whereas 
earlier it had been reported to be 5% (Higgins, Lee et al. 2015). It should be noted 
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that the prognosis of melanoma is similar for LMM as it is for other subtypes of 
similar Breslow thicknesses (Gershenwald, Scolyer et al. 2017). 
It has been speculated that the observed increased incidence of melanomas in 
situ could partially be due to improved registration and diagnosing melanomas at an 
earlier stage (Helvind, Holmich et al. 2015). Regarding the epidemiology of 
melanomas in situ, the registries are not as complete as for invasive melanoma 
(Higgins, Lee et al. 2015). However, it seems that there is a true increase in the 
incidence of LM and LMM, which poses a challenge for treatment, as LM/LMM is 
often located in the head and neck area, where preserving the function and 
cosmetic appearance is essential. 
The median age for developing LM/LMM has increased from >60 years to >70 
years, when comparing data before and after the year 2000 (Greveling, Wakkee et 
al. 2016, Mirzoyev, Knudson et al. 2014). Younger patients (mean age 68 years) 
tend to have smaller (diameter <10mm) and solitary LM lesions compared to older 
patients (mean age 71 years) who typically have larger (diameter >10mm) LM 
lesions with multiple surrounding freckles (Tiodorovic-Zivkovic, Argenziano et al. 
2015). 
BRAF mutations are less common than KIT and NRAS mutations in 
melanomas of chronically sun-exposed skin. It is also likely that there are common 
mutations yet to be discovered (Whiteman, Pavan et al. 2011, DeWane, Kelsey et 
al. 2019). Interestingly, melanomas with KIT mutations typically have ill-defined 
borders, akin to LM/LMM, mucosal and acral lentiginous melanomas (Whiteman, 
Pavan et al. 2011). 
Melanoma in situ patients are under increased risk of developing a recurrence, a 
new primary malignant melanoma, which is likely to occur in the same anatomic 
location as the preceding one, and other malignancies (Higgins, Lee et al. 2015, 
Youlden, Youl et al. 2014). The 5-year life expectancy is the same for melanoma in 
situ patients as it is for the general population (Higgins, Lee et al. 2015).  
There is evidence for the screening and prevention of all subtypes of melanoma, 
especially in high-risk groups, although with higher costs in the case of melanoma 
in situ (Higgins, Lee et al. 2015, Brunssen, Waldmann et al. 2017, Whiteman, Bray 
et al. 2008). The good-quality evidence on sunscreen’s preventative effect on 
melanoma is sparse, but there is some evidence that regular sunscreen use could 
have a decreasing effect on MM incidence. However, the evidence for melanoma in 
situ is indeterminate (Higgins, Lee et al. 2015). A systematic review and meta-
analysis concluded that the use of sunscreen is not a risk factor for skin cancer 
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(MM or KCs), but that in the general population the protective effect cannot be 
confirmed (Silva, Tavares et al. 2018). 
2.1.4.3 Risk factors for melanoma, lentigo maligna and lentigo maligna melanoma 
There are several genetic and environmental risk factors for melanoma, which are 
presented in Table 9. 
Table 9.  Risk factors for melanoma, information acquired and modified from (Nikolaou, 
Stratigos 2014). 
Genotype Phenotype Risks in environment Protective factors 
in environment 
Hereditary mutation in CDKN2A, 
CDK4 or BAP1 (familial melanoma) 
Fair complexion, light hair and 
eye colour  
UVR (solar, therapeutic, 
tanning beds) 
Smoking/nicotine 
(anti-inflammatory) 
Hereditary polymorphism/mutation in 
genes associating with pigment 
phenotype (MC1R, ASIP, TYR)  
Sensitivity to UVR and poor 
ability to tan (especially skin 
types I-II) 
Painful sunburns Use of NSAIDs?? 
Hereditary polymorphism/mutation in 
genes associating with nevi 
proliferation (PLA2G6, MTAP, IRF4) 
Freckling HIV/AIDS 
 
Hereditary polymorphism/mutation in 
genes associating with DNA repair 
pathways and apoptosis 
(TERT/CLPTM1L, TIPARP (formerly 
PARP-1), ATM, CASP8) 
Multiple nevi (melanoma of 
trunk and extremities) 
Use of TNFα 
 
Hereditary polymorphism/mutations in 
genes associating with gene's 
transcription activity (MITF*) 
Dysplastic/ atypical nevi 
(correlation of number and 
risk level) 
Immunosuppression related 
to organ transplantation  
 
 
Family history of melanoma Recent stressful life 
event??? 
 
 
Personal history of KC  Insecticides??? 
 
 
Personal history of childhood 
cancer 
Heavy metals??? 
 
 
Lymphoproliferative disease 
  
 
Parkinson’s disease**  
  
 
Heavy birth weight? 
  
* MITF, which is also associated with nevus count, non-blue eyes and renal cancer 
 
** Additionally melanoma patients have an increased risk for Parkinson’s disease 
 
? Result of one study, and the design should be repeated 
 
?? Evidence contradictory 
 
??? Observational design 
There is discussion that melanomas should not be regarded as a single entity, as 
all subtypes do not share exactly the same risk factors, and differences in aetiology 
could have an impact on prognosis (Whiteman, Pavan et al. 2011). Risk factors for 
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LM/LMM compared to SSM, the most common subtype, are presented in Table 
10. 
Table 10.  Comparing risk factors for LMM and SSM, information acquired and modified from 
(Kvaskoff, Siskind et al. 2012). 
LMM SSM 
Presence of solar 
lentigines 
Number of nevi 
Personal history skin 
cancer 
Multiple lifetime 
sunburns  
Fair complexion Fair complexion 
Freckling Freckling 
Sensitivity to UVR Sensitivity to UVR  
Number of AK Number of AK 
In a study from France, where risk factors of LM were compared to other 
melanomas including superficial, nodular, acral lentiginous and unclassified, 
sunburns were also associated with LM (Gaudy-Marqueste, Madjlessi et al. 2009). 
Kvaskoff et al. (information in Table 9) performed their study in Australia with 
higher ambient UVR doses, as did Gaudy-Marqueste et al. in France. The French 
compared the LM with all other subtypes, while the Australians only with SSM, 
which can influence the results. 
The relationship of UVR and melanoma is complex. The epidemiological 
evidence of the causal role of UVR in melanoma is strong, as melanoma is more 
common in populations living in lower latitudes closer to the equator, in fair-
skinned populations that have migrated to low latitudes, and in fair skin phototypes 
when compared to dark ones (Nikolaou, Stratigos 2014). The role of UVR in 
melanoma is particularly complex when looking at melanomas among indoor and 
outdoor workers, and the anatomic distribution of the melanoma. Chronic sun-
exposure is associated with head and neck melanoma only in low-latitude 
populations, but melanoma on the trunk is associated with intermittent exposure to 
sunburns in all latitudes. Additionally, there are differences in the anatomical 
distribution of different subtypes (Nikolaou, Stratigos 2014). 
There is much discussion on the role of UVR as an aetiological factor, and it 
seems that it is not clearly understood (Nikolaou, Stratigos 2014). In molecular and 
genetic studies, it seems that the role of UVR varies for different subtypes 
(Whiteman, Pavan et al. 2011, DeWane, Kelsey et al. 2019). The fact is that 
melanoma cannot be regarded as a single entity in the future (Nikolaou, Stratigos 
2014, Whiteman, Pavan et al. 2011, DeWane, Kelsey et al. 2019). 
 48 
In addition to LMM, the desmoplastic subtype seems to associate strongly with 
chronic sun-exposure, and interestingly LMM and a desmoplastic subtype occur 
together quite often (DeWane, Kelsey et al. 2019).  
2.1.4.4 Tumour cell origin and pathophysiology of melanoma, lentigo maligna and 
lentigo maligna melanoma 
Melanoma originates from melanocytes, but the precursors of melanocytes and 
their developmental origin could influence the cancerous potential of the 
melanocytes (Whiteman, Pavan et al. 2011). Melanocytes derive from the neural 
crest and migrate to the outermost layer of the fetus, the epidermal layer. Later in 
life, melanocytes can differentiate from multipotent precursor cells, which are 
preserved along nerve projections. In melanoma, the inhibiting pathways of these 
precursor cells are altered (Whiteman, Pavan et al. 2011). The variety of other cell 
types in the neural crest along the cranio-caudal axis can also affect the precursors 
via epigenetic factors. Thus, the origin of melanocytes is not uniform throughout 
the body (Whiteman, Pavan et al. 2011).  
The potential of melanocytes to develop into a melanoma also depends on the 
interactions and gene expression of the surrounding cells: keratinocytes, 
Langerhans cells and fibroblasts (Whiteman, Pavan et al. 2011). The density of 
melanocytes also varies throughout the body. This is probably related to 
melanocyte dispersal due to the varying growth periods of different body parts 
during childhood (Whiteman, Pavan et al. 2011). In an embryo there is a similar 
amount of melanocytes migrated to the different parts of the embryo, but during 
childhood the density of melanocytes changes with growing body parts. The 
morphology and functional properties of the melanocytes varies in different 
anatomical sites, and they also vary even between skin structures like hair follicles, 
the interfollicular epidermis, sebaceous glands and the dermis (Whiteman, Pavan et 
al. 2011). These morphological and functional differences can have an effect on the 
amount of pigment formed, on the amount of melanocytes and on nevus 
formation (Whiteman, Pavan et al. 2011).  
About 70% of melanomas arise de novo (Pampena, Kyrgidis et al. 2017). Family 
history is a well-known risk factor for melanoma, and part of this can be attributed 
to genetics, especially with regard to high penetration mutations. However, some 
of the risk can also be due to common life habits (Olsen, Carroll et al. 2010), as 
approximately only 7% of melanomas arise due to genetic familial risk (Olsen, 
Carroll et al. 2010). 
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High penetration gene mutations that incur a risk to develop melanoma are 
involved in cell cycle control, melanocyte senescence, melanocyte differentiation, 
DNA repair, and telomerase maintenance (Aoude, Wadt et al. 2015, Cust, Mishra 
et al. 2018). Many high penetration gene mutations also increase the risk to other 
cancers (Aoude, Wadt et al. 2015). Low to medium penetration gene mutations and 
variants that incur a risk to develop melanoma are involved in pigment phenotypes, 
melanocyte differentiation, melanocyte development and cell cycle control (Cust, 
Mishra et al. 2018, Aoude, Wadt et al. 2015). Environmental factors can lead to the 
development of driver mutations, especially in individuals carrying risk mutations 
or variants for melanoma (Cust, Mishra et al. 2018). 
The main, currently recognised signalling pathways involved in melanoma 
development are the mitogen-activated protein kinase (MAPK), cell cycle, DNA 
damage response and cell death, PI3K/Akt and telomerase pathways (Cancer 
Genome Atlas Network 2015). Epigenetic factors are also recognised as being 
involved (Cancer Genome Atlas Network 2015). In molecular melanoma classes, 
BRAF, NRAS and NF1 mutations affect the MAPK pathway, either upstream or 
downstream (Cancer Genome Atlas Network 2015). Activated MAPK pathway 
leads to mitogenic activity, and thus affects cell survival and proliferation (Romano, 
Schwartz et al. 2011). In triple-wild-type melanoma, KIT mutations are currently 
the most common recognised mutation (Cancer Genome Atlas Network 2015). 
KIT is a type III transmembrane receptor tyrosine kinase which is activated by 
stem cell factors, and when activated, affects the MAPK (cell proliferation), 
PI3K/Akt (cell proliferation) and JAK-STAT (transcription signal transducer and 
activator) pathways (Cancer Genome Atlas Network 2015, Romano, Schwartz et al. 
2011). Certain driver mutations are associated with typical histopathology, such as 
the association of BRAF with SSM (Kraft, Granter 2014). For LMM, no such 
associations have been found yet. It is likely that there are still many major 
oncogenes to discover (Kraft, Granter 2014, Whiteman, Pavan et al. 2011, Cust, 
Mishra et al. 2018). 
In sporadic melanoma, 80% of mutations in genes encoding proteins of the 
MAPK signalling pathway are BRAF or NRAS mutations, and interestingly these 
mutations also associate with nevi (Kraft, Granter 2014). In melanomas of 
chronically sun-exposed skin, some LMMs carry mutations in KIT (25–28%), and 
some desmoplastic melanomas in NF1 (up to 93%) (Kraft, Granter 2014). 
Interestingly, melanomas with KIT-mutations typically have ill-defined borders akin 
to LM/LMM, mucosal and acral lentiginous melanomas (Whiteman, Pavan et al. 
2011). In UV-damaged skin, alterations in genes for the serine phosphatase PPP6C, 
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and for the Ras-related Rho family GTPase RAC1, could be the driver mutations 
(Kraft, Granter 2014). In melanomas of chronically sun-exposed skin there is often 
a UVR signature in the alterations (Kraft, Granter 2014, DeWane, Kelsey et al. 
2019). 
Histopathologically, there are two phases in melanoma development: the radial 
and vertical growth phase (Kraft, Granter 2014). In the radial phase, the tumour is 
limited to the epidermis as in situ melanoma or to the superficial dermis without 
mitotic activity. In the vertical phase, the tumour invades deeper structures, or 
there is mitotic activity in the invasive component (Kraft, Granter 2014). In the 
case of LMM, the timeline between the in situ and invasive form can be long, even 
years, thus allowing a possibility for early diagnosis in the radial phase, which is 
crucial to the prognosis, treatment and follow-up. 
2.2 Sectioning of the tissue specimens and tumour margin 
assessment 
The traditional histopathological technique to examine samples is called “bread-
loafing”, i.e. serial sectioning. Only about 1% of the slice margins are examined 
with this method (Boehringer, Adam et al. 2015, Trakatelli, Morton et al. 2014). 
Usually the sections are cut into 1–5 mm in length (Boehringer, Adam et al. 2015), 
and the slices are a few micrometers in thickness. 
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Figure 5.  Serial sectioning of the elliptical excision specimen and the possible error in the method, 
where subclinical extensions or invasive parts might exist between the vertical sections 
and thus are not examined. 
In 21.9% of BCC specimens, a positive surgical margin was found when the 
tissue processing was performed with serial sections, whereas a three-dimensional 
microscopy method resembling MMS with 100% margin control found a positive 
margin in 42.6% of BCC specimens (Boehringer, Adam et al. 2015). Thus, with a 
method of 100% margin control, subclinical extensions i.e. tumour extensions not 
visible to the human eye in clinical examination, are discovered twice as often when 
compared to traditional serial sectioning, and this applies especially for aggressive 
BCCs (Boehringer, Adam et al. 2015). 
The existence of subclinical extensions is also nicely emphasised by the relation 
of the surgical margin and the recurrence rate of BCC. For example, with a 2-mm 
surgical margin the risk for recurrence is 10 times as high when compared to a 5-
mm surgical margin (Gulleth, Goldberg et al. 2010).  
The probability of detecting positive surgical margins in melanoma in situ with 
serial sectioning of 1, 2, 4 or 10 mm intervals was correspondingly 58, 37, 19 or 7 
% (Kimyai-Asadi, Katz et al. 2007). To gain a 100 % margin control in melanoma 
in situ, the serial section would need to be cut with 0.1 mm intervals (Kimyai-Asadi, 
Katz et al. 2007). 
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2.3 Non-invasive optical imaging 
Non-invasive imaging technologies can reduce the burden of care for the patient 
and ease the treatment process of skin neoplasms and inflammatory skin diseases 
(Tkaczyk 2017). These techniques are based on the optical features of biological 
tissue. Developing these non-invasive optical imaging methods requires the 
collaboration of both engineers and clinicians (Tkaczyk 2017). 
In optical imaging, the escape of illuminated light from tissue is used for 
diagnostic purposes, in contrast to the therapeutic use of light, where the emitted 
light is absorbed into the tissue and the absorption energy plays a major role in the 
desired therapeutic effect (Jacques 2013). Biological tissue has optical scattering, 
refractive, absorption and anisotropic properties, and these properties are due to 
tissue chromophores. Coefficients and indices can be calculated for these optical 
parameters, which can then be used in optical imaging (Jacques 2013). The main 
chromophores in biological tissue are melanin, blood (hemoglobin), water, fat and 
yellow pigments (bilirubin and beta-carotene) (Jacques 2013). The proportions of 
the chromophores affect the average optical parameters of the tissue, such as the 
average scattering coefficient (Jacques 2013). The average optical tissue parameters 
can also vary depending on the wavelength of the imaging device (Jacques 2013). It 
should also be noted that in in vivo imaging, the tissue parameters vary between 
subjects, anatomical sites, the time of imaging, and all these even within the same 
individual (Jacques 2013).  
The most widely used technologies in optical imaging are dermoscopy, optical 
coherence tomography (OCT) and reflectance confocal microscopy (RCM). Out of 
these methods, RCM can replace the biopsy procedure in the diagnosis of skin 
lesions in certain situations (Tkaczyk 2017). Optical diagnosis can remarkably 
reduce biopsies of benign lesions (Tkaczyk 2017). Non-invasive imaging methods 
can also make a difference in distinguishing LM and LMM from each other. 
According to a recent review, there are currently eleven different optical 
technologies for dermatological optical imaging (Tkaczyk 2017). The research in 
the field is active. From the optical non-invasive techniques, dermoscopy is the 
only one which is familiar to most dermatologists (Tkaczyk 2017). RCM is familiar 
to few dermatologists at the moment, but could be used by all dermatologists who 
are able to invest in the training (Tkaczyk 2017). At the moment OCT is familiar 
for few academic dermatologists (Tkaczyk 2017). All optical imaging methods 
demand training for their interpretation, but RCM may be the method that requires 
the most extensive training when compared to dermoscopy and OCT. For all three 
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aforementioned technologies, there are commercial products available (Tkaczyk 
2017). Thus in theory, they are available to everyone, although the price of an RCM 
device is 100-times more expensive than a dermoscope, and OCT even more 
(Tkaczyk 2017). 
Any other optical technology is not yet as easy to apply in practice as 
dermoscopy, which is a hand-held, pocket-sized device. Thus, dermoscope is like 
the stethoscope of a dermatologist. RCM and OCT are large devices, which move 
on wheels, and the optical probe is attached to the machine. RCM and OCT can 
have a hand-held probe, but the large machine still needs to be attached to it. In 
dermoscopy, the processing and interpretation of the image is performed while 
using the device. In RCM and OCT, the images need to be processed with the 
technology before interpretation. In practice the imaging process is similar for non-
invasive imaging devices: an optical probe is attached to the skin, light is emitted, 
information is detected, the image is processed, and finally the image is interpreted. 
Figure 6 presents a schematic illustration of the devices. 
 
Figure 6.  Non-invasive imaging devices: dermoscope, OCT/RCM 
Hyperspectral imaging is a more novel imaging method, when compared to the 
dermoscope, RCM and OCT. Hyperspectral imaging is one form of spectral 
imaging, and as of yet there are no commercial devices available. In the field of 
spectral imaging, there are two commercial products for triaging pigmented lesions, 
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i.e. to recognize melanoma from other pigmented lesions. If the device gives 
reason to suspect melanoma, the diagnosis would be confirmed with a biopsy. 
These two devices are Melafind and SiaScope, which are multispectral imaging 
devices (Tkaczyk 2017). The sensitivity is 98.3% for Melafind, but the specificity is 
only 9.9% (Tkaczyk 2017). For SiaScope, the sensitivity is 80% with a specificity of 
76% (Tkaczyk 2017). With these accuracies, the multispectral devices have not 
gained wide popularity in clinical practice. Multispectral imaging utilises about ten 
different wavelengths of light for the imaging (Tkaczyk 2017). Our HIS device uses 
70 different wavelengths, and thus there is much more data from the different 
levels of the skin, when compared to multispectral imaging.   
Different modalities have differing strengths and limitations. Table 11 presents 
the advantages and disadvantages of dermoscopy, RCM, OCT and hyperspectral 
imaging. 
Table 11.  Comparison of features of dermoscopy, RCM, OCT and hyperspectral imaging. 
Information aquired and modified from (Tkaczyk 2017). 
Modality Strengths Limitations Prospects for future 
Dermoscopy 
Rapid skin cancer 
screening 
Good evidence for 
improving the sensitivity 
and specificity of the user 
Highly user- and training-
dependent  
Only horizontal images 
Mobile apps  
Possibility to computational 
analyses  
RCM 
Cellular level images  
Able to visualise dendrites 
on melanocytes 
Highest accuracy 
Only horizontal images  
Time consuming 
Depth penetration only to the 
papillary dermis i.e. 0.25 mm in 
depth 
Intraoperative use  
Combining to fluorescence 
techniques 
OCT 
Penetration depth to 
around 1 mm  
Possibility to image flow 
with Doppler or speckle 
variance  
Provides vertical images 
Diagnostic accuracy limited by 
lateral resolution - though 
fourier-domain OCT 
overcomes this, but with limited 
penetration depth to 0.2 mm 
Intraoperative use  
Possibilities to improve the lateral 
resolution of the technology 
Spectral 
imaging 
Mapping of chemical 
compounds throughout the 
imaging depth 
Penetration depth to 
around 2 mm 
Dependent on the used 
algorithm  
Only horizontal images  
Research needed to study the 
correlation of spectral properties 
to different diseases  
Possibility to development of 
hand-held cameras and 
connection to tablets 
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2.3.1 Dermoscopy in basal cell carcinoma  
Dermoscopy has previously been called epiluminescence microscopy. The 
fundamental technology in dermoscopy is the use of polarised and unpolarised 
light (Tkaczyk 2017). When the scattering of light from the skin surface is reduced 
by immersion oils or with polarisation of the light, the morphology of the skin and 
subsurface components of the epidermis and papillary dermis can be visualised 
(Que 2016). Dermoscopes have about a 10-time magnification of the image, which 
is obtained when the user views the light-source illuminated target tissue through a 
lens. Nowadays, the light source is often light emitting diodes (LEDs). 
Dermoscopy is an important aid to the clinical diagnosis by improving the 
accuracy compared to naked eye, and also enhancing clinical diagnosis on 
histopathological subtyping and aiding follow-up after non-surgical treatment of 
sBCC (Trakatelli, Morton et al. 2014, Lallas, Apalla et al. 2014, Lallas, Tzellos et al. 
2014, Apalla, Lallas et al. 2014, Reiter, Mimouni et al. 2019) (Table 12). 
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2.3.2 Reflectance confocal microscopy in basal cell carcinoma 
In confocal microscopy, the light source is a near-infrared laser light at 830 nm. 
The light is refracted to the target tissue through a lens with a dichroid mirror. The 
light is reflected back from the target tissue and emitted as fluorescence of the 
target tissue to the detector of the microscope through a pinhole filter. With the 
pinhole filter the light outside of the desired focal plane is blocked and thus a good 
lateral resolution is obtained. (Que2016) 
RCM provides a cellular level image on the horizontal plane that is comparable 
to histology. The main limitation of RCM is its limited imaging depth of only 200 
μm (Que 2016) and field of view (FOV) of 1x1mm, where mosaicking makes it 
possible to obtain 14 mm2 per minute (Kose, Cordova et al. 2014). With video-
mosaicking the FOV can be enlarged to 240–360 mm2 per minute (Kose, Cordova 
et al. 2014). 
In diagnosis of BCC in vivo, a Cochrane review concluded that RCM could be 
used to avoid diagnostic biopsies in lesions which clinically appear highly 
suspicious for BCC (Dinnes, Deeks et al. 2018b). The Cochrane review included 
studies where RCM was compared to traditional clinical diagnosis by visual 
inspection with or without a dermoscope. Meta-analyses of equivocal lesions 
pooled data from three studies, and found a 94% sensitivity and 95% specificity in 
detecting BCC for RCM, compared to 85% sensitivity and 92% specificity for 
dermoscopy (Dinnes, Deeks et al. 2018b). In meta-analyses of any suspicious 
lesion, data was pooled from four studies, and found a 76% sensitivity and 95% 
specificity in detecting BCC for RCM (Dinnes, Deeks et al. 2018b). In equivocal 
lesions, RCM was more sensitive but less specific than clinical diagnosis. In 
equivocal lesions, utilising RCM could risk the misdiagnosis of melanoma as BCC 
(Dinnes, Deeks et al. 2018b).  
RCM seems to be useful and have good correlation with histopathology in the 
subtyping of BCC in vivo and ex vivo.  The accuracy of the subtyping could be 
improved by combining RCM pre- and intraoperatively (Villarreal-Martinez, 
Bennassar et al. 2018). In vivo subtyping of BCC with RCM has a lower specificity 
than punch biopsy (38% vs 79%) (Kadouch, Leeflang et al. 2017). 
In intraoperative ex vivo diagnosis of BCC between the MMS stages, RCM has 
an overall sensitivity of 88–99% and a specificity of 89–99% in the detection of 
BCC (Que 2016). In ex vivo RCM, dyeing with acridine orange improves the 
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accuracy. Furthermore, this dye does not disturb hematoxylin and eosin staining 
later on (Que 2016). The advantages of ex vivo diagnosis with RCM include saved 
time (RCM 5–7 min vs. frozen sections 20–45 min) and thus increased surgical 
efficiency compared to traditional frozen sections in MMS (Que 2016).  
RCM seems to be useful in the non-invasive follow-up after cryosurgery 
(Ahlgrimm-Siess, Horn et al. 2009), PDT (Venturini, Sala et al. 2013) and after or 
during vismodegib treatment (Couzan, Cinotti et al. 2018). In assessing 
methylaminolevulinate (MAL) -PDT outcome at three months, RCM recognised 
5/20 residual lesions compared to 2/20 by visual inspection and 3/20 by 
dermoscopy, where 1/3 were shown to be false positives by RCM (Venturini, Sala 
et al. 2013).  
2.3.3 Optical coherence tomography in basal cell carcinoma 
Conventional OCT provides vertical images and has an analogue with ultrasound, 
but instead of sound, a 1310 nm light wave is used. In OCT, the emitted light from 
the light source is divided in two with a beam splitter, where one is heading to the 
target tissue, and the other to a mirror. When the target tissue reflects the light 
back, only those bands which are coherent with the light reflecting back from the 
mirror are recorded with the detector. (Que 2016)  
With OCT, a better resolution is gained when compared to ultrasound (Que 
2016). The resolution of conventional OCT does not correlate with histology, but 
its imaging depth is up to 1.5 mm. In high-definition OCT, a resolution 
comparable to histology is possible to achieve, although at the cost of imaging 
depth: high-definition OCT reaches up to 570 µm in depth (Que 2016). In newer 
OCT devices, the properties of conventional and high-definition OCT are 
combined, and these devices are called frequency or Fourier-domain OCT (Reddy, 
Nguyen 2019). The frequency or Fourier-domain OCT also provides a horizontal 
plane in addition to the vertical image, which can offer more diagnostic 
information (von Braunmuhl, Hartmann et al. 2016). Dynamic OCT imaging also 
makes it possible to obtain en face images, especially of the vasculature of BCC, 
and this can help in the non-invasive subtyping of BCC (Themstrup, De Carvalho 
et al. 2018). It is also possible to discriminate the subtype of BCC with moderate 
accuracy from vertical slices of OCT (Holmes, von Braunmuhl et al. 2018). 3D 
visualisation is also possible with mathematical modeling in OCT with an image 
area sized 6x6x2mm (Verne, Magno et al. 2018).  
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In the diagnosis of BCC in vivo, a Cochrane review concluded that OCT could 
have a diagnostic role in clinically challenging lesions, but larger, more qualified and 
prospective trials are required. Additionally, the different imaging methods should 
be compared head-to-head (Ferrante di Ruffano, Dinnes et al. 2018). The meta-
analysis of the Cochrane review included two studies where OCT was compared to 
clinical evaluation by visual inspection with or without dermoscopy. In meta-
analyses the pooled sensitivity was 95% and specificity was 77% for conventional 
OCT compared to visual inspection alone, with sensitivity of 80% and specificity 
of 37%. The sensitivity rose to 86% and the specificity to 55% when visual 
inspection was aided with a dermoscope (Ferrante di Ruffano, Dinnes et al. 2018). 
In another systematic review on the in vivo performance of OCT in the diagnosis of 
BCC, conventional OCT had a sensitivity of 77.3% and a specificity of 57.5% 
compared to Fourier-domain OCT, which had a sensitivity of 93.7% and a 
specificity of 61.4% (Reddy, Nguyen 2019).  
Intraoperatively, in MMS conventional OCT does not perform well in ex vivo 
diagnosis, with a sensitivity of only 19% and a specificity of 56% (Que 2016). With 
newer frequency/Fourier-domain OCT, the performance in ex vivo diagnosis of 
BCC on MMS slices improves, reaching a 81.2% sensitivity and a 94.3% specificity 
(Rashed, Shah et al. 2017). 
OCT seems to be useful in the follow-up of non-invasively treated BCCs. In 
MAL-PDT-treated BCCs, OCT revealed a residual lesion in 7/18 cases, when 
residual lesions were clinically suspected in 5/18 cases three months after 
treatment (Themstrup, Banzhaf et al. 2014).  
2.3.4 Impact of non-invasive technologies on delineation of basal cell 
carcinoma 
Subclinical extensions in BCC can be a clinical problem, as 32–39% conventional 
excisions are re-excised (Cakir, Adamson et al. 2012), and in MMS, the subclinical 
extension can lead to additional stages (Que 2016).  
In the preoperative delineation of aggressive BCCs, dermoscopy has not 
reduced the stages of MMS (Que 2016). In MMS, the preoperative delineation of 
BCC by RCM reveals a subclinical extension outside of the dermoscopic margin in 
3/10 BCCs (Venturini, Gualdi et al. 2016). OCT delineates the margin as 1.4 +/- 
1.3 mm smaller than by clinical assessment in cases where one MMS stage was 
needed. In 100% of cases where more than one stage was needed, OCT recognised 
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the subclinical extension (Wang, Meekings et al. 2013). In another study, where 
OCT-delineated margins were compared to the margins assessed by the MMS 
surgeon, OCT recognised the subclinical extension in all cases where more than 
one MMS stage was required. However, there were 2/13 false positive cases by 
OCT (Tankam, Soh et al. 2019).  
In the assessment of the margin depth in combined RCM and OCT, a good 
correlation was found compared to the depth measurements in histopathology 
when dividing the lesions to shallow (depth<500 μm) and deep (depth>500 μm) 
(Sahu, Yelamos et al. 2018). In the evaluation of the depth in BCC, high-frequency 
ultrasound had a moderate correlation with histopathology, but low correlation 
with the width of the diameter (Nassiri-Kashani, Sadr et al. 2013). MMS stages 
were not reduced compared to the clinical evaluation when preoperatively assessing 
tumour margins with high-frequency ultrasound (Marmur, Berkowitz et al. 2010). 
2.3.5 Wood’s light in lentigo maligna and lentigo maligna melanoma 
The Wood lamp uses light with relatively short wavelengths from 320 to 400 nm. 
With these wavelengths, mainly dermal collagen and porphyrins absorb the energy 
and emit fluorescence, which can be detected. The Wood lamp is an old diagnostic 
tool used in several indications like pigmented lesions, porphyrias, bacterial 
infections and fungal infections. (Ponka and Badder 2012) 
Dermoscopy outperforms the Wood lamp in the delineation of LM (Robinson 
2004), as does hyperspectral imaging (Neittaanmaki-Perttu, Gronroos et al. 2015). 
2.3.6 Dermoscopy in lentigo maligna and lentigo maligna melanoma 
In the diagnosis of skin cancers, especially of pigmented lesions, dermoscopy 
improves the sensitivity and decreases the number of biopsies of benign lesions 
(Yelamos, Braun et al. 2019). In a Cochrane review and meta-analysis on the 
accuracy of dermoscopy in the diagnosis of MM in adults, the in-person sensitivity 
was 16 % better for dermoscopy with visual inspection versus visual inspection 
alone, and specificity was 20% better in a corresponding comparison (Dinnes, 
Deeks et al. 2018a). There are well-known features typical for melanoma in the 
dermoscopic criteria, and certain features associate with chronically sun-exposed 
skin, typically in the head and neck area (Jaimes, Marghoob 2013). These criteria 
for sun-exposed skin are typical for LM/LMM, and dermoscopy is particularly 
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useful in distinguishing LM/LMM from other macular lesions (Jaimes, Marghoob 
2013, Tschandl, Kittler et al. 2015) (Table 13). Extrafacial LM/LMM can differ 
from LM/LMM with a facial location, but they do share some common features 
(Gamo-Villegas, Pampin-Franco et al. 2019). In extrafacial LM, the most common 
features are erased areas, blue-grey regression and geometrical structures (Gamo-
Villegas, Pampin-Franco et al. 2019) 
Table 13.  Dermoscopic criteria in the distinction of facial solar lentigo/ thin seborrheic keratoses 
versus LM/LMM, information acquired and modified from (Lallas, Argenziano et al. 
2014). 
Solar lentigo/thin seborrheic 
keratoses 
LM/LMM 
Light brown fingerprint areas Asymmetric pigmented follicular opening 
Yellow opaque areas Dark rhomboidal structures 
Milia-like cysts Slate-grey globules 
Moth-eaten border Slate-grey dots 
Sharp demarcation   
Elongated brown circles 
 
When all criteria from Table 13 for LM/LMM on the face are present, the 
sensitivity is 89% and specificity 96% in predicting the lesion to be LM/LMM 
(Lallas, Argenziano et al. 2014). In flat, pigmented facial lesions, a pattern of circles 
heightens the suspicion for LM/LMM. Furthermore, any grey color, regardless of 
the pattern, is suspicious for a malignancy (Tschandl, Kittler et al. 2015). Certain 
dermoscopic criteria associate with a facial location. For example, asymmetrical 
pigmented follicular openings are more common on the nose and lower part of the 
face, and rhomboidal structures are more common on the upper part of the face 
than in other locations. Grey colouration is associated with all parts of the face 
(Tiodorovic-Zivkovic, Argenziano et al. 2015). In dermoscopy, a target-like pattern 
and a circle within a circle are more commonly seen in males than in females 
(Tiodorovic-Zivkovic, Argenziano et al. 2015). 
The deeper the dark brown, grey or blue colors, and the more structureless 
areas between follicles are present with scar-like and milky-red areas, the more 
probable it is that LM has progressed into LMM (Lallas, Argenziano et al. 2014). 
However, there are no dermoscopic criteria for a reliable distinction. Dermoscopy 
does offer a valuable tool for choosing a representative biopsy site for a 
histopathological LM/LMM diagnosis (Mataca, Migaldi et al. 2018).  
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2.3.7 Reflectance confocal microscopy in melanoma, lentigo maligna and 
lentigo maligna melanoma 
A Cochrane review found that if a Pellicani’s RCM was used in the diagnosis of 
MM, the pooled sensitivity was 92% and specificity 72% (Dinnes, Deeks et al. 
2018c). In the recognition of MM in any suspicious lesion, if sensitivity would 
assumed to be fixed at 90%, the specificity would be 82% for RCM compared to 
the 42% of dermoscopy, and in the recognition of MM in equivocal lesions 
sensitivity and specificity would be 86% and 49% correspondingly (Dinnes, Deeks 
et al. 2018c). However, in a head-to-head trial comparing RCM and dermoscopy in 
the diagnosis of LM/LMM, RCM had a sensitivity of 80% and a specificity of 81% 
compared to dermoscopy, which had a 61% sensitivity and a 92% specificity 
(Cinotti, Labeille et al. 2018). RCM is especially useful in the diagnosis of 
hypomelanotic and recurrent LM/LMM (Cinotti, Labeille et al. 2018). The clinical 
indication for using RCM in the recognition of melanoma is a lesion on chronically 
sun-damaged skin in the head and neck area, which shows regression in 
dermoscopy (Borsari, Pampena et al. 2016). RCM should be considered as an add-
on examination to dermoscopy in the diagnosis of MM, thus improving the 
accuracy in the diagnosis of MM (Edwards, Osei-Assibey et al. 2017). RCM is 
especially useful in the differential diagnosis of flat and pigmented macules on the 
face (Farnetani, Manfredini et al. 2019). There are also some RCM features, which 
could help distinguish desmoplastic MM, the other melanoma type of chronically 
sun-exposed skin, from melanoma in situ (Maher, Solinas et al. 2017). 
In the in vivo delineation of LM/LMM, RCM recognised a positive margin in 
55/60 cases compared to 21/60 cases for dermoscopy, and the dermoscopic 
dimensions of the lesion were 60% smaller than those defined by RCM (Edwards, 
Osei-Assibey et al. 2017). The dimensions defined by video-mosaic-RCM 
correlated well with the surgical defect of LM/LMM (Farnetani, Manfredini et al. 
2019). When comparing dermoscopically assisted clinical margin assessment of 
LM/LMM to hand-held RCM technology, the accuracy of clinical assessment was 
26%, and 91% for hand-held RCM, when the true margins were confirmed in 
histopathology (Farnetani, Manfredini et al. 2019).  
In ex vivo use, RCM seems to have good correlation with histopathology in 
measuring the thickness of MM when the larger area is first scanned, and 
measurements performed thereafter (Hartmann, Krammer et al. 2016).  
Both dermoscopy and RCM can guide the clinician in obtaining a 
representative, presurgical biopsy of LM/LMM to confirm the diagnosis, and help 
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in planning the surgery. However, RCM has better sensitivity for more robust 
histopathological criteria for the diagnosis (Mataca, Migaldi et al. 2018).  
RCM could also be useful in the follow-up of non-surgical treatment of LM. 
After treating LM with imiquimod, RCM recognised 70% of the responders, with 
no false negative cases compared to histopathological clearance (Alarcon, Carrera 
et al. 2014). 
2.3.8 Optical coherence tomography in melanoma, lentigo maligna and 
lentigo maligna melanoma 
A Cochrane review concluded that the data is too limited to make pooled analyses 
and conclusions on the performance of OCT in detecting MM (Ruffano 2018). A 
descriptive review on OCT in melanoma concluded that the performance of newer 
OCT devices is better than conventional OCT, and that OCT seems to be useful in 
the visualisation of MM (Rajabi-Estarabadi 2019). For high-definition OCT, a 
sensitivity of 74.1% and a specificity of 92.4% was reported (Rajabi-Estarabadi 
2019). In another systematic review for high-definition OCT, the pooled sensitivity 
was 81% and specificity 93.8%, although only two studies were included in the 
meta-analysis. Thus, some melanomas can be missed with OCT (Yi-Quan 2018). 
Interestingly, in a small study OCT showed potential in separating invasive 
melanomas from in situ ones and from benign nevi, when only pigmented lesions 
were compared to each other (Moares Pinto Blumetti 2015). 
In ex vivo use, the performance of frequency-domain OCT was lower for 
melanocytic lesions compared to KCs (Jerjes, Hamdoon et al. 2019). In detecting 
LM ex vivo with frequency-domain OCT, the sensitivity was 55% and specificity 
89.5%, and correspondingly for MM 43.8% and 76.2% (Jerjes, Hamdoon et al. 
2019). The diagnostic accuracy of OCT for BCC is good, but in detecting 
melanoma the performance of OCT is insufficient. Thus OCT should be used with 
caution especially in pink, equivocal amelanotic or hypomelanotic lesions (Maher, 
Blumetti et al. 2017). 
In assessing the thickness of melanocytic skin lesions, conventional OCT had a 
stronger correlation with histopathology than high-frequency ultrasound, although 
both techniques seemed to overestimate the depth (Hinz, Ehler et al. 2011). 
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2.3.9 Hyperspectral imaging in melanoma, lentigo maligna and lentigo 
maligna melanoma 
Hyperspectral imaging is a form of spectral imaging and is based on the wide range 
of electromagnetic radiation. In hyperspectral imaging, wavelengths from UVR 
from visible light to near infrared can be used. In hyperspectral imaging, the light is 
emitted, and the diffuse reflectance spectra is recorded. The diffuse reflectance 
spectra include the back-reflected light, as well as fluorescent and scattered light 
from the light source when it has interfered with the target tissue. The composition 
of tissue chromophores varies in different tissues, and between the healthy and 
diseased tissues. Thus, the diffuse reflectance spectra also differ similarly. For 
example, haemoglobin is a main tissue chromophore, and in neoplastic tissue, 
angiogenesis and hypermetabolism are hallmarks of a cancer, and thus the 
composition of oxygenated, and deoxygenated haemoglobin differs between 
healthy and neoplastic tissue. Thus, hyperspectral imaging makes it possible to 
non-invasively obtain information about the tissue composition. There is a third 
dimension in hyperspectral imaging which contains the information from the 
diffuse reflectance spectra when compared to ordinary two-dimensional 
photographs obtained with visible light. Thus, hyperspectral imaging combines the 
spatial information of ordinary photography with spectroscopy. (Lu and Fei 2014) 
The procedure of imaging is similar to the aforementioned non-invasive optical 
imaging techniques.  
Nagaoka et al. introduced a discrimination index to distinguish melanoma from 
other pigmented skin lesions based on hyperspectral imaging (Nagaoka, Kiyohara 
et al. 2015). Their method achieved a 96% sensitivity and a 87% specificity in 
detecting melanoma (Nagaoka, Kiyohara et al. 2015). 
In assessing the margins of LM/LMM, Neittaanmäki-Perttu et al. have shown 
that hyperspectrally defined borders corresponded to the histopathology in 94.7% 
of cases, and the hyperspectral imaging system (HIS) delineated the lesions more 
accurately in 52.6% of the cases compared to the clinical evaluation utilising a 
Wood’s light (Neittaanmaki-Perttu, Gronroos et al. 2015). 
Hyperspectral imaging has also been studied on pathological slices to enhance 
the diagnostics in histopathology (Gaudi, Meyer et al. 2014, Dicker, Lerner et al. 
2006). 
In one study by Dicker et al., hyperspectral imaging was studied in the follow-
up of RAF inhibitor treatment, and it seemed that the hyperspectral graph from a 
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biopsy of proven melanomas differed before and after the RAF inhibitor treatment 
(Dicker, Kahn et al. 2011). 
2.3.10 Comparison of non-invasive technologies in recognizing cutaneous 
malignant melanoma 
There are few head-to-head trials that test different technologies for their ability to 
recognize MM.  Most comparisons are made to dermoscopy and not to another 
new technology. In one cross-sectional study, the performance of a multispectral 
device (Melafind®) was compared to RCM (VivaScope 1500®) in detecting 
melanoma, and RCM outperformed multispectral imaging with a sensitivity of 
85.7% vs 71.4% and a specificity of 66.7% vs 25% (Song, Grant-Kels et al. 2016). 
The different technologies can also be divided into subgroups based on where 
they can be applied (Fink, Haenssle 2017). There are technologies for large-scale 
screening purposes (dermoscopy); for the assessment of a few preselected lesions, 
where some of the devices guide the user (multispectral imaging, electrical 
impedance spectroscopy, Raman spectroscopy); for the assessment of preselected 
lesions in specialised clinics with devices requiring expertise (RCM, multiphoton 
tomography) (Fink, Haenssle 2017). In addition to optical devices, there is a device 
called Nevisense®, which utilises electrical impedance to detect melanoma (Fink, 
Haenssle 2017). Table 14 compiles different technologies for detecting melanoma, 
but it should be noted that the information is gathered from different studies, and 
thus populations and study criteria vary. Table 14 should thus be considered as 
only indicative. 
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An interesting option to improve non-invasive imaging technologies is the 
combination of different technologies. There are studies combining OCT with 
RCM (Sahu, Yelamos et al. 2018), OCT with Raman spectrometry (Mazurenka, 
Behrendt et al. 2017), OCT with photoacoustic tomography (Zhou, Chen et al. 
2017), and even three technologies to multimodal systems (Varkentin, Mazurenka 
et al. 2018). It seems that it might be possible to overcome the shortcomings of 
one technology with another one. 
2.4 Treatment with surgery 
2.4.1  Surgery of basal cell carcinoma 
Surgery is the treatment of choice for BCC, but in selected low-risk cases the non-
surgical treatments could be the choice instead (Trakatelli, Morton et al. 2014). For 
surgical excision the five-year recurrence rate varies between 2-8% for primaries, 
but for recurrent lesions the five-year rate varies between 12-17% (Trakatelli, 
Morton et al. 2014). The location, size and histological type define the width of the 
surgical margin with the goal of minimising the removal of healthy tissue while not 
compromising the cure rate (Trakatelli, Morton et al. 2014).  
With a 2, 3, 4 and 5 mm surgical margin in excision, negative histological 
margins were achieved in 82, 85, 85 and 85% of the cases, respectively, but having 
a different risk for recurrence respectively at 3.96, 2.56, 1.62 and 0.39 %, compared 
to a 27% rate of risk for recurrence with a positive surgical margin (Gulleth, 
Goldberg et al. 2010). However, the risk for recurrence is higher than 27% for 
aggressive types of BCC, and with recurrent lesions the risk for a new recurrence 
with a positive margin is over 50% (Trakatelli, Morton et al. 2014).  
It should be noted that about 33% of recurrences appear during the first year, 
50% between two and five years, and up to 18% even later (Trakatelli, Morton et 
al. 2014). In a study with a 10-year follow-up of aggressive high-risk BCCs treated 
with excision or MMS, the recurrence occurred in 56% of primaries after 5 years 
(van Loo, Mosterd et al. 2014). 
For recurrent lesions and high-risk tumours, especially in the mid-face, MMS is 
recommended with 100% margin control and minimal removal of healthy tissue 
(Trakatelli, Morton et al. 2014). The 3–5 year cure rates for MMS vary between 97-
99% for primaries, and between 93-98% for recurrent lesions (Trakatelli, Morton 
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et al. 2014). In selected cases, MMS could be a cost-effective option compared to 
traditional excision (Trakatelli, Morton et al. 2014, Mosterd, Krekels et al. 2008, 
Tolkachjov, Brodland et al. 2017). MMS is recommended for facial recurrent 
BCCs, and for primary BCCs with a diameter over 1 cm and a location in the H-
zone. MMS could be used for SCC with similar indications (Murray, 
Sivajohanathan et al. 2019a). However, in complex situations like Gorlin syndrome, 
multiple KCs on the face, immunosuppressed patients and lesions in functionally 
and cosmetically important locations, MMS could only be used in tumours with a 
diameter less than 1 cm (Murray, Sivajohanathan et al. 2019a, Murray, 
Sivajohanathan et al. 2019b).  
In a head-to-head trial on the treatment of aggressive high-risk BCCs with a 10-
year follow-up, the cumulative recurrence rate for primaries was 4.4% for MMS 
and 12.2% for excision, and for recurrent ones 3.9% and 13.5% respectively (van 
Loo, Mosterd et al. 2014). In a study from Sweden, the five-year recurrence rate for 
aggressive and recurrent, i.e. high-risk, facial BCCs was 2.1% for primaries and 
5.2% for recurrent ones, and the defect after MMS was approximately twice as 
large as the defect would have been if the lesion had been removed on the visible 
border with 2 or 3 mm surgical margins (Paoli, Daryoni et al. 2011). Thus, the 
subclinical extensions of aggressive BCCs are a true challenge in the treatment of 
high-risk BCCs. 
2.4.2 Surgery of lentigo maligna and lentigo maligna melanoma 
For the treatment of LMM, surgery is the treatment of choice with a 1 cm excision 
margin for Breslow thickness ≤ 1 mm, and with a 2 cm excision margin for 
Breslow thickness > 1mm (Garbe, Peris et al. 2016, Wright, Souter et al. 2019, 
Swetter, Tsao et al. 2019). Generally, the surgery is the treatment of choice also for 
LM with an excision margin of 0.5–1 cm (Garbe, Peris et al. 2016, Wright, Souter 
et al. 2019, Swetter, Tsao et al. 2019). 
MMS is an option in the surgery of LM (Garbe, Peris et al. 2016, Swetter, Tsao 
et al. 2019), but in a recent Canadian systematic review and guideline on the 
indications for MMS, it was concluded that in the treatment of invasive melanoma 
or melanoma in situ, MMS does not show any survival or recurrence benefit over 
traditional surgical excision (Murray, Sivajohanathan et al. 2019b, Murray, 
Sivajohanathan et al. 2019a). However, MMS is capable of sparing tissue, if needed.  
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2.5 Topical and non-surgical treatment of basal cell carcinoma 
and lentigo maligna 
Generally, all the non-surgical options in the treatment of BCC are recommended 
for low-risk BCCs, and in cases where surgery is contraindicated or impractical 
(Trakatelli, Morton et al. 2014, Work Group, Invited Reviewers et al. 2018).  
The non-surgical options in the treatment of LM should be considered only in 
selected cases, but for LMM, the treatment is always surgery (Swetter, Tsao et al. 
2019, Garbe, Peris et al. 2016).  
2.5.1 Cryosurgery 
In the treatment of BCC, the lesions may or may not be debulked with curettage 
prior to cryotherapy (Trakatelli, Morton et al. 2014). The lesion and margins are 
frozen with liquid nitrogen, with tissue temperature reaching -50 to -60 degrees 
Celsius, thus destroying the treated area. Usually, two freeze-thaw cycles are used in 
the case of BCC (Trakatelli, Morton et al. 2014). In the treatment of low risk BCC, 
the recurrence rates vary between 6.3% and 40%, but when performed by an 
expert, the recurrence rate may be as low as 1% (Trakatelli, Morton et al. 2014, 
Work Group, Invited Reviewers et al. 2018). Thus, the experience of the physician 
can have a remarkable impact on the treatment outcome. 
A systematic review on cryosurgery concluded that the efficacy of cryosurgery 
for primary sBCCs or nBCCs is comparable to PDT, with the five-year recurrence 
rates being 19.6% for cryosurgery with curettage, 20% for cryosurgery alone, 22% 
for MAL-PDT, in comparison to 8.4% for surgical excision (Tchanque-Fossuo, 
Eisen 2018). In the systematic review the expertise of the physician was not 
reported, thus both cryosurgery and PDT could have better outcomes in 
experienced hands. 
2.5.2 Imiquimod 
Imiquimod is a pharmacological topical treatment option for sBCC (Trakatelli, 
Morton et al. 2014). Imiquimod is an immune modulator, and it is an agonist for 
toll-like-receptors 7 and 8. Furthermore, it induces proinflammatory cytokines, 
chemokines and other mediators, and thus activates innate immunity with the Th1-
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weighted anti-tumoural cellular response. It also induces tumour suppression, and 
apoptosis at higher concentrations (Trakatelli, Morton et al. 2014).  
Some 58 to 92 % of patients treated with imiquimod have side effects including 
erosion, ulceration, induration, itching, burning and pain, and the severity of the 
local reaction is associated to the treatment outcome (Trakatelli, Morton et al. 
2014). In the treatment of sBCC, imiquimod is applied once a day for five days per 
week, from six to twelve weeks (Arits, Aimee H M M, Mosterd et al. 2013, 
Trakatelli, Morton et al. 2014). This regimen is approved in the EU and the USA 
for treating sBCC in adults with a normal immune response, a lesion diameter up 
to 2 cm and a location on the neck, trunk or extremities (excluding hands and feet) 
(Trakatelli, Morton et al. 2014). Imiquimod is a cost-effective option compared to 
surgery in the treatment of sBCC (Trakatelli, Morton et al. 2014) (Trakatelli 2014). 
However, patient compliance should be evaluated carefully in the choice of the 
treatment, as a majority of patients will get local adverse events, and this will 
continue for weeks. For PDT, the occurrence of serious local post-treatment 
reactions was lower compared to imiquimod, but pain was higher when compared 
to topical pharmacological treatments. However, in PDT the duration of the pain 
is shorter (Collier, Haylett et al. 2018).  
The efficacy of imiquimod at three months is 81%, and the probability of 
overall treatment success at five years is 77.6% for low-risk sBCCs, and for nBCCs 
sized from 0.5 to 1.5 cm in diameter on low-risk locations the efficacy at six weeks 
was 76% with a regimen of daily applications for twelve weeks (Trakatelli, Morton 
et al. 2014). Most of the recurrences seem to occur during the first year after 
treatment (Trakatelli, Morton et al. 2014). 
A single-blinded, non-inferiority, controlled, prospective and randomised trial 
by Jansen et al. compared MAL-PDT, 5-FU and imiquimod in the treatment of 
sBCC, where imiquimod achieved a 83.5% cumulative tumour-free probability at 
one year and 80.5% at five years (Jansen, Mosterd et al. 2018). 
In selected cases of LM, topical imiquimod can be used instead of surgery with 
a 75–88% complete response rate, but as a treatment method without histological 
control, it requires close follow-up (Garbe, Peris et al. 2016, Swetter, Tsao et al. 
2019) (Garbe 2016).  
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2.5.3 5-fluorouracil 
5-fluorouracil (5-FU) is another pharmacological topical treatment option, but is 
poorly studied for treating sBCC (Trakatelli, Morton et al. 2014). In the treatment 
of sBCC, 5-FU is applied twice daily for four weeks with similar local reactions as 
imiquimod (Arits, Aimee H M M, Mosterd et al. 2013). Regarding the mode of 
action, 5-FU inhibits DNA synthesis, cell proliferation and thus causes tumour 
necrosis (Arits, Aimee H M M, Mosterd et al. 2013).  
In the trial by Jansen et al. the cumulative tumour-free probability for 5-FU at 
one year was 80.1%, and at five years 70.0% (Jansen, Mosterd et al. 2018). 
2.5.4 Photodynamic therapy 
2.5.4.1 Mode of action and photobleaching 
A light source with a wavelength equal to the activation spectrum of 
protoporphyrin IX (PpIX), a photoactive compound, is required for the PDT 
reaction. In addition to the light source, PpIX and oxygen are needed. The PDT 
reaction generates radical oxygen species, which cause cell apoptosis and death 
(Morton, Szeimies et al. 2015, Ozog, Rkein et al. 2016, Fantini, Greco et al. 2008). 
PpIX is generated endogenously in the heme synthesis pathway (Ozog, Rkein et al. 
2016). Administration of an exogenous photosensitiser leads to the accumulation 
of PpIX (Ozog, Rkein et al. 2016). Accumulation and the concentration of PpIX 
can be measured as fluorescence of PpIX, and during the illumination phase the 
accumulated PpIX is consumed in the PDT reaction (Tyrrell, Campbell et al. 
2010b). Thus, photobleaching can be calculated as the difference of the measured 
fluorescence before and after illumination. Photobleaching does not take place in 
the reaction without oxygen (Ericson, Grapengiesser et al. 2003), and in order to 
increase efficacy, the amount of accumulated PpIX and especially the degree of 
photobleaching is essential (Tyrrell, Paterson et al. 2019). Validated fluorescence 
measurements correlate with the efficacy of PDT (Tyrrell, Campbell et al. 2010a, 
Tyrrell, Paterson et al. 2019). It has been suggested that the measurement of singlet 
oxygen luminescence could be a more precise predictor of PDT efficacy than 
measuring fluorescence alone, but fluorescence measurements are easier to 
implement in practice (Mallidi, Anbil et al. 2014). 
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PDT is selective for tumour tissue due to abnormal epithelium, which allows 
the photosensitiser to better penetrate into the tumour tissue than into healthy skin 
(Kennedy, Pottier et al. 1990). Additionally, the accumulation of PpIX or the 
generation of reactive oxygen species correlates positively with the cell’s 
proliferation rate or metabolic activity (Wang, Shi et al. 2017). Often, tumour cells 
under treatment are more active in their proliferation and metabolism compared to 
the healthy surrounding skin.  
In a study performed on normal rat skin, the rat skin with stratum corneum had 
lower PpIX levels when compared to mucosa. Removing the stratum corneum 
enhanced PpIX production, and increasing the concentration or lengthening the 
incubation time further enhanced PpIX production (van den Akker, J T., Iani et al. 
2000). The accumulation of PpIX increases linearly with the length of the 
incubation time (Campbell, Brown et al. 2017). The location of the lesion affects 
PpIX production, but gender, lesion type or skin type do not (Campbell, Brown et 
al. 2017). However, PpIX production does decline with age (Nissen, Philipsen et al. 
2015). Accumulation of PpIX happens faster in the face and head area compared 
to other body parts (Campbell, Brown et al. 2017). On acral skin, the accumulation 
and photobleaching is reduced when compared to non-acral skin, due to thicker 
stratum corneum on acral sites (Tyrrell, Morton et al. 2011). Additionally, the 
temperature affects PpIX production: in higher temperatures, PpIX production 
increases compared to lower ones (Moan, Berg et al. 1999). 
2.5.4.2 Photosensitisers and light sources 
5-aminolevulinic acid (5-ALA) is a natural precursor of PpIX in the heme synthesis 
pathway, and when 5-ALA or another prodrug is administered exogenously, there 
is an oversupply of 5-ALA (Ozog, Rkein et al. 2016). In the heme synthesis 
pathway 5-ALA is converted through some steps to PpIX, but the cell’s ability to 
turn PpIX into heme is exceeded when an exogenous source is provided (Ozog, 
Rkein et al. 2016). Thus PpIX is accumulated, and when light activates PpIX, 
radical oxygen species are released (Ozog, Rkein et al. 2016). 
PpIX has a wide and strong absorption peak from 405 nm to 415 nm, and 
several smaller absorption peaks from 500 nm to 635 nm (Ozog, Rkein et al. 2016). 
Traditional light sources that are used in PDT include red (635 nm) and blue light 
(417 nm). Additionally, daylight is a widely used option (Ozog, Rkein et al. 2016). 
A daylight-imitating coherent white light source is an alternative for natural 
daylight, and it is practical in low latitudes with less daylight in the dark seasons 
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(Marra, LaRochelle et al. 2018). Different kinds of lasers can also be used as a light 
source (Ozog, Rkein et al. 2016). The official recommendation for the illumination 
of BCC is with red light, and blue light and daylight are indicated for AK. 
However, it seems that in sBCC daylight can also achieve a good efficacy (Wiegell, 
Skodt et al. 2014).  
Long wavelengths penetrate deeper into the skin compared to shorter ones, 
thus blue light penetrates to about 2 mm in depth, but red light penetrates deeper 
(Ozog, Rkein et al. 2016). Blue light excites PpIX effectively when near the wide 
and strong absorption peak of PpIX, but red light is preferred due to its depth 
(Ozog, Rkein et al. 2016). The depths for different wavelengths are reported as the 
depth where 50% of the photons have penetrated, as it is unclear how deep the 
rest of the photons penetrate (Ozog, Rkein et al. 2016). With narrow band devices 
like LEDs the relative response to treatment is better when compared to 
broadband lamps (Morton, Szeimies et al. 2015). With LED light, the 
photobleaching was more profound through the different layers of the skin when 
compared to intense pulse light or long-pulsed dye laser (Togsverd-Bo, Idorn et al. 
2012). 
In the illumination phase of PDT, it is important to consider the fluence 
(J/cm2) and the irradiance (mW/cm2), which affect the energy of excitation and the 
achieved photobleaching (Ozog, Rkein et al. 2016). To gain a similar excitation of 
PpIX, blue light needs a 10 J/cm2 light dose compared to that of red light at 100 
J/cm2 (Ozog, Rkein et al. 2016). Irradiance is the rate of the fluence, and it should 
not be too high as high rates consume tissue oxygen too rapidly and lead to the 
depletion of oxygen, and lower efficacy (Ozog, Rkein et al. 2016). Irradiance is 
recommended to be between 150 and 200 mW/cm2, and cumulative doses above 
40 J/cm2 consume available oxygen and are thus unnecessary (Ozog, Rkein et al. 
2016). The efficacy of PDT in the treatment of sBCC using 5-ALA has been 
observed to be better when it is delivered with a fractionated protocol, in which 
there is time for tissue re-oxygenation, compared to continuous illumination. This 
improved efficacy has not held true when using MAL, or when treating Morbus 
Bowen (Morton, Szeimies et al. 2015). In a head-to-head trial, Kessler et al. 
compared conventional MAL-PDT (fluence 37 J/cm2, irradiance 75 mW/cm2) to 
fractionated 5-ALA-PDT (20+80 J/cm2 with a two-hour dark interval, irradiance 
50 mW/cm2), and they achieved a probability for remaining tumour-free at one 
year of 92.3% for fractionated 5-ALA-PDT, and of 83.4% for conventional MAL-
PDT. However, there was no statistical significance in the difference (Kessels, J P 
H M., Kreukels et al. 2018). 
 74 
In standard MAL-PDT, the oxygen consumption and photobleaching seem to 
take place mostly in the first minutes of illumination, and blood perfusion increases 
towards the end of illumination, which is most likely due to the microvasculature 
compensating for the used oxygen (Tyrrell, Thorn et al. 2011). Interestingly, in a 
very recent study by Todd et al., it was shown that by increasing the total dose to 
75 J/cm2 in the treatment of BCC or Bowen’s disease (carcinoma in situ), the 
efficacy was 90.3% at one year, compared to 67.7% efficacy with the 
recommended 37 J/cm2 light dose (Todd, Lesar et al. 2019). It seems that at a 
higher light dose, the PDT reaction happens more efficiently deeper in the tissue, 
when compared to lower light doses (Todd, Lesar et al. 2019). Thus, 
photobleaching might not be enough for evaluating the efficacy of the reaction, as 
the measured fluorescence and photobleaching describe the superficial layers of 
skin. Furthermore, there could be more available oxygen present deeper in the 
tissue, even it is depleted in the superficial layers (Todd, Lesar et al. 2019). 
5-ALA was used in a dermatological indication for the treatment of BCC for 
the first time in the 1990’s with a 90 % clearance rate (Ozog, Rkein et al. 2016, 
Kennedy, Pottier et al. 1990). Earlier intravenous photosensitisers were used with 
photosensitisation lasting for days, but with 5-ALA the effect resolves within 24 to 
50 hours, thus making the treatment feasible in clinical practice (Kennedy, Pottier 
et al. 1990, Ozog, Rkein et al. 2016). Lipophilic esters of 5-ALA can be more 
powerful than 5-ALA in PDT, as they penetrate the fatty, rate-limiting stratum 
corneum more efficiently than 5-ALA. However, the vector of choice must be 
considered in their use, as some aqueous features are also required in order for the 
photosensitiser to penetrate deeper into the skin. Furthermore, conversion back to 
5-ALA is also required for PpIX formation (Lopez, Lange et al. 2004). 
There are three currently approved photosensitisers in the European market 
using red light in their protocols: MAL-containing Metvix (indication for non-
hyperkeratotic AKs, Bowen’s disease, sBCC and nBCC), 5-ALA-containing patch 
Alacare (indication for mild AK, without pretreatment), and nanoemulsion of 5-
aminolevulinic acid (BF-200 ALA) Ameluz containing 5-ALA in nanoparticles 
(indication for mild to moderate AK and sBCC) (Morton, Szeimies et al. 2015, 
Morton, Dominicus et al. 2018). Additionally, in the USA 5-ALA-containing 
Levulan is approved with a blue light protocol for AKs (Morton, Szeimies et al. 
2015, Ozog, Rkein et al. 2016).  
MAL is more lipophilic and has a shorter incubation, i.e. occlusion time, 
compared to 5-ALA (Ozog, Rkein et al. 2016, Morton, Szeimies et al. 2015). 
Nanoemulsion of BF-200 has a similar incubation time as MAL (Morton, Szeimies 
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et al. 2015), but a deeper penetration and stronger fluorescence than MAL (Maisch, 
Santarelli et al. 2010). The nanoparticles improve the stability of 5-ALA 
(Hurlimann, Hanggi et al. 1998). 
Another lipophilic photosensitiser is hexylaminolevulinate (HAL), which is 
approved for the photodynamic diagnosis of bladder cancers in Europe. HAL was 
selected for this because of its high fluorescence at low concentrations and 
satisfactory water solubility compared to 5-ALA, which was previously also used in 
bladder cancer fluorescence diagnosis (Fotinos, Campo et al. 2006). HAL has been 
used in the treatment of cervical neoplasia (Hillemanns, Garcia et al. 2015) and 
bladder cancers (Bader, Stepp et al. 2013). 
On nude murine skin, equimolar doses of HAL produce more intense 
fluorescence and achieve a deeper penetration compared to MAL or 5-ALA 
(Morrow, McCarron et al. 2010). In the human epidermis and superficial dermis, 
the fluorescence of 20% HAL is significantly stronger compared to 20% MAL 
(Togsverd-Bo, Idorn et al. 2012). Additionally, on human skin low concentration 
HAL and 5-ALA (0.2% and 2%) induced a stronger fluorescence compared to 
MAL at similar concentrations (Juzeniene, Juzenas et al. 2006). Half of the maximal 
PpIX fluorescence is reached with 2% 5-ALA, with 1% HAL and with 8% MAL 
(Juzeniene, Juzenas et al. 2006). Using cream as a vector induces the best 
fluorescence for HAL and 5-ALA, but the advantage of HAL is its more defined 
effect on the site of application and less of an effect on surrounding healthy skin 
compared to 5-ALA (Casas, Perotti et al. 2001).  
Different photosensitisers can have a different accumulation of PpIX in the 
vascular walls during PDT, and thus vascular damage can occur during the 
treatment (Middelburg, de Vijlder et al. 2014). The effect was stronger for HAL, 
than for 5-ALA, and for MAL the damage did not differ from normal skin. Thus, 
the fractioning of illumination might have an effect for HAL and 5-ALA but not 
for MAL (Middelburg, de Vijlder et al. 2014).  
The current protocol with MAL-PDT (curettage + 3 hours occlusion + 
illumination with Aktilite) seems to allow for a sufficient accumulation and 
photobleaching of PpIX in all indications (AKs, Morbus Bowen and BCC) 
regardless of patient age, gender and lesion size (Tyrrell, Campbell et al. 2011). 
2.5.4.3 Pretreatment and enhancing of photosensitiser’s penetration 
For sBCC, it is common practice to remove all scales and crusts as a pretreatment 
step to allow for the sufficient absorption and penetration of the photosensitiser. 
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In nBCC, pretreatment with curettage or a scalpel is recommended (Morton, 
Szeimies et al. 2015). In addition to curettage, there are multiple ways to enhance 
the penetration by chemical cleansers, tape-stripping, micro-needling and with 
ablative lasers (Morton, Szeimies et al. 2015, Ozog, Rkein et al. 2016). Regarding 
pre-handling, curettage is superior and enhances PpIX fluorescence significantly 
more when compared to a chemical pre-treatment (Nissen, Wiegell et al. 2016). 
When different pre-treatment modalities are compared, ablative fractional laser 
enhances PpIX fluorescence the most when compared to other options such as 
microdermabrasion, micro-needling, and curettage (Bay, Lerche et al. 2017). Bay et 
al. showed that the fluorescence of PpIX is stronger with more invasive pre-
treatment when compared to curettage. It should also be noted that after a certain 
threshold, the accumulation of PpIX does not improve the efficacy (Nissen, 
Heerfordt et al. 2017). The use of ablative fractional lasers enhances the 
accumulation of PpIX and increases the fluorescence and depth penetration (Haak, 
Christiansen et al. 2016, Haedersdal, Sakamoto et al. 2010). When nBCCs were 
treated with CO2-laser-assisted MAL-PDT compared to curettage as pre-
treatment, a better response rate and fluorescence was achieved in the laser group 
(Lippert, Smucler et al. 2013). 
2.5.4.4 Tolerability 
In PDT, post-treatment reactions usually include oedema, erythema, scaling and 
itching at the site of treatment (Morton, Szeimies et al. 2015, Ozog, Rkein et al. 
2016). More unusual, but possible local reactions include pustules, erosions and 
crusting, especially if treating thicker lesions (Morton, Szeimies et al. 2015). 
Uncommon reactions include hyperpigmentation, hypopigmentation and scarring, 
as usually the cosmetic outcome is good in PDT (Morton, Szeimies et al. 2015, 
Ozog, Rkein et al. 2016). Rare adverse events that are possible to encounter include 
contact allergy for the photosensitiser, urticaria, post-operative hypertension or 
localised bullous pemphigoid (Morton, Szeimies et al. 2015). Usually PDT is well 
tolerated with reasonable post-procedural local reactions. However, the pain during 
the illumination phase of the treatment can be intense (Morton, Szeimies et al. 
2015).  
Indeed, the main adverse event for PDT is pain, and a local reaction of some 
degree is common. Other adverse events are rare (Ibbotson, Wong et al. 2019, 
Morton, Szeimies et al. 2015, Wang, Shi et al. 2017). The exact mechanism of the 
pain is still unclear, but it is thought to be caused by the radical oxygen species, i.e. 
 77 
the same mediators that increase the efficacy (Wang, Shi et al. 2017). It is thought 
that either radical oxygen species activate nerve endings directly, or they are 
activated by inflammatory mediators released by the radical oxygen species (Wang, 
Shi et al. 2017). It has been suggested that nociceptive Aδ nerve fibers could 
initially deliver the pain in PDT, or that slow-acting C fibers could also play a role 
(Wang, Shi et al. 2017). GABA has an inhibitive effect on nociceptive neurons, and 
it seems that radical oxygen species can inhibit GABA-receptors, thus leading to a 
decrease in GABA activity and an increase in nociceptive signals (Wang, Shi et al. 
2017). 
The pain is typically unpredictable and individual (Wang, Shi et al. 2017). 
Typically, pain is more intense on well-innervated sites such as the face and scalp 
compared to other parts of the body. Pain intensity correlates positively with the 
size of the treatment area. Furthermore, the lesion type also affects the pain level, 
as BCC is less painful compared to AKs and Bowen’s disease (Wang, Shi et al. 
2017, Ang, Riaz et al. 2017). For AKs on the face and scalp the pain scores can be 
7.5/10 on the visual analogue scale (VAS) without analgesia, and for nonaggressive 
BCCs (superficial and thin nodular) the average pain score is 4.5/10 on a numerical 
scale from one to ten without analgesia (Morton, Szeimies et al. 2015, Morton, 
Dominicus et al. 2018). In noncancerous indications, the pain is even more severe, 
as the inflammatory diseases are metabolically active (Wang, Shi et al. 2017). There 
is no clear evidence that the pain would correlate with gender, age or Fitzpatrick 
skin type (Wang, Shi et al. 2017).  
The above-mentioned factors are not modifiable, but the protocol and 
treatment-related factors can be customized (Wang, Shi et al. 2017). There is some 
threshold where a sufficient amount of PpIX is accumulated sufficiently to increase 
efficacy, as excessive accumulation of PpIX leads to increased pain and erythema 
(Nissen, Heerfordt et al. 2017). There is no clear evidence that there would be 
differences in pain between the photosensitisers (Wang, Shi et al. 2017). However, 
in some studies, 5-ALA has caused more pain than MAL (Wang, Shi et al. 2017). 
When comparing pain levels in healthy human skin, at low concentrations of 0.2% 
and 2% HAL caused significantly less pain when compared to BF-200 ALA and 
MAL, and BF-200 ALA did not significantly differ from MAL (Neittaanmaki-
Perttu, Neittaanmaki et al. 2016). In erythema, only 0.2% HAL differed 
significantly when compared to BF-200 ALA and MAL, but no differences were 
found between 2% HAL, BF-200 ALA and MAL (Neittaanmaki-Perttu, 
Neittaanmaki et al. 2016).  
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For fluence rate and dose, a threshold limit probably exists under which the 
pain increases with rate and dose, and above the limit a plateau is reached (Wang, 
Shi et al. 2017). It has been suggested that the limit would be around 60 mW/cm2 
for the fluence rate, i.e. irradiance, and around 50 J/cm2 for dose, i.e. fluence 
(Wang, Shi et al. 2017). Thus, by modifying these parameters some control of pain 
can be achieved. For example, in daylight PDT the pain levels are clearly lower 
(Wang, Shi et al. 2017).  
Post-procedural pain can also be significant, as pain after PDT on wide areas on 
the face in the treatment of actinic damage was more severe than after facial 
surgery, which also included some wide facial operations (Dixon, Anderson et al. 
2015). 
2.5.4.5 Pain management 
Pain management can be divided into interventions on the PDT parameters and to 
interventions on pain during PDT (Ang, Riaz et al. 2017). 
Topically administered local anesthetics like Emla®, lidocaine hydrochlorine 
3%, Ampetop® (tetracaine 4%) or morphine gel have not increased the efficacy 
for pain management during illumination in double-blinded placebo-controlled 
trials (Wang, Shi et al. 2017).   
Nerve blocks using local anesthetics have good results in pain management, but 
this method is best suited for facial and scalp locations (Wang, Shi et al. 2017). In 
their study, Paoli et al. introduced nerve blocking in PDT by using trigeminal 
blocks for extensive facial AKs, and VAS decreased from 7.5/10 to 1.3/10: the 
change was -6.2 and significant (Paoli, Halldin et al. 2008). In several studies with 
nerve blocks on facial or scalp sites, the change in pain ranged from -4.2 to -6.3 
(Wang, Shi et al. 2017). Nerve blocking is also superior to cold air analgesia or oral 
analgesia (Wang, Shi et al. 2017). The limitation of the method is its requirement 
for expertise in the technique and limitation to certain sites (Wang, Shi et al. 2017). 
However, the most painful sites are covered with this technique. 
Nerves can also be blocked by subcutaneous infiltration anesthesia for pain 
control in PDT (Wang, Shi et al. 2017). The studies on this method are sparse. 
There is one study which used subcutaneous infusion-tumescent anesthesia, i.e. a 
continuous infusion during the illumination phase with ropivacaine and prilocaine, 
where the observed change in VAS was from 8 to 4.5 (Borelli, Herzinger et al. 
2007). In a case report, a similar method was used for a child with Gorlin 
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syndrome. Wide areas of BCC were treated on her back, and good pain 
management was gained without a loss in efficacy (Debu, Sleth et al. 2012). 
2.5.4.6 Efficacy and cosmetic outcome in basal cell carcinoma 
In a systematic review and meta-analysis on PDT of low-aggressive BCCs 
(including superficial and nodular subtypes), the pooled estimate for complete 
clearance rate was 86.4% (95% CI: 80.0–91.0%) for PDT compared to surgery with 
98.2% (95% CI: 95.5-99.3%) complete clearance rate (Wang, Xu et al. 2015). The 
recurrence rate at one year was 10.3% (95% CI 5.9-17.4%) for PDT and 0.6% 
(95% CI: 0.1-3.0%) for surgery, with a significant risk ratio of 12.42 (95% CI: 2.34–
66.02). However, no significant differences were observed when comparing PDT 
to cryosurgery with a risk ratio of 1.04 (95% CI: 0.46-2.39) or to pharmacological 
topical treatment (imiquimod and 5-FU) with a risk ratio of 1.67 (95% CI: 0.97-
2.85) (Wang, Xu et al. 2015). At five years, the recurrence rate was higher for PDT 
with a significant risk ratio of 6.27 (95% CI 2.21-17.75) compared to surgery, but 
no difference was observed when compared to cryosurgery with a risk ratio of 1.08 
(95% CI: 0.62-1.86) (Wang, Xu et al. 2015). In another systematic review on the 
treatment of sBCC, the pooled complete response rate at twelve weeks was 79% 
(95% CI 71-87%) for PDT and 86.2% (95% CI 82-90%) for imiquimod 
(Roozeboom, Arits, A H H M. et al. 2012).  
There is only one head-to-head trial in the treatment of superficial BCC which 
compares different non-invasive options (Jansen, Mosterd et al. 2018). This trial is 
of good quality, as it is a prospective, controlled, randomised and single-blinded 
trial with a large sample size. This trial was published after the aforementioned 
systematic review. In this trial, the efficacy for MAL-PDT was 62.7 (95% CI 55.3-
69.2), for 5-FU 70.0 (95% CI 62.9-76.0), and for imiquimod 80.5 (95% CI 74.0-
85.6) (Jansen, Mosterd et al. 2018). The hazard ratio for treatment failure was 0.48 
(95% CI: 0.32-0.71) when comparing imiquimod to MAL-PDT with a significant 
difference (p<0.001), and 0.74 (95% CI: 0.53-1.05) when comparing 5-FU to 
MAL-PDT with a non-significant difference (p=0.09) (Jansen, Mosterd et al. 2018).  
In the systematic review by Wang et al. the probability of a good to excellent 
cosmetic outcome was significantly higher for PDT, when comparing to surgery 
with a risk ratio of 1.87 (95% CI 1.54-2.26), or when comparing to cryosurgery 
with a risk ratio of 1.51 (95% CI 1.30-1.76), but a non-significant difference when 
comparing to pharmacological topical treatment with a risk ratio of 1.05 (95% CI 
0.91-1.21) (Wang, Xu et al. 2015).  
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In the trial by Jansen et al., pharmacological topical treatments were compared 
to MAL-PDT. Cosmetic outcome was superior in the MAL-PDT group with 
96.3% of patients having a good or excellent outcome as calculated in patients 
staying recurrence-free at five years, compared to 83.1% in imiquimod and 87% in 
5-FU groups. However, it should be noted that the efficacy is lower for MAL-
PDT, and 75% of the patients treated with surgery in the second line had a good or 
excellent cosmetic outcome (Jansen, Koekelkoren et al. 2018). 
In any case, the current evidence shows that imiquimod is superior to MAL-
PDT and 5-FU, and 5-FU is not inferior when compared to MAL-PDT in efficacy, 
and furthermore both pharmacological treatments have good cosmetic outcomes 
(Jansen, Koekelkoren et al. 2018, Jansen, Mosterd et al. 2018). Interestingly, MAL-
PDT could be more effective in elderly patients on the lower extremities 
(Roozeboom, Arits, Aimee H M M. et al. 2016). Thus, there is room for PDT as a 
non-invasive treatment option. 
A recent update on the PDT guideline by the British Association of 
Dermatologists concluded that PDT should be offered as an option in the 
treatment of sBCC in the following cases: when the site of the tumour is on a 
poorly healing site, in cosmetically sensitive areas, or when there are wide or 
multiple lesions (Wong, Morton et al. 2019). Furthermore, there are multiple 
parameters in PDT which can be adjusted, and thus it may be that the current 
protocols are suboptimal. Further research on fractionated PDT, and using higher 
light doses is required (Todd, Lesar et al. 2019, Collier, Haylett et al. 2018). 
2.5.4.7 Photodynamic therapy of lentigo maligna 
5-ALA, MAL and BF-200 ALA have been used as off-label indications for the 
experimental treatment of LM and amelanotic melanoma in situ (Chetty, Osborne 
et al. 2008, Karam, Simon et al. 2013, Rasanen, Neittaanmaki et al. 2019).  
Karam et al. retrospectively studied 5-ALA-PDT in the treatment of facial LM 
with higher light doses (average 60 J/cm2, compared to 37 J/cm2 in non-
pigmented lesions) and repeated sessions (from three to nine, compared to the 
usual two session in non-pigmented lesions). They observed clinical and 
histological healing in 12/15 lesions at a 10–29 month follow-up, and in 3/15 
lesions there was an instant treatment failure (Karam, Simon et al. 2013). 
Chetty et al. tried MAL-PDT for amelanotic melanoma in situ on the chin with a 
two-session treatment and a 40 J/cm2 light dose. At one month, the site was 
clinically showing some fine crusting and possible clearing, but at six months there 
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was a clinically suspected and histologically proven residual lesion outside of the 
originally treated area, which was clinically and histologically cleared. At ten 
months, a recurrence also appeared at the originally treated site (Chetty, Osborne 
et al. 2008). 
Rasanen et al. conducted a prospective, non-sponsored pilot study using 
ablative fractional laser-assisted PDT with BF-200 ALA in the treatment of facial 
LM, with three sessions and a 90 J/cm2 light dose. They achieved a 
histopathologically proven clearance in 7/10 cases. Pain was tolerable, ranging 
from 2.9 to 3.8 on the VAS, but some severe local adverse events occurred. It was 
concluded that due to the strong local reactions, PDT of LM should only be used 
in select, inoperable cases. (Rasanen, Neittaanmaki et al. 2019) 
2.5.5 Patients’ preferences and patient selection in treatment of basal cell 
carcinoma 
BCC is non-lethal but as it is often a chronic condition, it can have an impact on 
quality of life (Chen, Bertenthal et al. 2007, Chren, Sahay et al. 2007). Thus, 
patients’ preferences and quality of life should also be taken into account when 
considering treatment options (Essers, Arits et al. 2018, Martin, Schaarschmidt et 
al. 2016).  
In the topical treatment of sBCC, patients valuated different attributes in the 
following order: efficacy, cosmetic outcome, adverse events and treatment process 
(Essers, Arits et al. 2018). Interestingly, BCC patients with facial lesions or with 
multiple lesions were willing to risk the recurrence rate for cosmetic outcome 
(Martin, Schaarschmidt et al. 2016). 
For PDT, there are varying results in the efficacy, and the treatment protocol 
has many variables which can affect the outcome. The correct lesion and patient 
selection is essential when considering the outcome of a treatment, but for PDT, 
there is no clear factor at the individual level which would predict the treatment 
outcome (Hambly, Mansoor et al. 2017). 
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3 AIMS OF THE STUDY 
Skin cancers are a growing problem, and new options and innovations may ease 
the process and pressure on available resources. This dissertation was designed to 
test the feasibility of new, non-invasive options in the diagnosis and treatment of 
skin cancers, thereby contributing to a potentially more smooth and effective 
treatment process for skin cancer patients in the future.  
The specified aims were the following: 
 
1. To test the feasibility of a HIS in separating LM and LMM from each 
other. Additionally, to test the feasibility of the HIS in localising the 
invasion site. Separation of these two conditions is crucial for the 
prognosis, subsequent treatment and follow-up. 
2. To test the feasibility of a HIS in the delineation of ill-defined BBCs, which 
often exist in subclinical extensions, and thus pose a true clinical challenge. 
3. To study the efficacy, cosmetic outcome and adverse events of two novel 
photosensitisers, BF-200 ALA and HAL, compared to the older and widely 
used MAL in a non-sponsored, prospective, controlled, randomised and 
double-blinded trial. 
4. To test the feasibility of a fluorescence imaging system, which is easy to 
build up with simple equipment: a digital camera and Woods light, which 
are usually part of basic dermatological clinic equipment, and a yellow lens. 
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4 MATERIALS AND METHODS 
4.1 Study design 
4.1.1 Study I and II: Pilot studies 
The two pilot studies were designed to investigate the feasibility of a HIS in the 
preoperative assessment of skin cancers. In the two non-invasive imaging pilot 
studies, the lesions were assessed clinically and dermoscopically followed by 
preoperative hyperspectral imaging. Results were confirmed with histopathology. 
An experienced dermatopathologist assessed the specimens blinded to the HIS 
findings. 
4.1.2 Study III: Clinical trial 
The clinical trial was an investigator-initiated, prospective, randomised, double-
blinded and controlled trial designed to evaluate the efficacy, adverse events and 
cosmetic outcome of three different photosensitisers in PDT of non-aggressive 
BCCs. The patient and observers of outcomes were blinded regarding the 
photosensitiser that was used.  
The primary outcome of study III is the clearance of histologically verified 
lesions at the three-month follow-up visit. Non-responsive lesions were excised to 
see if aggressive growth patterns were present. A major secondary outcome 
included tolerability: pain during illumination with a long-acting local anaesthetic as 
pain management, and post-treatment reactions. Other secondary outcomes 
included cosmetic outcome, fluorescence at the beginning of illumination, and 
photobleaching, i.e. the difference in fluorescence measured in the beginning and 
end of illumination. 
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4.1.3 Sample size of the studies 
For studies I and II, it was not possible to calculate a sample size for the trials as 
they were pilot studies. We estimated that around 20–30 lesions in each study 
would be a sufficient sample size to test the feasibility. 
For study III, the power of the study was calculated to be 31 lesions per study 
arm, and this initial set was randomised with a web-based validated program called 
Research Randomizer (randomizer.org®). To account for error in clinical diagnosis 
at enrolment and for those patients lost in follow-up, a 25% buffer was added to 
the sample size. Thus, an additional set of 24 lesions were randomised with closed 
envelopes, due to problems with the use of Research Randomizer at the time. 
Thus, we ended up with 117 randomised lesions for the trial: 39 lesions per study 
arm. 
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4.1.4 Ethical aspects and approvals by authorities 
In studies I and II on hyperspectral imaging, the Declaration of Helsinki was 
followed, and protocols were approved by the Ethics committee of Tampere 
University Hospital and by Valvira (National Supervisory Authority for Welfare 
and Health). All participants were informed of the study procedures both orally 
and in writing, and they gave their written consent. 
Study III, the clinical trial, was approved by the Ethics committee of Tampere 
University Hospital and by Fimea (Finnish Medicines Agency), and it abided by the 
Declaration of Helsinki. All participants were informed orally and in writing, and 
they provided their written consent. 
4.2 Patients 
All patients were recruited from those referred to the Department of Dermatology 
and Allergology at the Päijät-Häme Social and Health Care Group in Lahti, 
Finland. In study I the patients were recruited between January 2012 and January 
2015; in study II between March 2014 and March 2017; and in study III between 
March 2015 and September 2018.  
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Table 15.  Patient and lesion characteristics. 
 Study I Study II Study III   
   MAL BF-200 ALA HAL 
Number of patients 31 16 27 26 24 
with single lesion 30 16 14 8 5 
with multiple lesions 1 0 13 18 19 
Female 16 7 10 5 12 
Male 15 9 17 21 12 
Average age in years (range) 77 (56-97) 77 (59-91) 71 (47-91)  74 (51-91) 74 (57-91) 
Skin phototype      
I 4 5 6 4 7 
II 17 9 10 13 8 
III 10 2 11 9 9 
IV 0 0 0 0 0 
Immunosuppression, cytostatics or 
radiotherapy on study area in history 0 1 2 1 2 
History of previous skin (pre)malignancies  
(AK, MB, SCC, BCC, MM) 15 13 19 20 19 
      
Number of lesions 32 16 31 33 31 
Average size in mm2 (range) - - 
439 (150-
1100) 
377 (130-
850) 
376 (160-
750) 
new 31 16 30 30 29 
recurrent 1 excluded 1 3 2 
Location on trunk LMM 1/LM 2 excluded 25 26 25 
Location on extremities LMM 1/LM 0 excluded 6 7 6 
Location on head and neck LMM 8/LM 20 16 excluded excluded excluded 
4.2.1 Inclusion and exclusion criteria 
In study I, patients aged over 18 with clinically and dermoscopically suspected, and 
histopathologically verified, LM or LMM in any location were included. In study II, 
patients aged over 18 with clinically and dermoscopically suspected, and 
histopathologically verified, ill-defined primary BCCs in the head and neck area 
were included. 
In study III, patients aged over 18 with clinically and dermoscopically assessed, 
mainly superficially growing BCCs on the trunk or extremities were included at 
enrolment. Multiple lesions on one patient were allowed, but they were required to 
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be 10 cm apart from each other to avoid mixing up the effect of different 
photosensitisers. It should also be noted that the lesions were randomised, not the 
patients. All diagnoses were confirmed with 3-mm punch biopsies. Histopathology 
excluded lesions other than BCC, i.e. aggressive types of BCC and thick nBCC, in 
which the bottom of the tumour reaches in to the middle third of the dermis, or 
deeper. Thus, in histopathology, only superficial and thin nodular BCCs, i.e. the 
bottom of the tumour reaching into the epidermal junction or into the uppermost 
third of the dermis, were included and defined as non-aggressive BCCs. 
In all studies, special groups such as children and pregnant or breastfeeding 
women were excluded. Study III also excluded patients with an intolerance or 
allergy to the used photosensitiser, porphyria or light-sensitivity. Study III required 
patients to be able to complete VAS pain scores by themselves, thus it was not 
possible to include patients with a memory illness or with some other diseases 
affecting their ability to understand instructions on pain scores. 
4.3 Hyperspectral imaging 
For study I and II, a handheld hyperspectral camera prototype with a field of view 
ranging from 2.5–12 cm2 (VTT FPI VIS-VNIR Spectral Camera) was developed by 
VTT, the Technical Research Centre of Finland. The camera uses wavelengths 
from visible light to near infrared light (500-900 nm). The mechanism of the 
camera is based on a Fabry-Perot interferometer with a tunable air gap between the 
mirrors inside the interferometer’s cavity, allowing the fast capture of 70 different 
wavelengths. Three wavelength peaks are obtained at one setting of the air gap, and 
it takes a few milliseconds to change the air gap. Thus the imaging process takes 
seconds, and the subsequent computational analyses can be completed in 5-10 
minutes.  
The camera contains objectives, microscope lenses, filters and a beam-splitter 
which divides the light into visible and near infrared regions. The emitted light 
(ring light around the lens system, a halogen-based fibre-optic illuminator; Dolan-
Jenner Fibre-Lite DC 950) is absorbed and scattered by the imaged tissue, and the 
remitted light (diffuse reflectance) is recorded with CMOS red-green-blue (RGB) 
colour sensors (MT009V022) in ENVI standard data format.  
A stack of images is created where every pixel has a hyperspectral graph of all 
imaged wavelengths. Thus, a data cube is created, where the x and y axes are the 
dimensions of the skin forming a 2D digital image with a resolution of 240x320 
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pixels, where one pixel is approx. 125 µm in width, and the z-axis is the third, 
hyperspectral dimension.  
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Visible to near infrared light in hyperspectral imaging is capable of reaching 
about 2 mm in depth. Short wavelengths penetrate superficially, while longer 
wavelengths penetrate deeper into the tissue. Thus, it is possible to obtain 
information beneath the surface of the skin.  
Chromophores are biological structures of tissue, which are behind the 
absorption and scattering of light. In skin, the main chromophores are melanin, 
hemoglobin and water. The structure of tissue differs between healthy and diseased 
skin, with the same being true for the number of chromophores. Based on this 
idea, there could be a unique hyperspectral graph profile for each different tumour 
or disease.  
In the imaging process, the obtained data cube contains a huge amount of 
spectral information. In order to be able to use this data, it must be processed 
computationally. The different wavelengths are recorded as different proportions 
of RGB sensor outputs. This data can be converted into reflectance (in numerical 
form). Black and white references, which are imaged at the beginning of the 
imaging process, are used in these calculations. 
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There are coefficients for the different chromophores of the skin, and with 
these coefficients, different algorithms can be applied on the calculated reflectance. 
Thus, certain chromophores, or a mixture of them, can be extracted from the data 
as end members, and be presented as an abundance map, i.e. a spectral image of 
the target, which the clinician can interpret. The used algorithms are mathematical 
models, and thus assumptions of the reality, but they offer a possibility to visualise 
the spectral dimension. 
4.3.1 Mathematical models used and their interpretation 
In study I, native imaging of the lesion was performed with an orientation mark, 
and a mathematical model of linear mixture was used bedside.  
In study II, the lesions were natively imaged with HIS using an orientation 
mark, and again after marking the clinically defined border on the skin with an 
orientation mark. A linear mixture model was used bedside, and afterwards three 
other models were developed and applied to the data. Thus, study II utilised a 
linear mixture, linear mixture with single scattering albedo, chromophore-specific 
with single-scattering albedo and standard variate model. If three out of four 
models gave the same borders, those were interpreted as the HIS finding. 
4.3.2 Linear mixture 
A linear mixture model assumes that the recorded reflectance is a linear mixture of 
limited numbers of characterized spectra of imaged tissue named end members. 
The model uses vertex component analyses and filter vector analyses to define end 
members. The recorded reflectance is an equation of mixing matrix and end 
members. Solved end members are then visually represented as abundance maps. 
4.3.3 Linear mixture with single scattering albedo 
Reflectance spectra of skin are nonlinear. Single-scattering albedo is an estimate 
calculated based on the scattering and total absorption coefficients of the skin. The 
non-linear reflectance is converted to be more linear with single-scattering albedo, 
and then the linear mixture model is applied to solve the end members for 
abundance maps. 
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4.3.4 Chromophore-specific with single-scattering albedo 
Single-scattering albedo is used to describe the recorded reflectance, and the filter 
vector analysis is used to solve the proportion of chromophores from the recorded 
reflectance, after which the chromophore coefficient is multiplied by the 
proportion of the chromophore in question. When this is performed for all 
chromophores, it is possible to solve chromophore-weighted end members, i.e. the 
characterized spectra of the chromophore in question, which can be represented as 
abundance maps of different chromophores. 
4.3.5 Standard variate 
This model has a statistical background, and basically it compares how different 
spectra differ from the mean spectrum, which is the homogeneous background. 
Here it is assumed that the lesion is the differing spectrum and the homogeneous 
background is the healthy skin surrounding the lesion. 
4.4 Dermoscopy 
In all studies, clinical diagnosis was aided by dermoscopy to improve the accuracy 
of the diagnosis. The dermoscopes used were Dermlite® DL3 or DL3N, 3GenCA, 
USA, or Heine Delta 20T®. 
4.5 Photographing and fluorescence imaging  
4.5.1 Digital photographing 
In all studies, the lesions were photographed with a digital camera (Canon Ixus 
130, 14.1 megapixel or Canon Ixus 115 HS, 12.1 megapixel). Dermoscopic pictures 
were obtained with a digital camera through the dermoscope. 
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4.5.2 Fluorescence imaging and Photobleaching 
A handheld experimental imaging system including a digital camera (Canon Ixus 
130, 14.1 megapixel with set-up: ISO800, FW 2.8, no zoom), Wood’s light (Philips 
Burton®, Somerset, USA, held by hand at about 8 cm distance) and a yellow filter 
lens (Hoya HMC, yellow-green xo, attached on top of Wood’s light) was used to 
obtain the fluorescence images. Prior to imaging, the photosensitiser cream was 
wiped off with saline solution. Photobleaching was calculated as the absolute 
difference of the mean fluorescence before and after illumination.  
To quantify the fluorescence, the obtained raw images were processed semi-
automatically with an affine transformation and manually selected matching points 
with Python 3.6, and the intensity was extracted in red-lights channel to get 
arbitrary units (A.U.) for fluorescence and photobleaching. 
4.6 Photodynamic therapy and outcome assessments of 
photodynamic therapy 
PDT followed European guidelines except for long-acting local anesthetics which 
were used prior to curettage (Figure 10). We chose to use local anesthetics as 
infiltration, which allowed us to retrieve feasible diagnostic punch biopsies during 
the first PDT session, while simultaneously offering pain management for 
illumination. The infiltration was repeated during the second session to achieve 
similar pain management as in the first session. 
  
 96 
 
Figure 10.  Treatment protocol for PDT I and II sessions. 
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Pain was measured at the beginning, in the middle and at the end of the 
illumination on a visual analogue scale (VAS). Patients were blinded to the 
photosensitiser that was used. For patients with multiple lesions, the illumination 
was performed in the order of randomisation for each lesion at the same session. 
Post-treatment reactions were photographed 8–14 days after the first PDT 
session, prior to the second treatment. Visual evaluation was performed on a five-
point-scale (none/minimal/mild/moderate/severe) by an experienced 
dermatologist blinded to the photosensitiser that was used. 
At the three-month follow-up visit, the blinded observer assessed the response 
to treatment with clinically guided 3-mm punch biopsies. The cosmetic outcome 
was visually evaluated on a four-point-scale (excellent/good/fair/poor). 
4.7 Tissue sampling for histopathology 
In study I, the first four lesions were excised directly after imaging with a 5-mm 
margin. In the rest of the LM/LMM, a diagnostic 3-mm punch biopsy was taken 
from the HIS-suspected site of invasion after imaging and interpretation. 
Subsequently, LM was excised with a 5-mm margin and LMM with a 10-mm 
margin. Both biopsies and specimens from the final excision were used in the 
results to analyse if the HIS-suspected invasion site could be confirmed in 
histopathology. All specimens were prepared with routine techniques and MART1 
staining if needed. All specimens were assessed by an experienced 
dermatopathologist blinded to the HIS findings. 
In study II, post-imaging 3-mm biopsies were taken from HIS-suspected 
subclinical extension sites, if the patient had an operation scheduled for another 
day than the imaging day. Finally, all lesions were excised with the same technique, 
where BCC was excised at the clinically defined tumour border, and the margin 
was excised as a separate 2-mm circumferential strip. Thus, in analyses we were 
able to assess if BCC was found in the margin strip specimens, and if a subclinical 
extension existed. If a margin was reported in the excised tumour piece, this could 
be interpreted as the actual tumour being smaller than was clinically assessed. If the 
margin in the tumour piece was reported to be <1 mm, this was interpreted as the 
tumour being of the same size as was clinically assessed. 
All specimens were marked with an orientation for histopathological analyses. 
Specimens were prepared with routine techniques with tightly sectioned margin 
strips. If HIS gave grounds for suspecting a subclinical extension, additional slices 
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were sectioned from the suspected site in the margin strip. HIS findings were 
compared to histopathology. All specimens were assessed by an experienced 
dermatopathologist blinded to the HIS findings. 
In study III, clinical diagnosis was confirmed with 3-mm punch biopsies. Prior 
to any procedures, the lesion, 5-mm margin area and the site of the punch biopsy 
were marked on plastic sheets with scaling (1x1mm squares). These sheets were 
used as guidance during the follow-up visit to obtain a control 3-mm punch biopsy 
near the original biopsy site. Additional 3-mm punch biopsies were taken from 
clinically suspicious sites, if needed. Non-responsive lesions were excised to see if 
aggressive growth patterns existed. All specimens were assessed by an experienced 
pathologist blinded to the treatment. 
4.8 Statistical analyses and calculations on accuracy 
In study I and II, the calculations on the performance and accuracy of the imaging 
system were performed by the authors. 
For study III, statistical analyses were performed by a professional statistician, 
Mika Helminen from Tampere University Hospital, who used SPSS 23.0 (IBM 
SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.), or the 
mathematician of our study group, Ilkka Pölönen from the University of Jyväskylä, 
with Python 3.6 using Numpy and Scipy libraries.  
To compare the efficacy, cosmetic outcome and post-treatment reactions of the 
treatment arms, Fisher’s exact test was used. In pain results, the comparison 
between the arms was calculated with the Kruskal-Wallis test, and comparison 
between the sessions was calculated with the Wilcoxon Signed Rank Test. In 
fluorescence and photobleaching, the comparison between the arms was calculated 
with ANOVA, and the Chi Square test was used for studying the correlation 
between efficacy, fluorescence and photobleaching. 
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5 SUMMARY OF RESULTS 
5.1 Study I 
In histopathology, 10/32 lesions were LMM with a Breslow thickness of 0.4–1.6 
mm (mean 0.85mm), and 22/32 were LM. With HIS, 9/10 invasion sites were 
recognised as LMM (true positives), but in 1/10 of LMM cases the invasion site 
was not suspected in HIS abundance maps, thus being a false negative.  
In 19/22 of LM cases, there was no suspicion of invasion based on HIS 
abundance maps (true negatives), but in 3/22 LM cases there was a suspected 
invasion site in HIS abundance maps without histopathological confirmation, thus 
being false positives. 
These results give HIS a positive predictive value of 75%, a negative predictive 
value of 95%, a sensitivity of 90% and a specificity of 86.3%. 
In HIS abundance maps, the LM lesions were seen as white homogeneous areas 
corresponding to the end member of LM, but in the case of LMM there was a hole 
(invasion site) inside the homogeneous white area (LM part of LMM). 
Furthermore, in the case of LMM, an additional end member and thus an 
additional abundance map was created in HIS analyses from the invasion site. In 
this map the above-mentioned “hole” was represented as a separate clear white 
area, representing the end member of LMM. Figure 1 of the original publication I 
of this dissertation presents an example of a LMM and the abundance maps of the 
LMM. Thus, the spectra of LMM differed from LM, and furthermore both 
differed from healthy skin. This can be shown as differing hyperspectral graphs 
(Figure 11).   
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Figure 11.  Unique hyperspectral graphs of LMM, LM, and healthy skin, Courtesy of Ilkka Pölönen. 
5.2 Study II 
In histopathology, 10/16 BCCs were aggressive subtypes, and 6/16 were nodular, 
superficial or a mixed type of these two. Clinically, all were ill-defined. 
HIS delineated 12/16 BCCs more accurately compared to clinical evaluation. In 
these, 4/16 were more widely delineated by HIS and confirmed in histopathology. 
Figure 2 of the original publication II of this dissertation presents an example case 
of an ill-defined BCC, were HIS delineated the lesion to be wider compared to 
clinical examination. Furthermore, 8/16 were more narrowly delineated by HIS 
and confirmed in histopathology. There were 2/16 false positive cases, where HIS 
delineated the lesion wider without histopathological confirmation, and 2/16 false 
negative cases, where HIS did not detect the subclinical extension found in 
histopathology. All four mathematical models gave similar results, but it is still 
unclear which model works best on BCC, and which has the least artefacts. Based 
on the results of study II, HIS seems to be a promising clinical aid for a clinician, 
but the results of the pilot study need to be confirmed in larger trials. 
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5.3 Study III 
A total of 54 patients with 95 lesions completed the study. A total of 98 lesions 
fulfilled all the inclusion criteria, thus the number of 98 lesions is used for the 
intention-to-treat analyses, even though 117 lesions were randomised. In our 
protocol of randomised lesions, those which were not BCC were excluded after we 
received histopathological reports. The protocol was designed in this way due to 
feasibility and limited resources.  
At the three-month follow-up, there were histologically verified, non-responsive 
lesions in all groups: 1/31 in MAL, 3/33 in BF-200 ALA and 2/31 in HAL group. 
The efficacies with histological verification with intention-to-treat analyses are 
93.8% (95% CI 79.9%-98.3%) for MAL, 90.9% (95% CI 76.4%-96.9%) for BF-200 
ALA and 87.9% (95% CI 72.7%-95.2%) for HAL (p=0.84).  
All secondary outcomes of the trial were analysed as described in the protocol. 
The cosmetic outcome was good or excellent for 77.4% in MAL group, 75.7% in 
BF-200 ALA, and 61.3% for HAL with no significant differences between the 
arms (p=0.61). 
In tolerability, no differences between the arms were found in post-treatment 
reaction (p=0.49). In pain during illumination, there were no differences between 
the arms (for 4 min and 8 min timepoints all p-values >0.18). In comparison of 
pain between the sessions, in the HAL group the pain differed between the first 
and second PDT sessions (4 min p=0.006, 8 min p=0.005). In other arms, no 
differences were found in the level of pain between the sessions (MAL 4 min 
p=0.17, 8 min p=0.79; BF-200 ALA 4 min p=0.45, 8 min p=0.43). 
Figure 3 of the original publication III of this dissertation presents a visual 
illustration of the cosmetic outcome, pain and post-treatment reaction results. 
There was a loss of images in fluorescence analyses, and thus for the first PDT 
session 84 lesions in 49 patients were analysed, and for the second PDT session 91 
lesions in 51 patients. When the arms were compared, there was lower fluorescence 
at the beginning of illumination in 2% HAL compared to 16% MAL and 7.8% BF-
200 ALA (PDT I p=0.043 and PDT II p=0.043), but in photobleaching no 
significant differences were found between the arms (PDT I p=0.09 and PDT II 
p=0.42). There was no correlation between the histological clearance and 
photobleaching (PDT I p=0.40, PDT II p=0.77) or between the histological 
clearance and fluorescence (PDT I p=0.77, PDT II p=0.55) in our material. It 
should be noted that our fluorescence measurement set-up was experimental and 
not validated. 
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6 DISCUSSION 
This dissertation was the first to report on the feasibility of a HIS in the delineation 
of ill-defined BCCs, and one of the first ones to report on the preliminary 
performance of the HIS in separating LMM from LM, and to actually visualise the 
localisation of the invasion site on a map. In the field of PDT, study III of this 
dissertation was the first to report on the efficacy of HAL in the treatment of non-
aggressive BCCs. 
6.1 Advantages and disadvantages of the hyperspectral 
imaging system 
When considering the features of a non-invasive imaging system, the following 
should be discussed: the field of view (FOV), resolution, imaging depth, 
orientation and form of the provided images, time consumed to obtain the images, 
and time consumed to acquire the computational analyses. Furthermore, it should 
be considered whether the system provides a classification or diagnosis for the 
user, or if the user needs to interpret the images themselves. In the latter situation, 
the necessary level of expertise is essential when considering the level of healthcare 
the particular imaging system is practical to use in.  
The advantages of HIS in non-invasive optical imaging are the following:  
1) An adaptable FOV up to 12 cm2, which is possible to obtain in a few seconds, 
compared to 1 mm2 in conventional RCM, where it is possible to obtain 14 mm2 
per minute with mosaicking (Kose, Cordova et al. 2014), or compared to 
conventional OCT, where 25 mm2 is obtained in 40 seconds (Cheng, Guitera 
2015).  
2) The adaptable filter is capable of reaching otherwise impracticable areas such as 
around the eyes and ears. 
3) An imaging depth of approximately 2 mm.  The depth of HIS is similar to that 
achieved with conventional OCT, compared to 250–300 μm in RCM. However, in 
OCT the superior resolution achieved with newer devices is compromised with a 
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loss in imaging depth (Cheng, Guitera 2015, Kang, Bahadoran et al. 2010, Reddy, 
Nguyen 2019). 
4) Computational analyses are quick, taking about 5–10 minutes to provide the HIS 
images, i.e. abundance maps. As computational analyses are part of the imaging 
system, in the future it will be easy to add artificial intelligence to the analyses. 
5) The interpretation of the abundance maps is easy to learn. 
The disadvantages of the HIS are the following: 
1) Lateral resolution of approximately 125 μm, compared to 1 μm in RCM (Que 
2016), or to 10–15 μm in conventional OCT (with 2 mm depth), or 1–3 μm in 
high-definition OCT (with 570–750 μm depth), or 7.5 μm in frequency/Fourier-
domain OCT (with 1.2–1.8 mm depth) (Reddy, Nguyen 2019). 
2) Artefacts of the imaging, which can reduce the quality of abundance maps. 
Artefacts that we have noticed are very light skin type, which can cause excessive 
reflectance, and rounded or sharp surfaces, which can also create artefacts in the 
imaging. 
3) Exact depth measurements are not provided. At the moment, HIS does not 
provide vertical sections or 3D images. With the current system it is possible to 
obtain 2D images, although in these 2D abundance maps the information is 
obtained from the hyperspectral graph, which contains information from the whole 
imaging depth. 
4) Mathematical modelling and computational analyses only provide assumptions of 
the reality, but if the assumptions can be proved to be correct in a clinical trial, 
then the system is useful. 
5) At the moment, we do not have any knowledge concerning how the system works 
on dark skin types. 
Considering the current features of our HIS, i.e. easy, fast, and adaptable, the 
possible users could be specialists from different fields who treat large numbers of 
lesions, like dermatologists, ear-nose-throat specialists and plastic surgeons. HIS 
could be a useful tool in preoperative margin assessment and a useful tool for 
clinicians to obtain biopsies from an optimal site to achieve a correct 
histopathological diagnosis. 
At the moment, HIS is not a diagnostic tool that could provide the diagnosis in 
equivocal lesions akin to RCM, but HIS can provide additional information when 
the diagnosis is based on some other method. The right place for RCM could be 
highly specialized skin cancer centers, as RCM demands a high level of expertise, 
and extensive training to learn how to interpret the images on the cellular level. 
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HIS is a more straightforward system compared to RCM when considering the 
interpretation. Thus, HIS could also be useful in places with less expertise, but HIS 
could also be useful in high expertise centers, as another option in the toolbox.  
HIS is currently an add-on tool, which provides subclinical information not 
possible to obtain by visual inspection or by a dermoscope. 
6.2 Separating in situ melanoma versus invasive melanoma, 
and localising the site of invasion 
Our results from study I showed that the hyperspectral graph is unique to LM and 
LMM, and thus these two lesions differ from each other in diffuse reflectance. 
Thus, it is possible to distinguish the two from each other based on the 
hyperspectral data. Nagaoka et al. have shown that the hyperspectral graphs of 
melanocytic nevi and LMM also differ from each other (Nagaoka, Kiyohara et al. 
2015). Nagaoka et al. created a discrimination index from a hyperspectral data 
cube, which is capable of distinguishing melanoma from other pigmented skin 
lesions with good accuracy (Nagaoka, Kiyohara et al. 2015). We chose to create 
abundance maps, which also appeared capable of separating LM and LMM from 
each other with good accuracy. Furthermore, our abundance maps had the 
particular advantage of being able to localise and visualise the exact invasion site. 
RCM performs well in the diagnosis of LM from other flat facial lesions with a 
LM score developed by Guitera et al., and interestingly in separating amelanotic 
lesions only, the sensitivity and specificity are higher for the LM score (Guitera, 
Pellacani et al. 2010). Pellacani et al. have introduced a RCM score for separating 
melanoma from equivocal melanocytic lesions with good accuracy (Pellacani, 
Guitera et al. 2007). However, if the goal is to separate LM from LMM, RCM is 
not the most suitable modality. This is due to its limited penetration depth: RCM 
reaches the epidermis and superficial papillary dermis (Que 2016), and the invasion 
is below these structures.  
Mataca et al. showed that RCM is as just as useful as dermoscopy in guiding the 
clinician to obtain a representative biopsy (Mataca, Migaldi et al. 2018). When 
considering which method is capable of achieving the most robust 
histopathological criteria for diagnosis of LM/LMM, RCM is more accurate than 
dermoscopy and the naked eye, and dermoscopy is more accurate than the naked 
eye in guiding the biopsy site selection (Mataca, Migaldi et al. 2018). When these 
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two methods are compared to HIS, the advantage of HIS is its ability to visualise 
the exact invasion site in vivo. 
In separating LM and LMM, measuring the depth of the lesion could be one 
option. Scanning the lesion with an imaging system that provides vertical sections 
also enables the localisation and measurement of the invasion site. OCT or high-
frequency ultrasound (HFUS) are capable of measuring tumour depth. When 
comparing spectral-domain OCT (axial resolution 5.5 μm) to HFUS (axial 
resolution 16 μm) in the measurement of melanocytic lesions, Varkentin et al. 
reported that OCT is more precise than HFUS in measuring the depth, but both 
methods underestimated the depth when the thickness of the lesion increased. 
Thus, both perform best in lesions less than 1 mm in thickness (Varkentin, 
Mazurenka et al. 2017). Another study by Hinz et al. compared conventional OCT 
to HFUS in measuring the depth of melanocytic lesions, with the result of OCT 
having better correlation with histopathology. However, both technologies 
overestimated the depth (Hinz, Ehler et al. 2011). Conventional OCT with vertical 
sections seems to be capable of distinguishing melanoma in situ, invasive 
melanoma, junctional nevus, and compound nevus from each other (Moraes Pinto 
Blumetti, Tatiana Cristina, Cohen et al. 2015). 
Dynamic OCT provides horizontal sections while speckle-variance OCT 
provides horizontal and vertical sections of the tumour microvasculature. De 
Carvalho et al. demonstrated that the microvascular pattern of melanoma 
correlates with the Breslow thickness (De Carvalho, Welzel et al. 2018). In a case 
report, De Carvalho et al. demonstrated that by imaging the microvasculature, the 
transformation of a junctional nevus to melanoma in situ could be visualised and 
localised with speckle-variance OCT (De Carvalho, Ciardo et al. 2016). Thus, both 
dynamic and speckle-variance OCT, and HIS seem to be promising options in 
preoperatively localising the site of invasion in vivo. 
Furthermore, in LM/LMM the value of non-invasive imaging lies especially in 
its ability to guide the pathologist in obtaining the sections from the right place, as 
with wide lesions there exists a risk for error when using the traditional bread 
loafing technique. Thus, with correct diagnosis, the treatment and follow-up can be 
planned appropriately. HIS is an interesting option for this, as we demonstrated in 
our pilot study. 
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6.3 Detecting subclinical extensions in ill-defined basal cell 
carcinomas and recognising the true borders of the lesion 
This study is the first to report results on non-invasive imaging of BCCs with a 
HIS. Our study showed that the HIS delineated the margins more accurately in 
75% of the clinically ill-defined lesions and revealed a subclinical extension in 25% 
of the lesions, compared to clinical evaluation with a dermoscope. 
Even though dermoscopy is an excellent aid for diagnosing BCC, it has not 
proved to be capable of revealing subclinical extensions in ill-defined BCC. For 
example, dermoscopic margin assessment has not reduced the stages in MMS 
compared to visual inspection alone (Jayasekera, Dodd et al. 2018). The same is 
true for high-frequency ultrasound, which also did not reduce the stages in MMS 
compared to visual inspection (Marmur, Berkowitz et al. 2010). 
Similarly to what we showed, Venturini et al. demonstrated that with RCM, in 
30 % of cases a subclinical extension in ill-defined BCC was revealed (Venturini, 
Gualdi et al. 2016). Aggressive BCCs are often ill-defined, and subclinical 
extensions can lie deeper than the maximum penetration depth of RCM. Thus, the 
HIS makes it possible to obtain more subclinical information. 
With Fourier-domain OCT, the subclinical extension was revealed to be present 
in 21 % of the BCCs treated with MMS, with no false positive or false negative 
cases (Wang, Meekings et al. 2013). Interestingly, Fourier-domain combined with 
dynamic OCT is capable of visualising BCCs in 3D form, which is an exciting step 
toward detecting the true dimensions of BCC in vivo. 
Non-invasive imaging could have an impact on treatment capacity as the 
number of re-excisions could be reduced, and resources of MMS could be directed 
to the most high-risk cases where it is truly needed. It could be speculated that 
non-invasive imaging could reduce the number of high-risk BCCs by preventing 
several recurrent lesions. A recurrence in high-risk location is always a high-risk 
BCC, and aggressive subtypes often have subclinical extensions. Thus, if subclinical 
extensions are revealed, perhaps recurrences could be avoided. 
The performance of the HIS should be confirmed in larger trials than this pilot 
study, but based on our results, HIS seems to be an interesting option for 
preoperative lateral margin assessment in ill-defined BCC. 
 107 
6.4 Advantages and disadvantages of non-invasive treatments 
of non-aggressive basal cell carcinoma 
Efficacy and recurrence rate are not the only parameters affecting a clinician’s 
treatment decision for BCC. If the lesion is solitary and operable, the decision is 
easy, as surgery is the most effective treatment with few recurrences. 
Sometimes, BCC can be a chronic condition with multiple primaries and 
multiple recurrences. When the treatment needs to be repeated multiple times, 
surgery is not always the best option. The patient’s preferences and demographics 
can also affect the choice of treatment. Examples of these are cosmetic outcome, 
age of the patient, or the logistics involved in patients coming to the treatment. In 
the case of aggressive BCCs, the choice is easy: surgery is the most effective and 
recommended option. However, in the case of non-aggressive and low risk 
tumours, there is room for non-invasive options. When there are multiple options 
for non-invasive treatment, the decision on the choice of treatment should be 
made in cooperation with the patient by explaining the adverse events and 
treatment protocols.  
The following can be regarded as advantages of non-invasive treatment: 
1) Cost-effectiveness 
2) Cosmetic outcome 
3) Possibility to treat multiple lesions at once 
4) Possibility to easily treat wide areas 
5) Possibility for application at home (easy for patient, if arriving to treatment 
or time spent in treatment are an issue, minimization of consumed 
resources) 
The following can be regarded as disadvantages: 
6) Loss of control in histological clearance 
7) Lower efficacy compared to surgery 
8) Higher risk for recurrence compared to surgery 
9) Possibility for application at home (demands good patient selection and 
compliance, as there is a loss of control for treatment delivery) 
As the number of BCCs is constantly rising, the number of non-invasive 
treatments is also likely to increase in the future. In non-invasive treatment, the 
control of treatment outcome and follow-up are essential when considering the risk 
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for recurrence. At the moment, the clinical practice is to evaluate the treatment 
outcome visually with a dermoscope, and by obtaining punch biopsies, if needed. 
Non-invasive imaging could offer a more accurate surveillance of the treatment in 
the future, and thus decrease the risk for error in the assessment of treatment 
outcome.  
6.5 Possible advantages of hexylaminolevulinate 
In our results, we showed that with 2% HAL, a similar lesion clearance can be 
achieved as with 7.8% BF-200 ALA or 16% MAL in PDT of non-aggressive 
BCCs, with no differences in adverse events.  
Preclinical studies present some evidence that HAL could be more effective in 
equimolar doses compared to MAL and 5-ALA (Morrow, McCarron et al. 2010). 
Preclinical evidence also shows that due to its lipophilic nature, HAL could be used 
in PDT at lower concentrations, as HAL induces stronger fluorescence, i.e. PpIX 
accumulation, when compared to the more hydrophilic MAL or 5-ALA (Kiesslich, 
Helander et al. 2014, Togsverd-Bo, Lerche et al. 2012, Togsverd-Bo, Idorn et al. 
2012). Our results support these findings from preclinical studies.  
In a safety study, Neittaanmäki-Perttu et al. reported that 0.2% and 2% HAL 
are significantly less painful on healthy human skin compared to 7.8% BF-200 
ALA and 16% MAL, when illuminated with red light (Neittaanmaki-Perttu, 
Neittaanmaki et al. 2016). Thus, it seems that with a low concentration, pain could 
be reduced. In our results, there were no differences between the three 
photosensitisers in the level of pain when treating BCC with red light. One reason 
behind this could be that the accumulation of an exogenous photosensitiser is 
tumour tissue-selective (Kennedy, Pottier et al. 1990), and that metabolically active 
and proliferating tumour cells accumulate more PpIX (Wang, Shi et al. 2017). We 
did not find differences in the level of pain for sBCC. Perhaps the pain sensation 
threshold is exceeded anyhow in tumour cells, and when using low concentrations 
on healthy human skin, this threshold is not exceeded, but higher concentrations 
on healthy human skin exceed the threshold.  
With regard to the efficacy of HAL, the 2% concentration might be suboptimal 
for the treatment of sBCC. The same may also be true for the three-hour 
incubation time. Thus, a dose-determining study with different concentrations and 
incubation times should be performed with HAL in the future. By optimizing the 
protocol, the efficacy of low concentration HAL-PDT could potentially be 
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increased. Interestingly, when an ultralow concentration of 0.2% HAL was used 
for daylight-PDT of thin actinic keratosis, Neittaanmäki et al. achieved a similar 
lesion clearance as with 16% MAL at the one-year time point (Neittaanmaki-Perttu, 
Karppinen et al. 2017). So, for different types of lesions the optimal concentration 
could vary. 
With regard to the cost-effectiveness, some savings could be made in 
manufacturing a low-concentration HAL cream, as a good outcome is achieved 
already at low concentrations. Furthermore, new and effective options in 
photosensitisers provide competition to the market, as there are currently few 
photosensitiser options in dermatological PDT. Thus, HAL is an interesting option 
for dermatological PDT, as there could be some advantages in the use of low 
concentrations without compromising the response rate, as we showed in our trial. 
6.6 Usefulness of local infiltration anesthesia 
The exact mechanism of pain during PDT is unclear, but the pain sensation 
probably arises from apoptosis and necrosis caused by radical oxygen species 
created during the PDT reaction, or due to the direct effect of radical oxygen 
species on neurons (Wang, Shi et al. 2017). Regardless of the exact mechanism, 
nociceptive neurons are stimulated and thus a sensation of pain is created. In the 
head and neck area, nerve blocking is a good pain management method (Wang, Shi 
et al. 2017, Paoli, Halldin et al. 2008), but for solitary lesions local anesthetics are 
more practical.  
The studies on local infiltration anesthesia are few. Borelli et al. used 
subcutaneous infiltration anesthesia during illumination as a continuous infusion of 
Ringer solution with ropivacaine, prilocaine and epinephrine in a split-half-face-
trial, in the treatment of treated extensive facial actinic keratosis with 5-ALA-PDT 
(Borelli, Herzinger et al. 2007). There was a significant difference in pain, as 
subcutaneous infiltration anesthesia was a more effective pain management 
method when compared to oral analgesia with an air-cooling device (Borelli, 
Herzinger et al. 2007). Debu et al. have a case report on a paediatric patient with 
Gorlin syndrome, where a similar continuous infusion was used subcutaneously 
with good success in the treatment of multiple BCCs on the patient’s back (Debu, 
Sleth et al. 2012). 
In our results, the mean and median pain score was 2.3 on the VAS scale for 
the treatment of sBCC with a local, long-acting infiltration anesthetic which was 
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injected three hours prior to illumination. In the PDT study on non-aggressive 
BCCs by Morton et al., the mean pain score on a numerical scale (1-10) was 4.5 
without analgesia (Morton, Dominicus et al. 2018). Our study had similar inclusion 
criteria for tumour subtype and similar incubation time in PDT as Morton et al. 
Interestingly, Morton et al. used RhodoLED as a light source, which has a gradual 
increase in light dose, but a similar total dose of 37 J/cm2 as Aktilite, which was 
used in our study. Zaar et al. have shown that RhodoLED causes significantly less 
pain compared to Aktilite (Zaar, Sjoholm Hylen et al. 2018). Yet, our pain scores 
were lower with our pain management method compared to Morton et al., even 
though we had the more painful light source. 
Solid conclusions cannot be made when two different studies are compared. 
However, if our mean pain score of 2.3 is compared to the mean pain score of 4.5 
in Morton et al.’s study, it seems that with our method some pain management is 
achieved, and thus further studies are warranted. 
6.7 Strengths and limitations of the study 
The strengths of the hyperspectral imaging studies were histopathological controls 
for the camera findings, the comparison of different mathematical models, and our 
operation technique in the ill-defined BCC study. MMS was not available to us, but 
with our operation technique the clinically assessed border was clearly marked, and 
comparisons to the findings of the hyperspectral camera were straightforward to 
do. An additional strength was that if there was a subclinical extension suspected 
by HIS in a specific site, additional sections were made for the histopathology of 
this site. 
The limitations in the hyperspectral imaging studies include the rather small 
number of imaged lesions, the lack of in-depth visualisation, and the possible 
sources of artefacts in the imaging. Due to study I and II being pilot studies, it was 
not possible to calculate sample sizes.  
In our clinical trial, strengths included the non-sponsored, randomised, 
controlled, prospective and double-blinded design, the histopathological 
confirmation of diagnosis and treatment outcome, as well as the excision of non-
responsive lesions, as this allowed to evaluate if there were aggressive underlying 
subtypes of BCC. 
The limitations of our PDT trial were its small sample size, and optimistic 
assumptions in the power calculations, including multiple lesions (possible 
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confounding factors for results), and taking biopsies during the first PDT session 
(healing due to inflammation induced by the biopsy can be a confounding factor). 
In pain analyses, the lack of a control group was a limitation. In fluorescence 
analyses, the lack of a validated fluorescence imaging system was a major limitation. 
It should also be noted that it was optimistic to assume that a low concentration 
HAL could be more effective than a high concentration MAL. Evaluating 
retrospectively, perhaps equal or non-inferior efficacies would have been more 
accurate assumptions.  
6.8 Clinical implications 
Our results showed the capability of the HIS to localise the invasion site in LMM 
and to detect the borders of ill-defined BCCs more accurately than by clinical 
assessment. Additionally, Neittaanmäki-Perttu et al. have shown that the same HIS 
is useful in the preoperative in vivo margin delineation of LM/LMM by revealing 
subclinical extensions (Neittaanmaki-Perttu, Gronroos et al. 2015). Thus, with HIS, 
the accuracy of diagnostic biopsies could be increased, the subclinical extensions 
could be revealed, and the number of re-excisions could be reduced by avoiding 
repeated visits and operations. In the future, the results of the pilot studies need to 
be confirmed. The HIS could be a useful aid for clinicians and should be further 
developed. 
In PDT, our results support the findings of previous studies for the use of BF-
ALA for PDT of sBCC. BF-200 ALA is a commercial product of Ameluz, and 
thus easily available for clinicians. Our results also provide a new HAL option, but 
as it is currently more for research use, it is not yet easily accessible. HAL is 
available as a powder used for the photodynamic diagnosis of bladder cancer, but 
should be commercialised as a cream before wider use in dermatological PDT. As 
photosensitisers are expensive raw materials, a low concentration cream could 
provide cost benefits in manufacturing. Although we did not find the novel 
photosensitisers to be superior, our results support the similarity of them, and thus 
offer more options for clinicians in PDT. Usually, multiple options are beneficial in 
the treatment of patients.  
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6.9 Future prospects 
In the future, it would be interesting to explore whether the HIS is capable of 
converting the information into a 3D map of the tumour, or at least capable of 
obtaining vertical sections, which combined with current horizontal images would 
provide additional information for the clinician.  The 3D information could 
potentially be acquired by combining hyperspectral imaging with OCT. 
In the case of aggressive BCCs, it would be interesting to repeat the design of 
study II, but compare the results to MMS where 100% of the margins are assessed. 
In this way, it is likely that more precise information on the performance of HIS 
would be gained. This design could also possibly allow for the evaluation of 
whether hyperspectral imaging could reduce the stages of MMS. Furthermore, in 
the case of aggressive BCC, it would be interesting to investigate if the HIS could 
recognise a perineural invasion, as in LMM we showed that the invasion site could 
be localised. Perhaps the hyperspectral signature of perineural invasion is also 
unique. 
Far in the future, if hyperspectral imaging proves to be an advantageous method 
in skin imaging, a library of skin lesions could be collected, and artificial intelligence 
could be combined to data processing. Thus, the HIS could also be used as a 
diagnostic method.  
Furthermore, it would be interesting to study if the use of photosensitisers 
could improve the results of the HIS in tumour delineation. It would also be 
worthwhile to explore the performance of HIS in non-invasive treatment 
monitoring. 
In PDT for HAL, a dose-finding study is warranted in the future. It would also 
be intriguing to study which incubation and illumination time (i.e. total light dose) 
are optimal in the treatment of non-aggressive BCCs. Additionally, it would be 
interesting to study if the efficacy of fractionated illumination increases with low-
concentration HAL. Studies using HAL-PDT on carcinomas in situ and thick 
actinic keratosis are warranted and interesting to perform. Pain would be valuable 
to study with our pain management method in a controlled and randomised 
fashion in non-aggressive BCC and in carcinoma in situ, and it would also be 
interesting to include some pain measurement for a few post-procedural days. 
 113 
7 CONCLUSIONS 
The results of this dissertation introduce the potential of hyperspectral imaging in 
the treatment of BCC and LMM. Furthermore, this dissertation presents a first-
time report on the efficacy of HAL in the treatment of non-aggressive BCCs.  
The following conclusions can be drawn from the results of this dissertation:  
1) The HIS is an interesting option in optical, non-invasive skin imaging in 
preoperative tumour assessment due to its demonstrated potential in 
visualising and localising subclinical findings. 
2) Hyperspectral imaging could be a useful clinical tool as the system provides 
a large imaging field, good penetration depth, and fast reception and 
processing of subclinical visual data, which can be interpreted bedside.  
3) Novel photosensitisers, BF-200 ALA and HAL, are not superior in 
efficacy, but have similar adverse event profiles as the widely used MAL in 
PDT of non-aggressive BCCs. HAL in particular is a new, interesting 
option for dermatological PDT, because it achieves a good efficacy already 
at low concentrations.  
4) Infiltration of long-acting local anesthetics seems to reduce pain in non-
aggressive BCCs during illumination. 
5) A validated imaging system should be used to obtain reliable fluorescence 
images. 
Thus, new options for skin cancer diagnosis and treatment are presented, although 
these results need to be confirmed in larger trials. This dissertation also provides 
plenty of ideas for further research. 
 114 
 
 115 
REFERENCES 
AHLGRIMM-SIESS, V., HORN, M., KOLLER, S., LUDWIG, R., GERGER, A. and 
HOFMANN-WELLENHOF, R., 2009. Monitoring efficacy of cryotherapy for 
superficial basal cell carcinomas with in vivo reflectance confocal microscopy: a 
preliminary study. Journal of Dermatological Science, 53(1), pp. 60-64. 
AHNLIDE, I. and BJELLERUP, M., 2013. Accuracy of clinical skin tumour 
diagnosis in a dermatological setting. Acta Dermato-Venereologica, 93(3), pp. 
305-308. 
ALARCON, I., CARRERA, C., ALOS, L., PALOU, J., MALVEHY, J. and PUIG, 
S., 2014. In vivo reflectance confocal microscopy to monitor the response of 
lentigo maligna to imiquimod. Journal of the American Academy of Dermatology, 
71(1), pp. 49-55. 
ANG, J.M., RIAZ, I.B., KAMAL, M.U., PARAGH, G. and ZEITOUNI, N.C., 
2017. Photodynamic therapy and pain: A systematic review. Photodiagnosis & 
Photodynamic Therapy, 19, pp. 308-344. 
AOUDE, L.G., WADT, K.A.W., PRITCHARD, A.L. and HAYWARD, N.K., 
2015. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell 
& Melanoma Research, 28(2), pp. 148-160. 
APALLA, Z., LALLAS, A., SOTIRIOU, E., LAZARIDOU, E., VAKIRLIS, E., 
TRAKATELLI, M., KYRGIDIS, A. and IOANNIDES, D., 2016. Farmers 
develop more aggressive histologic subtypes of basal cell carcinoma. 
Experience from a Tertiary Hospital in Northern Greece. Journal of the 
European Academy of Dermatology & Venereology, 30(Suppl 3), pp. 17-20. 
APALLA, Z., LALLAS, A., TZELLOS, T., SIDIROPOULOS, T., LEFAKI, I., 
TRAKATELLI, M., SOTIRIOU, E., LAZARIDOU, E., EVANGELOU, 
G., PATSATSI, A., KYRGIDIS, A., STRATIGOS, A., ZALAUDEK, I., 
ARGENZIANO, G. and IOANNIDES, D., 2014. Applicability of 
dermoscopy for evaluation of patients' response to nonablative therapies for 
the treatment of superficial basal cell carcinoma. British Journal of Dermatology, 
170(4), pp. 809-815. 
ARITS, A H M M., SCHLANGEN, M.H.J., NELEMANS, P.J. and 
KELLENERS-SMEETS, N.W.J., 2011. Trends in the incidence of basal cell 
carcinoma by histopathological subtype. Journal of the European Academy of 
Dermatology & Venereology, 25(5), pp. 565-569. 
  
 116 
ARITS, AIMEE H M M, MOSTERD, K., ESSERS, B.A., SPOORENBERG, E., 
SOMMER, A., DE ROOIJ, MICHETTE J M, VAN PELT, HAN P A, 
QUAEDVLIEG, P.J.F., KREKELS, G.A.M., VAN NEER, PIERRE A F 
A, RIJZEWIJK, J.J., VAN GEEST, A.J., STEIJLEN, P.M., NELEMANS, 
P.J. and KELLENERS-SMEETS, N.W.J., 2013. Photodynamic therapy 
versus topical imiquimod versus topical fluorouracil for treatment of 
superficial basal-cell carcinoma: a single blind, non-inferiority, randomised 
controlled trial. Lancet Oncology, 14(7), pp. 647-654. 
ARMSTRONG, B.K. and KRICKER, A., 2001. The epidemiology of UV induced 
skin cancer. Journal of Photochemistry & Photobiology.B - Biology, 63(1-3), pp. 8-18. 
ARMSTRONG, B.K. and CUST, A.E., 2017. Sun exposure and skin cancer, and 
the puzzle of cutaneous melanoma: A perspective on Fears et al. 
Mathematical models of age and ultraviolet effects on the incidence of skin 
cancer among whites in the United States. American Journal of 
Epidemiology 1977; 105: 420-427. Cancer Epidemiology, 48, pp. 147-156. 
AXELROD, M.L., JOHNSON, D.B. and BALKO, J.M., 2018. Emerging 
biomarkers for cancer immunotherapy in melanoma. Seminars in Cancer 
Biology, 52(Pt 2), pp. 207-215. 
BADER, M.J., STEPP, H., BEYER, W., PONGRATZ, T., SROKA, R., 
KRIEGMAIR, M., ZAAK, D., WELSCHOF, M., TILKI, D., STIEF, C.G. 
and WAIDELICH, R., 2013. Photodynamic therapy of bladder cancer - a 
phase I study using hexaminolevulinate (HAL). Urologic Oncology, 31(7), pp. 
1178-1183. 
BARTON, D.T., ZENS, M.S., NELSON, H.H., CHRISTENSEN, B.C., STORM, 
C.A., PERRY, A.E. and KARAGAS, M.R., 2016. Distinct Histologic 
Subtypes and Risk Factors for Early Onset Basal Cell Carcinoma: A 
Population-Based Case Control Study from New Hampshire. Journal of 
Investigative Dermatology, 136(2), pp. 533-535. 
BARTON, V., ARMESON, K., HAMPRAS, S., FERRIS, L.K., VISVANATHAN, 
K., ROLLISON, D. and ALBERG, A.J., 2017. Nonmelanoma skin cancer 
and risk of all-cause and cancer-related mortality: a systematic review. 
Archives of Dermatological Research, 309(4), pp. 243-251. 
BATH-HEXTALL, F., LEONARDI-BEE, J., SOMCHAND, N., WEBSTER, A., 
DELITT, J. and PERKINS, W., 2007. Interventions for preventing non-
melanoma skin cancers in high-risk groups. Cochrane Database of Systematic 
Reviews, (4), pp. CD005414. 
BAY, C., LERCHE, C.M., FERRICK, B., PHILIPSEN, P.A., TOGSVERD-BO, 
K. and HAEDERSDAL, M., 2017. Comparison of Physical Pretreatment 
Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: 
A Randomized Clinical Trial. JAMA Dermatology, 153(4), pp. 270-278. 
  
 117 
BENTZEN, J., KJELLBERG, J., THORGAARD, C., ENGHOLM, G., 
PHILLIP, A. and STORM, H.H., 2013. Costs of illness for melanoma and 
nonmelanoma skin cancer in Denmark. European Journal of Cancer Prevention, 
22(6), pp. 569-576. 
BERLIN, N.L., FERRUCCI, L.M., CARTMEL, B., WANG, S., LEFFELL, D.J., 
MCNIFF, J.M. and MAYNE, S.T., 2015. Subsequent skin cancer in patients 
with early-onset basal cell carcinoma. Australasian Journal of Dermatology, 56(3), 
pp. 236-237. 
BETTI, R., RADAELLI, G., BOMBONATO, C., CROSTI, C., CERRI, A. and 
MENNI, S., 2010. Anatomic location of Basal cell carcinomas may favor 
certain histologic subtypes. Journal of Cutaneous Medicine & Surgery, 14(6), pp. 
298-302. 
BOEHRINGER, A., ADAM, P., SCHNABL, S., HAFNER, H. and 
BREUNINGER, H., 2015. Analysis of incomplete excisions of basal-cell 
carcinomas after breadloaf microscopy compared with 3D-microscopy: a 
prospective randomized and blinded study. Journal of Cutaneous Pathology, 
42(8), pp. 542-553. 
BORELLI, C., HERZINGER, T., MERK, K., BERKING, C., KUNTE, C., 
PLEWIG, G. and DEGITZ, K., 2007. Effect of subcutaneous infiltration 
anesthesia on pain in photodynamic therapy: a controlled open pilot trial. 
Dermatologic Surgery, 33(3), pp. 314-318. 
BORSARI, S., PAMPENA, R., LALLAS, A., KYRGIDIS, A., MOSCARELLA, 
E., BENATI, E., RAUCCI, M., PELLACANI, G., ZALAUDEK, I., 
ARGENZIANO, G. and LONGO, C., 2016. Clinical Indications for Use of 
Reflectance Confocal Microscopy for Skin Cancer Diagnosis. JAMA 
Dermatology, 152(10), pp. 1093-1098. 
BRUNSSEN, A., WALDMANN, A., EISEMANN, N. and KATALINIC, A., 
2017. Impact of skin cancer screening and secondary prevention campaigns 
on skin cancer incidence and mortality: A systematic review. Journal of the 
American Academy of Dermatology, 76(1), pp. 129-139.e10. 
BURDON-JONES, D. and THOMAS, P.W., 2006. One-fifth of basal cell 
carcinomas have a morphoeic or partly morphoeic histology: implications 
for treatment. Australasian Journal of Dermatology, 47(2), pp. 102-105. 
CAKIR, B.O., ADAMSON, P. and CINGI, C., 2012. Epidemiology and economic 
burden of nonmelanoma skin cancer. Facial Plastic Surgery Clinics of North 
America, 20(4), pp. 419-422. 
CAMPBELL, C.L., BROWN, C.T.A., WOOD, K., SALVIO, A.G., INADA, 
N.M., BAGNATO, V.S. and MOSELEY, H., 2017. A quantitative study of 
in vivo protoporphyrin IX fluorescence build up during occlusive treatment 
phases. Photodiagnosis & Photodynamic Therapy, 18, pp. 204-207. 
CANCER GENOME ATLAS NETWORK, 2015. Genomic Classification of 
Cutaneous Melanoma. Cell, 161(7), pp. 1681-1696. 
 118 
CASAS, A., PEROTTI, C., FUKUDA, H., ROGERS, L., BUTLER, A.R. and 
BATLLE, A., 2001. ALA and ALA hexyl ester-induced porphyrin synthesis 
in chemically induced skin tumours: the role of different vehicles on 
improving photosensitization. British Journal of Cancer, 85(11), pp. 1794-1800. 
CHEN, A.C., MARTIN, A.J., CHOY, B., FERNANDEZ-PENAS, P., 
DALZIELL, R.A., MCKENZIE, C.A., SCOLYER, R.A., DHILLON, 
H.M., VARDY, J.L., KRICKER, A., ST GEORGE, G., CHINNIAH, N., 
HALLIDAY, G.M. and DAMIAN, D.L., 2015. A Phase 3 Randomized Trial 
of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of 
Medicine, 373(17), pp. 1618-1626. 
CHEN, T., BERTENTHAL, D., SAHAY, A., SEN, S. and CHREN, M., 2007. 
Predictors of skin-related quality of life after treatment of cutaneous basal 
cell carcinoma and squamous cell carcinoma. Archives of Dermatology, 143(11), 
pp. 1386-1392. 
CHENG, H.M. and GUITERA, P., 2015. Systematic review of optical coherence 
tomography usage in the diagnosis and management of basal cell carcinoma. 
British Journal of Dermatology, 173(6), pp. 1371-1380. 
CHETTY, N.C., OSBORNE, V. and HARLAND, C., 2008. Amelanotic 
melanoma in situ: lack of sustained response to photodynamic therapy. 
Clinical & Experimental Dermatology, 33(2), pp. 204-206. 
CHREN, M., SAHAY, A.P., BERTENTHAL, D.S., SEN, S. and LANDEFELD, 
C.S., 2007. Quality-of-life outcomes of treatments for cutaneous basal cell 
carcinoma and squamous cell carcinoma. Journal of Investigative Dermatology, 
127(6), pp. 1351-1357. 
CINOTTI, E., LABEILLE, B., DEBARBIEUX, S., CARRERA, C., 
LACARRUBBA, F., WITKOWSKI, A.M., MOSCARELLA, E., 
ARZBERGER, E., KITTLER, H., BAHADORAN, P., GONZALEZ, S., 
GUITERA, P., AGOZZINO, M., FARNETANI, F., HOFMANN-
WELLENHOF, R., ARDIGO, M., RUBEGNI, P., TOGNETTI, L., 
LUDZIK, J., ZALAUDEK, I., ARGENZIANO, G., LONGO, C., 
RIBERO, S., MALVEHY, J., PELLACANI, G., CAMBAZARD, F. and 
PERROT, J.L., 2018. Dermoscopy vs. reflectance confocal microscopy for 
the diagnosis of lentigo maligna. Journal of the European Academy of Dermatology 
& Venereology, 32(8), pp. 1284-1291. 
COLLIER, N.J., HAYLETT, A.K., WONG, T.H., MORTON, C.A., 
IBBOTSON, S.H., MCKENNA, K.E., MALLIPEDDI, R., MOSELEY, H., 
SEUKERAN, D., WARD, K.A., MOHD MUSTAPA, M.F., EXTON, L.S., 
GREEN, A.C. and RHODES, L.E., 2018. Conventional and combination 
topical photodynamic therapy for basal cell carcinoma: systematic review and 
meta-analysis. British Journal of Dermatology, 179(6), pp. 1277-1296. 
COORY, M., BAADE, P., AITKEN, J., SMITHERS, M., MCLEOD, G.R.C. and 
RING, I., 2006. Trends for in situ and invasive melanoma in Queensland, 
Australia, 1982-2002. Cancer Causes & Control, 17(1), pp. 21-27. 
 119 
COUZAN, C., CINOTTI, E., LABEILLE, B., VERCHERIN, P., RUBEGNI, P., 
CAMBAZARD, F. and PERROT, J.L., 2018. Reflectance confocal 
microscopy identification of subclinical basal cell carcinomas during and 
after vismodegib treatment. Journal of the European Academy of Dermatology & 
Venereology, 32(5), pp. 763-767. 
COX, N.H., AITCHISON, T.C. and MACKIE, R.M., 1998. Extrafacial lentigo 
maligna melanoma: analysis of 71 cases and comparison with lentigo maligna 
melanoma of the head and neck. British Journal of Dermatology, 139(3), pp. 439-
443. 
COX, N.H., AITCHISON, T.C., SIREL, J.M. and MACKIE, R.M., 1996. 
Comparison between lentigo maligna melanoma and other histogenetic types 
of malignant melanoma of the head and neck. Scottish Melanoma Group. 
British Journal of Cancer, 73(7), pp. 940-944. 
CROWSON, A.N., 2006. Basal cell carcinoma: biology, morphology and clinical 
implications. Modern Pathology, 19(Suppl 2), pp. 127. 
CUST, A.E., MISHRA, K. and BERWICK, M., 2018. Melanoma - role of the 
environment and genetics. Photochemical & Photobiological Sciences, 17(12), pp. 
1853-1860. 
DE CARVALHO, N., CIARDO, S., CESINARO, A.M., JEMEC, G., ULRICH, 
M., WELZEL, J., HOLMES, J. and PELLACANI, G., 2016. In vivo micro-
angiography by means of speckle-variance optical coherence tomography 
(SV-OCT) is able to detect microscopic vascular changes in naevus to 
melanoma transition. Journal of the European Academy of Dermatology & 
Venereology, 30(10), pp. e67-e68. 
DE CARVALHO, N., WELZEL, J., SCHUH, S., THEMSTRUP, L., ULRICH, 
M., JEMEC, G.B.E., HOLMES, J., KALECI, S., CHESTER, J., BIGI, L., 
CIARDO, S. and PELLACANI, G., 2018. The vascular morphology of 
melanoma is related to Breslow index: An in vivo study with dynamic optical 
coherence tomography. Experimental dermatology, 27(11), pp. 1280-1286. 
DE VRIES, E., MICALLEF, R., BREWSTER, D.H., GIBBS, J.H., FLOHIL, S.C., 
SAKSELA, O., SANKILA, R., FORREST, A.D., TRAKATELLI, M., 
COEBERGH, J.W.W., PROBY, C.M. and EPIDERM GROUP, 2012. 
Population-based estimates of the occurrence of multiple vs first primary 
basal cell carcinomas in 4 European regions. Archives of Dermatology, 148(3), 
pp. 347-354. 
DEADY, S., SHARP, L. and COMBER, H., 2014. Increasing skin cancer 
incidence in young, affluent, urban populations: a challenge for prevention. 
British Journal of Dermatology, 171(2), pp. 324-331. 
DEBU, A., SLETH, J., GIRARD, C., BESSIS, D., GUILLOT, B. and 
BLATIERE, V., 2012. The use of subcutaneous infusion tumescent 
anesthesia in photodynamic therapy pain control. Paediatric Anaesthesia, 22(6), 
pp. 600-601. 
 120 
DESSINIOTI, C., ANTONIOU, C., KATSAMBAS, A. and STRATIGOS, A.J., 
2010. Basal cell carcinoma: what's new under the sun. Photochemistry & 
Photobiology, 86(3), pp. 481-491. 
DEWANE, M.E., KELSEY, A., OLIVIERO, M., RABINOVITZ, H. and 
GRANT-KELS, J.M., 2019. Melanoma on chronically sun-damaged skin: 
Lentigo maligna and desmoplastic melanoma. Journal of the American Academy 
of Dermatology, 81(3), pp. 823-833. 
DICKER, D.T., LERNER, J., VAN BELLE, P., BARTH, S.F., GUERRY D 4TH, 
HERLYN, M., ELDER, D.E. and EL-DEIRY, W.S., 2006. Differentiation 
of normal skin and melanoma using high resolution hyperspectral imaging. 
Cancer Biology & Therapy, 5(8), pp. 1033-1038. 
DICKER, D.T., KAHN, N., FLAHERTY, K.T., LERNER, J. and EL-DEIRY, 
W.S., 2011. Hyperspectral imaging: a non-invasive method of imaging 
melanoma lesions in a patient with stage IV melanoma, being treated with a 
RAF inhibitor. Cancer Biology & Therapy, 12(4), pp. 326-334. 
DINNES, J., DEEKS, J.J., CHUCHU, N., FERRANTE DI RUFFANO, L., 
MATIN, R.N., THOMSON, D.R., WONG, K.Y., ALDRIDGE, R.B., 
ABBOTT, R., FAWZY, M., BAYLISS, S.E., GRAINGE, M.J., 
TAKWOINGI, Y., DAVENPORT, C., GODFREY, K., WALTER, F.M., 
WILLIAMS, H.C. and COCHRANE SKIN CANCER DIAGNOSTIC 
TEST ACCURACY GROUP, 2018a. Dermoscopy, with and without visual 
inspection, for diagnosing melanoma in adults. Cochrane Database of Systematic 
Reviews, 12, pp. 011902. 
DINNES, J., DEEKS, J.J., CHUCHU, N., SALEH, D., BAYLISS, S.E., 
TAKWOINGI, Y., DAVENPORT, C., PATEL, L., MATIN, R.N., 
O'SULLIVAN, C., PATALAY, R., WILLIAMS, H.C. and COCHRANE 
SKIN CANCER DIAGNOSTIC TEST ACCURACY GROUP, 2018b. 
Reflectance confocal microscopy for diagnosing keratinocyte skin cancers in 
adults. Cochrane Database of Systematic Reviews, 12, pp. 013191. 
DINNES, J., DEEKS, J.J., SALEH, D., CHUCHU, N., BAYLISS, S.E., PATEL, 
L., DAVENPORT, C., TAKWOINGI, Y., GODFREY, K., MATIN, R.N., 
PATALAY, R., WILLIAMS, H.C. and COCHRANE SKIN CANCER 
DIAGNOSTIC TEST ACCURACY GROUP, 2018c. Reflectance confocal 
microscopy for diagnosing cutaneous melanoma in adults. Cochrane Database 
of Systematic Reviews, 12, pp. 013190. 
DIXON, A.J., ANDERSON, S.J., DIXON, M.P. and DIXON, J.B., 2015. Post 
procedural pain with photodynamic therapy is more severe than skin surgery. 
Journal of Plastic, Reconstructive & Aesthetic Surgery, 68(2), pp. 28. 
EDWARDS, S.J., OSEI-ASSIBEY, G., PATALAY, R., WAKEFIELD, V. and 
KARNER, C., 2017. Diagnostic accuracy of reflectance confocal microscopy 
using VivaScope for detecting and monitoring skin lesions: a systematic 
review. Clinical & Experimental Dermatology, 42(3), pp. 266-275. 
 121 
EISEMANN, N., WALDMANN, A., GELLER, A.C., WEINSTOCK, M.A., 
VOLKMER, B., GREINERT, R., BREITBART, E.W. and KATALINIC, 
A., 2014. Non-melanoma skin cancer incidence and impact of skin cancer 
screening on incidence. Journal of Investigative Dermatology, 134(1), pp. 43-50. 
ERICSON, M.B., GRAPENGIESSER, S., GUDMUNDSON, F., WENNBERG, 
A., LARKO, O., MOAN, J. and ROSEN, A., 2003. A spectroscopic study of 
the photobleaching of protoporphyrin IX in solution. Lasers in Medical Science, 
18(1), pp. 56-62. 
ESSERS, B.A.B., ARITS, A.H., HENDRIKS, M.R., MOSTERD, K. and 
KELLENERS-SMEETS, N.W., 2018. Patient preferences for the attributes 
of a noninvasive treatment for superficial basal cell carcinoma: a discrete 
choice experiment. British Journal of Dermatology, 178(1), pp. e26-e27. 
FANTINI, F., GRECO, A., CESINARO, A.M., SURRENTI, T., PERIS, K., 
VASCHIERI, C., MARCONI, A., GIANNETTI, A. and PINCELLI, C., 
2008. Pathologic changes after photodynamic therapy for Basal cell 
carcinoma and Bowen disease: a histologic and immunohistochemical 
investigation. Archives of Dermatology, 144(2), pp. 186-194. 
FARNETANI, F., MANFREDINI, M., CHESTER, J., CIARDO, S., 
GONZALEZ, S. and PELLACANI, G., 2019. Reflectance confocal 
microscopy in the diagnosis of pigmented macules of the face: differential 
diagnosis and margin definition. Photochemical & Photobiological Sciences, 18(5), 
pp. 963-969. 
FERRANTE DI RUFFANO, L., DINNES, J., DEEKS, J.J., CHUCHU, N., 
BAYLISS, S.E., DAVENPORT, C., TAKWOINGI, Y., GODFREY, K., 
O'SULLIVAN, C., MATIN, R.N., TEHRANI, H., WILLIAMS, H.C. and 
COCHRANE SKIN CANCER DIAGNOSTIC TEST ACCURACY 
GROUP, 2018. Optical coherence tomography for diagnosing skin cancer in 
adults. Cochrane Database of Systematic Reviews, 12, pp. 013189. 
FINK, C. and HAENSSLE, H.A., 2017. Non-invasive tools for the diagnosis of 
cutaneous melanoma. Skin Research & Technology, 23(3), pp. 261-271. 
FINNISH CANCER REGISTRY, Cancer 2017, a yearly report on the cancer statistics in 
Finland. Accessed [February 20th, 2020], available online at 
https://syoparekisteri.fi/tilastot/syopa-2017-raportti/ 
FLOHIL, S.C., PROBY, C.M., FORREST, A.D., VAN TIEL, S., SAKSELA, O., 
PITKANEN, S., AHTI, T., MICALLEF, R., DE VRIES, E. and EPIDERM 
GROUP, 2012. Basal cell carcinomas without histological confirmation and 
their treatment: an audit in four European regions. British Journal of 
Dermatology, 167(Suppl 2), pp. 22-28. 
FLOHIL, S.C., VAN DER LEEST, ROBERT J T, ARENDS, L.R., DE VRIES, 
E. and NIJSTEN, T., 2013. Risk of subsequent cutaneous malignancy in 
patients with prior keratinocyte carcinoma: a systematic review and meta-
analysis. European Journal of Cancer, 49(10), pp. 2365-2375. 
  
 122 
FOTINOS, N., CAMPO, M.A., POPOWYCZ, F., GURNY, R. and LANGE, N., 
2006. 5-Aminolevulinic acid derivatives in photomedicine: Characteristics, 
application and perspectives. Photochemistry & Photobiology, 82(4), pp. 994-
1015. 
FRIEDMAN, R.J., GUTKOWICZ-KRUSIN, D., FARBER, M.J., WARYCHA, 
M., SCHNEIDER-KELS, L., PAPASTATHIS, N., MIHM MC JR, 
GOOGE, P., KING, R., PRIETO, V.G., KOPF, A.W., POLSKY, D., 
RABINOVITZ, H., OLIVIERO, M., COGNETTA, A., RIGEL, D.S., 
MARGHOOB, A., RIVERS, J., JOHR, R., GRANT-KELS, J.M. and 
TSAO, H., 2008. The diagnostic performance of expert dermoscopists vs a 
computer-vision system on small-diameter melanomas. Archives of 
Dermatology, 144(4), pp. 476-482. 
GAMBICHLER, T., SCHMID-WENDTNER, M.H., PLURA, I., 
KAMPILAFKOS, P., STUCKER, M., BERKING, C. and MAIER, T., 
2015. A multicentre pilot study investigating high-definition optical 
coherence tomography in the differentiation of cutaneous melanoma and 
melanocytic naevi. Journal of the European Academy of Dermatology & Venereology, 
29(3), pp. 537-541. 
GAMO-VILLEGAS, R., PAMPIN-FRANCO, A., FLORISTAN-MURUZABAL, 
U., GARCIA-ZAMORA, E., PINEDO-MORALEDA, F. and LOPEZ-
ESTEBARANZ, J.L., 2019. Key dermoscopic signs in the diagnosis and 
progression of extrafacial lentigo maligna: Evaluation of a series of 41 cases. 
Australasian Journal of Dermatology, 60(4), pp. 288-293. 
GARBE, C., PERIS, K., HAUSCHILD, A., SAIAG, P., MIDDLETON, M., 
BASTHOLT, L., GROB, J., MALVEHY, J., NEWTON-BISHOP, J., 
STRATIGOS, A.J., PEHAMBERGER, H., EGGERMONT, A.M., 
EUROPEAN DERMATOLOGY FORUM, (., EUROPEAN 
ASSOCIATION OF DERMATO-ONCOLOGY, (EADO) and 
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT 
OF CANCER, (EORTC), 2016. Diagnosis and treatment of melanoma: 
European consensus-based interdisciplinary guideline - Update 2016. 
European Journal of Cancer, 63, pp. 201-217. 
GAUDI, S., MEYER, R., RANKA, J., GRANAHAN, J.C., ISRAEL, S.A., 
YACHIK, T.R. and JUKIC, D.M., 2014. Hyperspectral imaging of 
melanocytic lesions. American Journal of Dermatopathology, 36(2), pp. 131-136. 
GAUDY-MARQUESTE, C., MADJLESSI, N., GUILLOT, B., AVRIL, M. and 
GROB, J., 2009. Risk factors in elderly people for lentigo maligna compared 
with other melanomas: a double case-control study. Archives of Dermatology, 
145(4), pp. 418-423. 
GAULIN, C., SEBARATNAM, D.F. and FERNANDEZ-PENAS, P., 2015. 
Quality of life in non-melanoma skin cancer. Australasian Journal of 
Dermatology, 56(1), pp. 70-76. 
 123 
GERSHENWALD, J.E. and SCOLYER, R.A., 2018. Melanoma Staging: American 
Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of 
Surgical Oncology, 25(8), pp. 2105-2110. 
GERSHENWALD, J.E., SCOLYER, R.A., HESS, K.R., SONDAK, V.K., 
LONG, G.V., ROSS, M.I., LAZAR, A.J., FARIES, M.B., KIRKWOOD, 
J.M., MCARTHUR, G.A., HAYDU, L.E., EGGERMONT, A.M.M., 
FLAHERTY, K.T., BALCH, C.M., THOMPSON, J.F. and FOR 
MEMBERS OF THE AMERICAN JOINT COMMITTEE ON CANCER 
MELANOMA EXPERT PANEL AND THE INTERNATIONAL 
MELANOMA DATABASE AND DISCOVERY PLATFORM, 2017. 
Melanoma staging: Evidence-based changes in the American Joint 
Committee on Cancer eighth edition cancer staging manual. CA: a Cancer 
Journal for Clinicians, 67(6), pp. 472-492. 
GLOSTER, H.M.J. and NEAL, K., 2006. Skin cancer in skin of color. Journal of the 
American Academy of Dermatology, 55(5), pp. 741-760. 
GLUD, M., GNIADECKI, R. and DRZEWIECKI, K.T., 2009. 
Spectrophotometric intracutaneous analysis versus dermoscopy for the 
diagnosis of pigmented skin lesions: prospective, double-blind study in a 
secondary reference centre. Melanoma Research, 19(3), pp. 176-179. 
GOLDENBERG, G., KARAGIANNIS, T., PALMER, J.B., LOTYA, J., 
O'NEILL, C., KISA, R., HERRERA, V. and SIEGEL, D.M., 2016. 
Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced 
BCC (LABCC) in a large commercially insured population in the United 
States: A retrospective cohort study. Journal of the American Academy of 
Dermatology, 75(5), pp. 957-966.e2. 
GREVELING, K., WAKKEE, M., NIJSTEN, T., VAN DEN BOS, RENATE R. 
and HOLLESTEIN, L.M., 2016. Epidemiology of Lentigo Maligna and 
Lentigo Maligna Melanoma in the Netherlands, 1989-2013. Journal of 
Investigative Dermatology, 136(10), pp. 1955-1960. 
GUITERA, P., PELLACANI, G., CROTTY, K.A., SCOLYER, R.A., LI, L.X., 
BASSOLI, S., VINCETI, M., RABINOVITZ, H., LONGO, C. and 
MENZIES, S.W., 2010. The impact of in vivo reflectance confocal 
microscopy on the diagnostic accuracy of lentigo maligna and equivocal 
pigmented and nonpigmented macules of the face. Journal of Investigative 
Dermatology, 130(8), pp. 2080-2091. 
GULLETH, Y., GOLDBERG, N., SILVERMAN, R.P. and GASTMAN, B.R., 
2010. What is the best surgical margin for a Basal cell carcinoma: a meta-
analysis of the literature. Plastic & Reconstructive Surgery, 126(4), pp. 1222-1231. 
HAAK, C.S., CHRISTIANSEN, K., ERLENDSSON, A.M., TAUDORF, E.H., 
THAYSEN-PETERSEN, D., WULF, H.C. and HAEDERSDAL, M., 2016. 
Ablative fractional laser enhances MAL-induced PpIX accumulation: Impact 
of laser channel density, incubation time and drug concentration. Journal of 
Photochemistry & Photobiology.B - Biology, 159, pp. 42-48. 
 124 
HAEDERSDAL, M., SAKAMOTO, F.H., FARINELLI, W.A., DOUKAS, A.G., 
TAM, J. and ANDERSON, R.R., 2010. Fractional CO(2) laser-assisted drug 
delivery. Lasers in Surgery & Medicine, 42(2), pp. 113-122. 
HAMBLY, R., MANSOOR, N., QUINLAN, C., SHAH, Z., LENANE, P., 
RALPH, N. and MOLONEY, F.J., 2017. Topical photodynamic therapy for 
primary Bowen disease and basal cell carcinoma: optimizing patient 
selection. British Journal of Dermatology, 177(3), pp. e55-e57. 
HARTMANN, D., KRAMMER, S., RUINI, C., RUZICKA, T. and VON 
BRAUNMUHL, T., 2016. Correlation of histological and ex-vivo confocal 
tumor thickness in malignant melanoma. Lasers in Medical Science, 31(5), pp. 
921-927. 
HAUSCHILD, A., CHEN, S.C., WEICHENTHAL, M., BLUM, A., KING, H.C., 
GOLDSMITH, J., SCHARFSTEIN, D. and GUTKOWICZ-KRUSIN, D., 
2014. To excise or not: impact of MelaFind on German dermatologists' 
decisions to biopsy atypical lesions. Journal der Deutschen Dermatologischen 
Gesellschaft, 12(7), pp. 606-614. 
HELVIND, N.M., HOLMICH, L.R., SMITH, S., GLUD, M., ANDERSEN, 
K.K., DALTON, S.O. and DRZEWIECKI, K.T., 2015. Incidence of In Situ 
and Invasive Melanoma in Denmark From 1985 Through 2012: A National 
Database Study of 24,059 Melanoma Cases. JAMA Dermatology, 151(10), pp. 
1087-1095. 
HIGGINS, H.W.2., LEE, K.C., GALAN, A. and LEFFELL, D.J., 2015. 
Melanoma in situ: Part I. Epidemiology, screening, and clinical features. 
Journal of the American Academy of Dermatology, 73(2), pp. 181-190. 
HILLEMANNS, P., GARCIA, F., PETRY, K.U., DVORAK, V., SADOVSKY, 
O., IVERSEN, O. and EINSTEIN, M.H., 2015. A randomized study of 
hexaminolevulinate photodynamic therapy in patients with cervical 
intraepithelial neoplasia 1/2. American Journal of Obstetrics & Gynecology, 212(4), 
pp. 465.e1-465.e7. 
HINZ, T., EHLER, L.K., VOTH, H., FORTMEIER, I., HOELLER, T., 
HORNUNG, T. and SCHMID-WENDTNER, M.H., 2011. Assessment of 
tumor thickness in melanocytic skin lesions: comparison of optical 
coherence tomography, 20-MHz ultrasound and histopathology. Dermatology, 
223(2), pp. 161-168. 
HOLM, A., NISSEN, C.V. and WULF, H.C., 2016. Basal Cell Carcinoma is as 
Common as the Sum of all Other Cancers: Implications for Treatment 
Capacity. Acta Dermato-Venereologica, 96(4), pp. 505-509. 
HOLMES, J., VON BRAUNMUHL, T., BERKING, C., SATTLER, E., 
ULRICH, M., REINHOLD, U., KURZEN, H., DIRSCHKA, T., 
KELLNER, C., SCHUH, S. and WELZEL, J., 2018. Optical coherence 
tomography of basal cell carcinoma: influence of location, subtype, observer 
variability and image quality on diagnostic performance. British Journal of 
Dermatology, 178(5), pp. 1102-1110. 
 125 
HURLIMANN, A.F., HANGGI, G. and PANIZZON, R.G., 1998. Photodynamic 
therapy of superficial basal cell carcinomas using topical 5-aminolevulinic 
acid in a nanocolloid lotion. Dermatology, 197(3), pp. 248-254. 
IBBOTSON, S.H., WONG, T.H., MORTON, C.A., COLLIER, N.J., HAYLETT, 
A., MCKENNA, K.E., MALLIPEDDI, R., MOSELEY, H., RHODES, 
L.E., SEUKERAN, D.C., WARD, K.A., MOHD MUSTAPA, M.F. and 
EXTON, L.S., 2019. Adverse effects of topical photodynamic therapy: a 
consensus review and approach to management. British Journal of Dermatology, 
180(4), pp. 715-729. 
INSKIP, M. and ROSENDAHL, C., 2016. Extrafacial lentigo maligna melanoma 
is reported often in Australia, more so at lower latitudes. Australasian Journal 
of Dermatology, 57(1), pp. 70-71. 
JACQUES, S.L., 2013. Optical properties of biological tissues: a review. Physics in 
Medicine & Biology, 58(11), pp. 37. 
JAIMES, N. and MARGHOOB, A.A., 2013. The morphologic universe of 
melanoma. Dermatologic Clinics, 31(4), pp. 599-613. 
JANSEN, M.H.E., KOEKELKOREN, F.H.J., NELEMANS, P.J., ARITS, 
AIMEE H M M., ROOZEBOOM, M.H., KELLENERS-SMEETS, N.W.J. 
and MOSTERD, K., 2018. Comparison of long-term cosmetic outcomes for 
different treatments of superficial basal cell carcinoma. Journal of the American 
Academy of Dermatology, 79(5), pp. 961-964. 
JANSEN, M.H.E., MOSTERD, K., ARITS, AIMEE H M M, ROOZEBOOM, 
M.H., SOMMER, A., ESSERS, B.A.B., VAN PELT, HAN P A, 
QUAEDVLIEG, P.J.F., STEIJLEN, P.M., NELEMANS, P.J. and 
KELLENERS-SMEETS, N.W.J., 2018. Five-Year Results of a Randomized 
Controlled Trial Comparing Effectiveness of Photodynamic Therapy, 
Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial 
Basal Cell Carcinoma. Journal of Investigative Dermatology, 138(3), pp. 527-533. 
JAYASEKERA, P.S.A., DODD, J., OLIPHANT, T., LANGTRY, J.A.A. and 
LAWRENCE, C.M., 2018. Dermoscopy prior to Mohs micrographic surgery 
does not improve tumour margin assessment and leads to fewer Mohs 
stages. British Journal of Dermatology, 178(2), pp. 565-566. 
JENSEN, A.O., BAUTZ, A., OLESEN, A.B., KARAGAS, M.R., SORENSEN, 
H.T. and FRIIS, S., 2008. Mortality in Danish patients with nonmelanoma 
skin cancer, 1978-2001. British Journal of Dermatology, 159(2), pp. 419-425. 
JERJES, W., HAMDOON, Z., AL RAWI, N. and HOPPER, C., 2019. OCT in 
the diagnosis of head and neck pre-cancerous and cancerous cutaneous 
lesions: An immediate ex vivo study. Photodiagnosis & Photodynamic Therapy, 
27, pp. 481-486. 
JUZENIENE, A., JUZENAS, P., MA, L., IANI, V. and MOAN, J., 2006. Topical 
application of 5-aminolaevulinic acid, methyl 5-aminolaevulinate and hexyl 
5-aminolaevulinate on normal human skin. British Journal of Dermatology, 
155(4), pp. 791-799. 
 126 
KADOUCH, D.J., LEEFLANG, M.M., ELSHOT, Y.S., LONGO, C., ULRICH, 
M., VAN DER WAL, A C., WOLKERSTORFER, A., BEKKENK, M.W. 
and DE RIE, M.A., 2017. Diagnostic accuracy of confocal microscopy 
imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma. 
Journal of the European Academy of Dermatology & Venereology, 31(10), pp. 1641-
1648. 
KANG, H.Y., BAHADORAN, P. and ORTONNE, J.P., 2010. Reflectance 
confocal microscopy for pigmentary disorders. Experimental Dermatology, 
19(3), pp. 233-239. 
KARAM, A., SIMON, M., LEMASSON, G. and MISERY, L., 2013. The use of 
photodynamic therapy in the treatment of lentigo maligna. Pigment Cell & 
Melanoma Research, 26(2), pp. 275-277. 
KENNEDY, J.C., POTTIER, R.H. and PROSS, D.C., 1990. Photodynamic 
therapy with endogenous protoporphyrin IX: basic principles and present 
clinical experience. Journal of Photochemistry & Photobiology.B - Biology, 6(1-2), 
pp. 143-148. 
KESSELS, J P H M., KREUKELS, H., NELEMANS, P.J., ROOZEBOOM, 
M.H., VAN PELT, H., MOSTERD, K., DE HAAS, E R M. and 
KELLENERS-SMEETS, N.W.J., 2018. Treatment of superficial basal cell 
carcinoma by topical photodynamic therapy with fractionated 5-
aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: 
results of a randomized controlled trial. British Journal of Dermatology, 178(5), 
pp. 1056-1063. 
KIESSLICH, T., HELANDER, L., ILLIG, R., OBERDANNER, C., WAGNER, 
A., LETTNER, H., JAKAB, M. and PLAETZER, K., 2014. Real-time 
analysis of endogenous protoporphyrin IX fluorescence from delta-
aminolevulinic acid and its derivatives reveals distinct time- and dose-
dependent characteristics in vitro. Journal of Biomedical Optics, 19(8), pp. 
085007. 
KIMYAI-ASADI, A., KATZ, T., GOLDBERG, L.H., AYALA, G.B., WANG, 
S.Q., VUJEVICH, J.J. and JIH, M.H., 2007. Margin involvement after the 
excision of melanoma in situ: the need for complete en face examination of 
the surgical margins. Dermatologic Surgery, 33(12), pp. 1434-1439. 
KOH, D., WANG, H., LEE, J., CHIA, K.S., LEE, H.P. and GOH, C.L., 2003. 
Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: 
analysis of the Singapore Cancer Registry data 1968-97. British Journal of 
Dermatology, 148(6), pp. 1161-1166. 
KOSE, K., CORDOVA, M., DUFFY, M., FLORES, E.S., BROOKS, D.H. and 
RAJADHYAKSHA, M., 2014. Video-mosaicing of reflectance confocal 
images for examination of extended areas of skin in vivo. British Journal of 
Dermatology, 171(5), pp. 1239-1241. 
 127 
KRAFT, S. and GRANTER, S.R., 2014. Molecular pathology of skin neoplasms of 
the head and neck. Archives of Pathology & Laboratory Medicine, 138(6), pp. 759-
787. 
KUO, K.Y., BATRA, P., CHO, H.G., LI, S., CHAHAL, H.S., RIEGER, K.E., 
TANG, J.Y. and SARIN, K.Y., 2017. Correlates of multiple basal cell 
carcinoma in a retrospective cohort study: Sex, histologic subtypes, and 
anatomic distribution. Journal of the American Academy of Dermatology, 77(2), pp. 
233-234.e2. 
KVASKOFF, M., SISKIND, V. and GREEN, A.C., 2012. Risk factors for lentigo 
maligna melanoma compared with superficial spreading melanoma: a case-
control study in Australia. Archives of Dermatology, 148(2), pp. 164-170. 
LAI, V., CRANWELL, W. and SINCLAIR, R., 2018. Epidemiology of skin cancer 
in the mature patient. Clinics in Dermatology, 36(2), pp. 167-176. 
LALLAS, A., APALLA, Z., ARGENZIANO, G., LONGO, C., MOSCARELLA, 
E., SPECCHIO, F., RAUCCI, M. and ZALAUDEK, I., 2014. The 
dermatoscopic universe of basal cell carcinoma. Dermatology Practical & 
Conceptual, 4(3), pp. 11-24. 
LALLAS, A., ARGENZIANO, G., MOSCARELLA, E., LONGO, C., 
SIMONETTI, V. and ZALAUDEK, I., 2014. Diagnosis and management 
of facial pigmented macules. Clinics in Dermatology, 32(1), pp. 94-100. 
LALLAS, A., TZELLOS, T., KYRGIDIS, A., APALLA, Z., ZALAUDEK, I., 
KARATOLIAS, A., FERRARA, G., PIANA, S., LONGO, C., 
MOSCARELLA, E., STRATIGOS, A. and ARGENZIANO, G., 2014. 
Accuracy of dermoscopic criteria for discriminating superficial from other 
subtypes of basal cell carcinoma. Journal of the American Academy of Dermatology, 
70(2), pp. 303-311. 
LANGLEY, R.G., WALSH, N., SUTHERLAND, A.E., PROPPEROVA, I., 
DELANEY, L., MORRIS, S.F. and GALLANT, C., 2007. The diagnostic 
accuracy of in vivo confocal scanning laser microscopy compared to 
dermoscopy of benign and malignant melanocytic lesions: a prospective 
study. Dermatology, 215(4), pp. 365-372. 
LASITHIOTAKIS, K.G., PETRAKIS, I.E. and GARBE, C., 2010. Cutaneous 
melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma 
research, 20(3), pp. 163-170. 
LINDELOF, B., LAPINS, J. and DAL, H., 2017. Shift in Occupational Risk for 
Basal Cell Carcinoma from Outdoor to Indoor Workers: A Large 
Population-based Case-control Register Study from Sweden. Acta Dermato-
Venereologica, 97(7), pp. 830-833. 
LINOS, E., LI, W.Q., HAN, J., LI, T., CHO, E. and QURESHI, A.A., 2017. 
Lifetime ultraviolet radiation exposure and lentigo maligna melanoma. British 
Journal of Dermatology, 176(6), pp. 1666-1668. 
 128 
LIPPERT, J., SMUCLER, R. and VLK, M., 2013. Fractional carbon dioxide laser 
improves nodular basal cell carcinoma treatment with photodynamic therapy 
with methyl 5-aminolevulinate. Dermatologic Surgery, 39(8), pp. 1202-1208. 
LIU, V. and MIHM, M.C., 2003. Pathology of malignant melanoma. Surgical Clinics 
of North America, 83(1), pp. 31-60. 
LOMAS, A., LEONARDI-BEE, J. and BATH-HEXTALL, F., 2012. A systematic 
review of worldwide incidence of nonmelanoma skin cancer. British Journal of 
Dermatology, 166(5), pp. 1069-1080. 
LOPEZ, R.F.V., LANGE, N., GUY, R. and BENTLEY, MARIA VITORIA 
LOPES BADRA, 2004. Photodynamic therapy of skin cancer: controlled 
drug delivery of 5-ALA and its esters. Advanced Drug Delivery Reviews, 56(1), 
pp. 77-94. 
LOWENSTEIN, S.E., GARRETT, G., TOLAND, A.E., JAMBUSARIA-
PAHLAJANI, A., ASGARI, M.M., GREEN, A., ENGELS, E.A., ARRON, 
S.T. and NATIONAL CANCER INSTITUTE KERATINOCYTE 
CARCINOMA CONSORTIUM, 2017. Risk prediction tools for 
keratinocyte carcinoma after solid organ transplantation: a review of the 
literature. British Journal of Dermatology, 177(5), pp. 1202-1207. 
LU, G., and FEI, B., 2014. Medical hyperspectral imaging: a review. Journal 
Biomedical optics, 19(1):10901, 2014 Jan. 
LUBEEK, S.F.K., VAN VUGT, L.J., ABEN, K.K.H., VAN DE KERKHOF, 
PETER C M. and GERRITSEN, M.P., 2017. The Epidemiology and 
Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years 
and Older: A Systematic Review. JAMA Dermatology, 153(1), pp. 71-78. 
LUI, H., ZHAO, J., MCLEAN, D. and ZENG, H., 2012. Real-time Raman 
spectroscopy for in vivo skin cancer diagnosis. Cancer Research, 72(10), pp. 
2491-2500. 
MAHER, N.G., BLUMETTI, T.P., GOMES, E.E., CHENG, H.M., 
SATGUNASEELAN, L., LO, S., REZZE, G.G., SCOLYER, R.A. and 
GUITERA, P., 2017. Melanoma diagnosis may be a pitfall for optical 
coherence tomography assessment of equivocal amelanotic or 
hypomelanotic skin lesions. British Journal of Dermatology, 177(2), pp. 574-577. 
MAHER, N.G., SOLINAS, A., SCOLYER, R.A., PUIG, S., PELLACANI, G. and 
GUITERA, P., 2017. Detection of desmoplastic melanoma with 
dermoscopy and reflectance confocal microscopy. Journal of the European 
Academy of Dermatology & Venereology, 31(12), pp. 2016-2024. 
MAISCH, T., SANTARELLI, F., SCHREML, S., BABILAS, P. and SZEIMIES, 
R., 2010. Fluorescence induction of protoporphyrin IX by a new 5-
aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-
thickness ex vivo skin model. Experimental Dermatology, 19(8), pp. 302. 
  
 129 
MALLIDI, S., ANBIL, S., LEE, S., MANSTEIN, D., ELRINGTON, S., 
KOSITRATNA, G., SCHOENFELD, D., POGUE, B., DAVIS, S.J. and 
HASAN, T., 2014. Photosensitizer fluorescence and singlet oxygen 
luminescence as dosimetric predictors of topical 5-aminolevulinic acid 
photodynamic therapy induced clinical erythema. Journal of Biomedical Optics, 
19(2), pp. 028001. 
MANESTAR-BLAZIC, T., BATINAC, T., HADZISEJDIC, I. and BRAJAC, I., 
2007. Apoptosis and immune response are responsible for the site-specific 
incidence of non-melanoma skin cancer. Medical Hypotheses, 68(4), pp. 853-
855. 
MARMUR, E.S., BERKOWITZ, E.Z., FUCHS, B.S., SINGER, G.K. and YOO, 
J.Y., 2010. Use of high-frequency, high-resolution ultrasound before Mohs 
surgery. Dermatologic Surgery, 36(6), pp. 841-847. 
MARRA, K., LAROCHELLE, E.P., CHAPMAN, M.S., HOOPES, P.J., 
LUKOVITS, K., MAYTIN, E.V., HASAN, T. and POGUE, B.W., 2018. 
Comparison of Blue and White Lamp Light with Sunlight for Daylight-
Mediated, 5-ALA Photodynamic Therapy, in vivo. Photochemistry & 
Photobiology, 94(5), pp. 1049-1057. 
MARTIN, I., SCHAARSCHMIDT, M., GLOCKER, A., HERR, R., 
SCHMIEDER, A., GOERDT, S. and PEITSCH, W.K., 2016. Patient 
Preferences for Treatment of Basal Cell Carcinoma: Importance of Cure and 
Cosmetic Outcome. Acta Dermato-Venereologica, 96(3), pp. 355-360. 
MATACA, E., MIGALDI, M. and CESINARO, A.M., 2018. Impact of 
Dermoscopy and Reflectance Confocal Microscopy on the Histopathologic 
Diagnosis of Lentigo Maligna/Lentigo Maligna Melanoma. American Journal 
of Dermatopathology, 40(12), pp. 884-889. 
MAZURENKA, M., BEHRENDT, L., MEINHARDT-WOLLWEBER, M., 
MORGNER, U. and ROTH, B., 2017. Development of a combined OCT-
Raman probe for the prospective in vivo clinical melanoma skin cancer 
screening. Review of Scientific Instruments, 88(10), pp. 105103. 
MIDDELBURG, T.A., DE VIJLDER, H.C., DE BRUIJN, H.S., VAN DER 
PLOEG-VAN DEN HEUVEL, ANGELIQUE, NEUMANN, H.A.M., 
DE HAAS, ELLEN R M. and ROBINSON, D.J., 2014. Topical 
photodynamic therapy using different porphyrin precursors leads to 
differences in vascular photosensitization and vascular damage in normal 
mouse skin. Photochemistry & Photobiology, 90(4), pp. 896-902. 
MIRZOYEV, S.A., KNUDSON, R.M., REED, K.B., HOU, J.L., LOHSE, C.M., 
FROHM, M.L., BREWER, J.D., OTLEY, C.C. and ROENIGK, R.K., 2014. 
Incidence of lentigo maligna in Olmsted County, Minnesota, 1970 to 2007. 
Journal of the American Academy of Dermatology, 70(3), pp. 443-448. 
MOAN, J., BERG, K., GADMAR, O.B., IANI, V., MA, L. and JUZENAS, P., 
1999. The temperature dependence of protoporphyrin IX production in cells 
and tissues. Photochemistry & Photobiology, 70(4), pp. 669-673. 
 130 
MOHAN, S.V. and CHANG, A.L.S., 2014. Advanced Basal Cell Carcinoma: 
Epidemiology and Therapeutic Innovations. Current Dermatology Reports, 3, 
pp. 40-45. 
MOHR, P., BIRGERSSON, U., BERKING, C., HENDERSON, C., TREFZER, 
U., KEMENY, L., SUNDERKOTTER, C., DIRSCHKA, T., MOTLEY, R., 
FROHM-NILSSON, M., REINHOLD, U., LOQUAI, C., BRAUN, R., 
NYBERG, F. and PAOLI, J., 2013. Electrical impedance spectroscopy as a 
potential adjunct diagnostic tool for cutaneous melanoma. Skin Research & 
Technology, 19(2), pp. 75-83. 
MONCRIEFF, M., COTTON, S., CLARIDGE, E. and HALL, P., 2002. 
Spectrophotometric intracutaneous analysis: a new technique for imaging 
pigmented skin lesions. British Journal of Dermatology, 146(3), pp. 448-457. 
MONHEIT, G., COGNETTA, A.B., FERRIS, L., RABINOVITZ, H., GROSS, 
K., MARTINI, M., GRICHNIK, J.M., MIHM, M., PRIETO, V.G., 
GOOGE, P., KING, R., TOLEDANO, A., KABELEV, N., WOJTON, M. 
and GUTKOWICZ-KRUSIN, D., 2011. The performance of MelaFind: a 
prospective multicenter study. Archives of Dermatology, 147(2), pp. 188-194. 
MORAES PINTO BLUMETTI, TATIANA CRISTINA, COHEN, M.P., 
GOMES, E.E., PETACCIA DE MACEDO, M., FERREIRA DE SOUZA 
BEGNAMI, MARIA DIRLEI, TAVARES GUERREIRO FREGNANI, 
JOSE HUMBERTO, DUPRAT, J.P., PELLACANI, G. and REZZE, G.G., 
2015. Optical coherence tomography (OCT) features of nevi and melanomas 
and their association with intraepidermal or dermal involvement: A pilot 
study. Journal of the American Academy of Dermatology, 73(2), pp. 315-317. 
MORROW, D.I.J., MCCARRON, P.A., WOOLFSON, A.D., JUZENAS, P., 
JUZENIENE, A., IANI, V., MOAN, J. and DONNELLY, R.F., 2010. 
Hexyl aminolaevulinate is a more effective topical photosensitiser precursor 
than methyl aminolaevulinate and 5-aminolaevulinic acids when applied in 
equimolar doses. Journal of Pharmaceutical Sciences, 99(8), pp. 3486-3498. 
  
 131 
MORTON, C.A., DOMINICUS, R., RADNY, P., DIRSCHKA, T., 
HAUSCHILD, A., REINHOLD, U., ASCHOFF, R., ULRICH, M., 
KEOHANE, S., EKANAYAKE-BOHLIG, S., IBBOTSON, S., 
OSTENDORF, R., BERKING, C., GRONE, D., SCHULZE, H.J., 
OCKENFELS, H.M., JASNOCH, V., KURZEN, H., SEBASTIAN, M., 
STEGE, H., STAUBACH, P., GUPTA, G., HUBINGER, F., ZIABREVA, 
I., SCHMITZ, B., GERTZMANN, A., LUBBERT, H. and SZEIMIES, R., 
2018. A randomized, multinational, noninferiority, phase III trial to evaluate 
the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl 
aminolaevulinate cream in the treatment of nonaggressive basal cell 
carcinoma with photodynamic therapy. British Journal of Dermatology, 179(2), 
pp. 309-319. 
MORTON, C., SZEIMIES, R., SIDOROFF, A., WENNBERG, A., BASSET-
SEGUIN, N., CALZAVARA-PINTON, P., GILABERTE, Y., 
HOFBAUER, G., HUNGER, R., KARRER, S., LEHMANN, P., 
PIASERICO, S., ULRICH, C., BRAATHEN, L. and EUROPEAN 
DERMATOLOGY FORUM, 2015. European Dermatology Forum 
Guidelines on topical photodynamic therapy. European Journal of Dermatology, 
25(4), pp. 296-311. 
MOSTERD, K., KREKELS, G.A.M., NIEMAN, F.H., OSTERTAG, J.U., 
ESSERS, B.A.B., DIRKSEN, C.D., STEIJLEN, P.M., VERMEULEN, A., 
NEUMANN, H. and KELLENERS-SMEETS, N.W.J., 2008. Surgical 
excision versus Mohs' micrographic surgery for primary and recurrent basal-
cell carcinoma of the face: a prospective randomised controlled trial with 5-
years' follow-up. Lancet Oncology, 9(12), pp. 1149-1156. 
MURRAY, C., SIVAJOHANATHAN, D., HANNA, T.P., BRADSHAW, S., 
SOLISH, N., MORAN, B., HEKKENBERG, R., WEI, A.C. and 
PETRELLA, T., 2019a. Patient indications for Mohs micrographic surgery: a 
clinical practice guideline. Current Oncology, 26(1), pp. e94-e99. 
MURRAY, C., SIVAJOHANATHAN, D., HANNA, T.P., BRADSHAW, S., 
SOLISH, N., MORAN, B., HEKKENBERG, R., WEI, A.C. and 
PETRELLA, T., 2019b. Patient Indications for Mohs Micrographic Surgery: 
A Systematic Review. Journal of Cutaneous Medicine & Surgery, 23(1), pp. 75-90. 
NAGAOKA, T., KIYOHARA, Y., KOGA, H., NAKAMURA, A., SAIDA, T. 
and SOTA, T., 2015. Modification of a melanoma discrimination index 
derived from hyperspectral data: a clinical trial conducted in 2 centers 
between March 2011 and December 2013. Skin Research & Technology, 21(3), 
pp. 278-283. 
NAGAOKA, T., NAKAMURA, A., OKUTANI, H., KIYOHARA, Y., KOGA, 
H., SAIDA, T. and SOTA, T., 2013. Hyperspectroscopic screening of 
melanoma on acral volar skin. Skin Research & Technology, 19(1), pp. 290. 
 132 
NAGAOKA, T., NAKAMURA, A., OKUTANI, H., KIYOHARA, Y. and SOTA, 
T., 2012. A possible melanoma discrimination index based on hyperspectral 
data: a pilot study. Skin Research & Technology, 18(3), pp. 301-310. 
NASSIRI-KASHANI, M., SADR, B., FANIAN, F., KAMYAB, K., 
NOORMOHAMMADPOUR, P., SHAHSHAHANI, M.M., ZARTAB, H., 
NAGHIZADEH, M., SARRAF-YAZDY, M. and FIROOZ, A., 2013. Pre-
operative assessment of basal cell carcinoma dimensions using high 
frequency ultrasonography and its correlation with histopathology. Skin 
Research & Technology, 19(1), pp. 132. 
NCCN Clinical Practice Guidelines In Oncology, NCCN Guidelines®: Referenced 
with permission from the NCCN Guidelines® for Basal Cell Skin 
Cancer V.1.2020 © National Comprehensive Cancer Network, Inc. 2019. 
All rights reserved. Accessed [February 20th, 2020]. Available online at 
www.NCCN.org. NCCN makes no warranties of any kind whatsoever 
regarding their content, use or application and disclaims any responsibility 
for their application or use in any way. 
NEITTAANMAKI-PERTTU, N., GRONROOS, M., JESKANEN, L., 
POLONEN, I., RANKI, A., SAKSELA, O. and SNELLMAN, E., 2015. 
Delineating margins of lentigo maligna using a hyperspectral imaging system. 
Acta Dermato-Venereologica, 95(5), pp. 549-552. 
NEITTAANMAKI-PERTTU, N., KARPPINEN, T.T., TANI, T., SNELLMAN, 
E. and GRONROOS, M., 2017. Long-term Outcome of Low-concentration 
Hexyl-5-aminolaevulinate Daylight Photodynamic Therapy for Treatment of 
Actinic Keratoses. Acta Dermato-Venereologica, 97(1), pp. 120-121. 
NEITTAANMAKI-PERTTU, N., NEITTAANMAKI, E., POLONEN, I., 
SNELLMAN, E. and GRONROOS, M., 2016. Safety of Novel Amino-5-
laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy 
Human Skin. Acta Dermato-Venereologica, 96(1), pp. 108-110. 
NGUYEN-NIELSEN, M., WANG, L., PEDERSEN, L., OLESEN, A.B., HOU, 
J., MACKEY, H., MCCUSKER, M., BASSET-SEGUIN, N., FRYZEK, J. 
and VYBERG, M., 2015. The incidence of metastatic basal cell carcinoma 
(mBCC) in Denmark, 1997-2010. European Journal of Dermatology, 25(5), pp. 
463-468. 
NIKOLAOU, V. and STRATIGOS, A.J., 2014. Emerging trends in the 
epidemiology of melanoma. British Journal of Dermatology, 170(1), pp. 11-19. 
NISSEN, C.V., HEERFORDT, I.M., WIEGELL, S.R., MIKKELSEN, C.S. and 
WULF, H.C., 2017. Increased protoporphyrin IX accumulation does not 
improve the effect of photodynamic therapy for actinic keratosis: a 
randomized controlled trial. British Journal of Dermatology, 176(5), pp. 1241-
1246. 
  
 133 
NISSEN, C.V., PHILIPSEN, P.A. and WULF, H.C., 2015. Protoporphyrin IX 
formation after topical application of methyl aminolaevulinate and BF-200 
aminolaevulinic acid declines with age. British Journal of Dermatology, 173(3), 
pp. 760-766. 
NISSEN, C.V., WIEGELL, S.R., PHILIPSEN, P.A. and WULF, H.C., 2016. 
Short-term chemical pretreatment cannot replace curettage in photodynamic 
therapy. Photodermatology, Photoimmunology & Photomedicine, 32(3), pp. 146-152. 
OLSEN, C.M., CARROLL, H.J. and WHITEMAN, D.C., 2010. Familial 
melanoma: a meta-analysis and estimates of attributable fraction. Cancer 
Epidemiology, Biomarkers & Prevention, 19(1), pp. 65-73. 
OZOG, D.M., RKEIN, A.M., FABI, S.G., GOLD, M.H., GOLDMAN, M.P., 
LOWE, N.J., MARTIN, G.M. and MUNAVALLI, G.S., 2016. 
Photodynamic Therapy: A Clinical Consensus Guide. Dermatologic Surgery, 
42(7), pp. 804-827. 
PAMPENA, R., KYRGIDIS, A., LALLAS, A., MOSCARELLA, E., 
ARGENZIANO, G. and LONGO, C., 2017. A meta-analysis of nevus-
associated melanoma: Prevalence and practical implications. Journal of the 
American Academy of Dermatology, 77(5), pp. 938-945.e4. 
PAOLI, J., HALLDIN, C., ERICSON, M.B. and WENNBERG, A., 2008. Nerve 
blocks provide effective pain relief during topical photodynamic therapy for 
extensive facial actinic keratoses. Clinical & Experimental Dermatology, 33(5), 
pp. 559-564. 
PAOLI, J., DARYONI, S., WENNBERG, A., MOLNE, L., GILLSTEDT, M., 
MIOCIC, M. and STENQUIST, B., 2011. 5-year recurrence rates of Mohs 
micrographic surgery for aggressive and recurrent facial basal cell carcinoma. 
Acta Dermato-Venereologica, 91(6), pp. 689-693. 
PELLACANI, G., GUITERA, P., LONGO, C., AVRAMIDIS, M., SEIDENARI, 
S. and MENZIES, S., 2007. The impact of in vivo reflectance confocal 
microscopy for the diagnostic accuracy of melanoma and equivocal 
melanocytic lesions. Journal of Investigative Dermatology, 127(12), pp. 2759-2765. 
PELUCCHI, C., DI LANDRO, A., NALDI, L., LA VECCHIA, C. and 
ONCOLOGY STUDY GROUP OF THE ITALIAN GROUP FOR 
EPIDEMIOLOGIC RESEARCH IN DERMATOLOGY, (GISED), 2007. 
Risk factors for histological types and anatomic sites of cutaneous basal-cell 
carcinoma: an italian case-control study. Journal of Investigative Dermatology, 
127(4), pp. 935-944. 
PERNICIARO, C., 1997. Dermatopathologic variants of malignant melanoma. 
Mayo Clinic proceedings, 72(3), pp. 273-279. 
PIACENTINI, R.D., DELLA CECA, L.S. and IPINA, A., 2018. Climate change 
and its relationship with non-melanoma skin cancers. Photochemical & 
Photobiological Sciences, 17(12), pp. 1913-1917. 
PONKA, D. and BADDAR, F., 2012. Wood lamp examination. Canadian Family 
Physician, 58(9), pp. 976 
 134 
PUIG, S. and BERROCAL, A., 2015. Management of high-risk and advanced 
basal cell carcinoma. Clinical & Translational Oncology: Official Publication of the 
Federation of Spanish Oncology Societes & of the National Cancer Institute of Mexico, 
17(7), pp. 497-503. 
PYNE, J.H., MYINT, E., BARR, E.M., CLARK, S.P., DAVID, M., NA, R. and 
HOU, R., 2017. Superficial basal cell carcinoma: A comparison of superficial 
only subtype with superficial combined with other subtypes by age, sex and 
anatomic site in 3150 cases. Journal of Cutaneous Pathology, 44(8), pp. 677-683. 
QUE, S.K.T., 2016. Research Techniques Made Simple: Noninvasive Imaging 
Technologies for the Delineation of Basal Cell Carcinomas. Journal of 
Investigative Dermatology, 136(4), pp. 33. 
RAASCH, B.A., BUETTNER, P.G. and GARBE, C., 2006. Basal cell carcinoma: 
histological classification and body-site distribution. British Journal of 
Dermatology, 155(2), pp. 401-407. 
RASANEN, J.E., NEITTAANMAKI, N., JESKANEN, L., POLONEN, I., 
SNELLMAN, E. and GRONROOS, M., 2019. Ablative fractional laser-
assisted photodynamic therapy for lentigo maligna: a prospective pilot study. 
Journal of the European Academy of Dermatology & Venereology, ahead of print, 
DOI: 10.1111/jdv.15925. 
RASHED, D., SHAH, D., FREEMAN, A., COOK, R.J., HOPPER, C. and 
PERRETT, C.M., 2017. Rapid ex vivo examination of Mohs specimens 
using optical coherence tomography. Photodiagnosis & Photodynamic Therapy, 
19, pp. 243-248. 
REDDY, N. and NGUYEN, B.T., 2019. The utility of optical coherence 
tomography for diagnosis of basal cell carcinoma: a quantitative review. 
British Journal of Dermatology, 180(3), pp. 475-483. 
REITER, O., MIMOUNI, I., GDALEVICH, M., MARGHOOB, A.A., LEVI, A., 
HODAK, E. and LESHEM, Y.A., 2019. The diagnostic accuracy of 
dermoscopy for basal cell carcinoma: A systematic review and meta-analysis. 
Journal of the American Academy of Dermatology, 80(5), pp. 1380-1388. 
RICHMOND-SINCLAIR, N.M., PANDEYA, N., WARE, R.S., NEALE, R.E., 
WILLIAMS, G.M., VAN DER POLS, JOLIEKE C and GREEN, A.C., 
2009. Incidence of basal cell carcinoma multiplicity and detailed anatomic 
distribution: longitudinal study of an Australian population. Journal of 
Investigative Dermatology, 129(2), pp. 323-328. 
ROBINSON, J.K., 2004. Use of Digital Epiluminescence Microscopy to Help 
Define the Edge of Lentigo Maligna. Archives of Dermatology. 140(9), pp. 1095-
100 
ROMANO, E., SCHWARTZ, G.K., CHAPMAN, P.B., WOLCHOCK, J.D. and 
CARVAJAL, R.D., 2011. Treatment implications of the emerging molecular 
classification system for melanoma. Lancet Oncology, 12(9), pp. 913-922. 
  
 135 
ROOZEBOOM, M.H., ARITS, A H H M., NELEMANS, P.J. and 
KELLENERS-SMEETS, N.W.J., 2012. Overall treatment success after 
treatment of primary superficial basal cell carcinoma: a systematic review and 
meta-analysis of randomized and nonrandomized trials. British Journal of 
Dermatology, 167(4), pp. 733-756. 
ROOZEBOOM, M.H., ARITS, AIMEE H M M., MOSTERD, K., SOMMER, A., 
ESSERS, B.A.B., DE ROOIJ, MICHETTE J M., QUAEDVLIEG, P.J.F., 
STEIJLEN, P.M., NELEMANS, P.J. and KELLENERS-SMEETS, N.W.J., 
2016. Three-Year Follow-Up Results of Photodynamic Therapy vs. 
Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell 
Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. 
Journal of Investigative Dermatology, 136(8), pp. 1568-1574. 
SAHU, A., YELAMOS, O., IFTIMIA, N., CORDOVA, M., ALESSI-FOX, C., 
GILL, M., MAGULURI, G., DUSZA, S.W., NAVARRETE-DECHENT, 
C., GONZALEZ, S., ROSSI, A.M., MARGHOOB, A.A., 
RAJADHYAKSHA, M. and CHEN, C.J., 2018. Evaluation of a Combined 
Reflectance Confocal Microscopy-Optical Coherence Tomography Device 
for Detection and Depth Assessment of Basal Cell Carcinoma. JAMA 
Dermatology, 154(10), pp. 1175-1183. 
SANCHEZ, G., NOVA, J., RODRIGUEZ-HERNANDEZ, A.E., MEDINA, 
R.D., SOLORZANO-RESTREPO, C., GONZALEZ, J., OLMOS, M., 
GODFREY, K. and AREVALO-RODRIGUEZ, I., 2016. Sun protection 
for preventing basal cell and squamous cell skin cancers. Cochrane Database of 
Systematic Reviews, 7, pp. 011161. 
SCRIVENER, Y., GROSSHANS, E. and CRIBIER, B., 2002. Variations of basal 
cell carcinomas according to gender, age, location and histopathological 
subtype. British Journal of Dermatology, 147(1), pp. 41-47. 
SGOUROS, D., LALLAS, A., JULIAN, Y., RIGOPOULOS, D., ZALAUDEK, I., 
LONGO, C., MOSCARELLA, E., SIMONETTI, V. and ARGENZIANO, 
G., 2014. Assessment of SIAscopy in the triage of suspicious skin tumours. 
Skin Research & Technology, 20(4), pp. 440-444. 
SILVA, E.S.D., TAVARES, R., PAULITSCH, F.D.S. and ZHANG, L., 2018. Use 
of sunscreen and risk of melanoma and non-melanoma skin cancer: a 
systematic review and meta-analysis. European Journal of Dermatology, 28(2), pp. 
186-201. 
SONG, E., GRANT-KELS, J.M., SWEDE, H., D'ANTONIO, J.L., 
LACHANCE, A., DADRAS, S.S., KRISTJANSSON, A.K., FERENCZI, 
K., MAKKAR, H.S. and ROTHE, M.J., 2016. Paired comparison of the 
sensitivity and specificity of multispectral digital skin lesion analysis and 
reflectance confocal microscopy in the detection of melanoma in vivo: A 
cross-sectional study. Journal of the American Academy of Dermatology, 75(6), pp. 
1187-1192.e2. 
 136 
SU, W.P., 1997. Malignant melanoma: basic approach to clinicopathologic 
correlation. Mayo Clinic Proceedings, 72(3), pp. 267-272. 
SWETTER, S.M., BOLDRICK, J.C., JUNG, S.Y., EGBERT, B.M. and 
HARVELL, J.D., 2005. Increasing incidence of lentigo maligna melanoma 
subtypes: northern California and national trends 1990-2000. Journal of 
Investigative Dermatology, 125(4), pp. 685-691. 
SWETTER, S.M., TSAO, H., BICHAKJIAN, C.K., CURIEL-
LEWANDROWSKI, C., ELDER, D.E., GERSHENWALD, J.E., GUILD, 
V., GRANT-KELS, J.M., HALPERN, A.C., JOHNSON, T.M., SOBER, 
A.J., THOMPSON, J.A., WISCO, O.J., WYATT, S., HU, S. and LAMINA, 
T., 2019. Guidelines of care for the management of primary cutaneous 
melanoma. Journal of the American Academy of Dermatology, 80(1), pp. 208-250. 
SZEWCZYK, M., PAZDROWSKI, J., GOLUSINSKI, P., DANCZAK-
PAZDROWSKA, A., LUCZEWSKI, L., MARSZALEK, S., MAJCHRZAK, 
E. and GOLUSINSKI, W., 2016. Basal cell carcinoma in farmers: an 
occupation group at high risk. International Archives of Occupational & 
Environmental Health, 89(3), pp. 497-501. 
TANKAM, P., SOH, J., CANAVESI, C., LANIS, M., HAYES, A., COGLIATI, 
A., ROLLAND, J.P. and IBRAHIM, S.F., 2019. Gabor-domain optical 
coherence tomography to aid in Mohs resection of basal cell carcinoma. 
Journal of the American Academy of Dermatology, 80(6), pp. 1766-1769. 
TCHANQUE-FOSSUO, C.N. and EISEN, D.B., 2018. A systematic review on 
the use of cryotherapy versus other treatments for basal cell carcinoma. 
Dermatology Online Journal, 24(11):3, DOI: 10.1111/jdv.15925. 
THEMSTRUP, L., BANZHAF, C.A., MOGENSEN, M. and JEMEC, G.B.E., 
2014. Optical coherence tomography imaging of non-melanoma skin cancer 
undergoing photodynamic therapy reveals subclinical residual lesions. 
Photodiagnosis & Photodynamic Therapy, 11(1), pp. 7-12. 
THEMSTRUP, L., DE CARVALHO, N., NIELSEN, S.M., OLSEN, J., 
CIARDO, S., SCHUH, S., NORNBERG, B.M., WELZEL, J., ULRICH, M., 
PELLACANI, G. and JEMEC, G.B.E., 2018. In vivo differentiation of 
common basal cell carcinoma subtypes by microvascular and structural 
imaging using dynamic optical coherence tomography. Experimental 
Dermatology, 27(2), pp. 156-165. 
TIODOROVIC-ZIVKOVIC, D., ARGENZIANO, G., LALLAS, A., THOMAS, 
L., IGNJATOVIC, A., RABINOVITZ, H., MOSCARELLA, E., LONGO, 
C., HOFMANN-WELLENHOF, R. and ZALAUDEK, I., 2015. Age, 
gender, and topography influence the clinical and dermoscopic appearance 
of lentigo maligna. Journal of the American Academy of Dermatology, 72(5), pp. 
801-808. 
TKACZYK, E., 2017. Innovations and Developments in Dermatologic Non-
invasive Optical Imaging and Potential Clinical Applications. Acta Dermato-
Venereologica, (Suppl 218), pp. 5-13. 
 137 
TODD, B.K., LESAR, A., O'MAHONEY, P., EADIE, E. and IBBOTSON, S.H., 
2019. Is there an optimal irradiation dose for PDT: 37 Jcm-2 or 75 Jcm-2 ?. 
British Journal of Dermatology, ahead of print, DOI: 10.1111/bjd.18644. 
TOENDER, A., KJAER, S.K. and JENSEN, A., 2014. Increased incidence of 
melanoma in situ in Denmark from 1997 to 2011: results from a nationwide 
population-based study. Melanoma Research, 24(5), pp. 488-495. 
TOGSVERD-BO, K., IDORN, L.W., PHILIPSEN, P.A., WULF, H.C. and 
HAEDERSDAL, M., 2012. Protoporphyrin IX formation and 
photobleaching in different layers of normal human skin: methyl- and 
hexylaminolevulinate and different light sources. Experimental Dermatology, 
21(10), pp. 745-750. 
TOGSVERD-BO, K., LERCHE, C.M., PHILIPSEN, P.A., POULSEN, T., 
WULF, H.C. and HAEDERSDAL, M., 2012. Porphyrin biodistribution in 
UV-exposed murine skin after methyl- and hexyl-aminolevulinate 
incubation. Experimental Dermatology, 21(4), pp. 260-264. 
TOLKACHJOV, S.N., BRODLAND, D.G., COLDIRON, B.M., FAZIO, M.J., 
HRUZA, G.J., ROENIGK, R.K., ROGERS, H.W., ZITELLI, J.A., 
WINCHESTER, D.S. and HARMON, C.B., 2017. Understanding Mohs 
Micrographic Surgery: A Review and Practical Guide for the 
Nondermatologist. Mayo Clinic Proceedings, 92(8), pp. 1261-1271. 
TRAKATELLI, M., MORTON, C., NAGORE, E., ULRICH, C., DEL 
MARMOL, V., PERIS, K., BASSET-SEGUIN, N. and BCC 
SUBCOMMITTEE OF THE GUIDELINES COMMITTEE OF THE 
EUROPEAN DERMATOLOGY FORUM, 2014. Update of the European 
guidelines for basal cell carcinoma management. European Journal of 
Dermatology, 24(3), pp. 312-329. 
TSCHANDL, P., ROSENDAHL, C. and KITTLER, H., 2015. Dermatoscopy of 
flat pigmented facial lesions. Journal of European Academy of Dermatology and 
Venereology, 29(1), pp.120-127. 
TYRRELL, J.S., MORTON, C., CAMPBELL, S.M. and CURNOW, A., 2011. 
Comparison of protoporphyrin IX accumulation and destruction during 
methylaminolevulinate photodynamic therapy of skin tumours located at 
acral and nonacral sites. British Journal of Dermatology, 164(6), pp. 1362-1368. 
TYRRELL, J., THORN, C., SHORE, A., CAMPBELL, S. and CURNOW, A., 
2011. Oxygen saturation and perfusion changes during dermatological 
methylaminolaevulinate photodynamic therapy. British Journal of Dermatology, 
165(6), pp. 1323-1331. 
TYRRELL, J.S., CAMPBELL, S.M. and CURNOW, A., 2010a. The relationship 
between protoporphyrin IX photobleaching during real-time dermatological 
methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent 
clinical outcome. Lasers in Surgery & Medicine, 42(7), pp. 613-619. 
  
 138 
TYRRELL, J., CAMPBELL, S.M. and CURNOW, A., 2011. Monitoring the 
accumulation and dissipation of the photosensitizer protoporphyrin IX 
during standard dermatological methyl-aminolevulinate photodynamic 
therapy utilizing non-invasive fluorescence imaging and quantification. 
Photodiagnosis & Photodynamic Therapy, 8(1), pp. 30-38. 
TYRRELL, J., CAMPBELL, S. and CURNOW, A., 2010b. Validation of a non-
invasive fluorescence imaging system to monitor dermatological PDT. 
Photodiagnosis & Photodynamic Therapy, 7(2), pp. 86-97. 
TYRRELL, J., PATERSON, C. and CURNOW, A., 2019. Regression Analysis of 
Protoporphyrin IX Measurements Obtained During Dermatological 
Photodynamic Therapy. Cancers, 11(1),. 
VAN DEN AKKER, J T., IANI, V., STAR, W.M., STERENBORG, H.J. and 
MOAN, J., 2000. Topical application of 5-aminolevulinic acid hexyl ester 
and 5-aminolevulinic acid to normal nude mouse skin: differences in 
protoporphyrin IX fluorescence kinetics and the role of the stratum 
corneum. Photochemistry & Photobiology, 72(5), pp. 681-689. 
VAN DER LEUN, JAN C., PIACENTINI, R.D. and DE GRUIJL, F.R., 2008. 
Climate change and human skin cancer. Photochemical & Photobiological Sciences, 
7(6), pp. 730-733. 
VAN LOO, E., MOSTERD, K., KREKELS, G.A., ROOZEBOOM, M.H., 
OSTERTAG, J.U., DIRKSEN, C.D., STEIJLEN, P.M., NEUMANN, H.A., 
NELEMANS, P.J. and KELLENERS-SMEETS, N.W., 2014. Surgical 
excision versus Mohs' micrographic surgery for basal cell carcinoma of the 
face: A randomised clinical trial with 10 year follow-up. European Journal of 
Cancer, 50(17), pp. 3011-3020. 
VARKENTIN, A., MAZURENKA, M., BLUMENROTHER, E., BEHRENDT, 
L., EMMERT, S., MORGNER, U., MEINHARDT-WOLLWEBER, M., 
RAHLVES, M. and ROTH, B., 2018. Trimodal system for in vivo skin 
cancer screening with combined optical coherence tomography-Raman and 
colocalized optoacoustic measurements. Journal of Biophotonics, 11(6), pp. 
e201700288. 
VARKENTIN, A., MAZURENKA, M., BLUMENROTHER, E., 
MEINHARDT-WOLLWEBER, M., RAHLVES, M., BROEKAERT, 
S.M.C., SCHAD-TRCKA, S., EMMERTINST, S., MORGNER, U. and 
ROTH, B., 2017. Comparative study of presurgical skin infiltration depth 
measurements of melanocytic lesions with OCT and high frequency 
ultrasound. Journal of Biophotonics, 10(6-7), pp. 854-861. 
VENTURINI, M., SALA, R., GONZALEZ, S. and CALZAVARA-PINTON, 
P.G., 2013. Reflectance confocal microscopy allows in vivo real-time 
noninvasive assessment of the outcome of methyl aminolaevulinate 
photodynamic therapy of basal cell carcinoma. British Journal of Dermatology, 
168(1), pp. 99-105. 
 139 
VENTURINI, M., GUALDI, G., ZANCA, A., LORENZI, L., PELLACANI, G. 
and CALZAVARA-PINTON, P.G., 2016. A new approach for presurgical 
margin assessment by reflectance confocal microscopy of basal cell 
carcinoma. British Journal of Dermatology, 174(2), pp. 380-385. 
VERKOUTEREN, J.A.C., RAMDAS, K.H.R., WAKKEE, M. and NIJSTEN, T., 
2017. Epidemiology of basal cell carcinoma: scholarly review. British Journal of 
Dermatology, 177(2), pp. 359-372. 
VERKOUTEREN, J.A.C., SMEDINGA, H., STEYERBERG, E.W., HOFMAN, 
A. and NIJSTEN, T., 2015. Predicting the Risk of a Second Basal Cell 
Carcinoma. Journal of Investigative Dermatology, 135(11), pp. 2649-2656. 
VERNE, S.H., MAGNO, R.J., EBER, A.E., CERVANTES, J., PERPER, M. and 
NOURI, K., 2018. Optical coherence tomography image processing for in 
vivo 3-dimensional visualization of basal cell carcinoma. Skin Research & 
Technology, 24(3), pp. 509-511. 
VILLARREAL-MARTINEZ, A., BENNASSAR, A., GONZALEZ, S., 
MALVEHY, J. and PUIG, S., 2018. Application of in vivo reflectance 
confocal microscopy and ex vivo fluorescence confocal microscopy in the 
most common subtypes of basal cell carcinoma and correlation with 
histopathology. British Journal of Dermatology, 178(5), pp. 1215-1217. 
VON BRAUNMUHL, T., HARTMANN, D., TIETZE, J.K., CEKOVIC, D., 
KUNTE, C., RUZICKA, T., BERKING, C. and SATTLER, E.C., 2016. 
Morphologic features of basal cell carcinoma using the en-face mode in 
frequency domain optical coherence tomography. Journal of the European 
Academy of Dermatology & Venereology, 30(11), pp. 1919-1925. 
WALDMAN, R.A. and GRANT-KELS, J.M., 2019. The role of sunscreen in the 
prevention of cutaneous melanoma and nonmelanoma skin cancer. Journal of 
the American Academy of Dermatology, 80(2), pp. 574-576.e1. 
WANG, B., SHI, L., ZHANG, Y.F., ZHOU, Q., ZHENG, J., SZEIMIES, R.M. 
and WANG, X.L., 2017. Gain with no pain? Pain management in 
dermatological photodynamic therapy. British Journal of Dermatology, 177(3), 
pp. 656-665. 
WANG, G.Y., WANG, J., MANCIANTI, M. and EPSTEIN, E.H.J., 2011. Basal 
cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer 
Cell, 19(1), pp. 114-124. 
WANG, H., XU, Y., SHI, J., GAO, X. and GENG, L., 2015. Photodynamic 
therapy in the treatment of basal cell carcinoma: a systematic review and 
meta-analysis. Photodermatology, Photoimmunology & Photomedicine, 31(1), pp. 44-
53. 
WANG, K.X., MEEKINGS, A., FLUHR, J.W., MCKENZIE, G., LEE, D.A., 
FISHER, J., MARKOWITZ, O. and SIEGEL, D.M., 2013. Optical 
coherence tomography-based optimization of mohs micrographic surgery of 
Basal cell carcinoma: a pilot study. Dermatologic Surgery, 39(4), pp. 627-633. 
 140 
WEISS, S.A., HANNIFORD, D., HERNANDO, E. and OSMAN, I., 2015. 
Revisiting determinants of prognosis in cutaneous melanoma. Cancer, 
121(23), pp. 4108-4123. 
WELLS, R., GUTKOWICZ-KRUSIN, D., VELEDAR, E., TOLEDANO, A. and 
CHEN, S.C., 2012. Comparison of diagnostic and management sensitivity to 
melanoma between dermatologists and MelaFind: a pilot study. Archives of 
Dermatology, 148(9), pp. 1083-1084. 
WHITEMAN, D.C., BRAY, C.A., SISKIND, V., GREEN, A.C., HOLE, D.J. and 
MACKIE, R.M., 2008. Changes in the incidence of cutaneous melanoma in 
the west of Scotland and Queensland, Australia: hope for health promotion?. 
European Journal of Cancer Prevention, 17(3), pp. 243-250. 
WHITEMAN, D.C., PAVAN, W.J. and BASTIAN, B.C., 2011. The melanomas: a 
synthesis of epidemiological, clinical, histopathological, genetic, and 
biological aspects, supporting distinct subtypes, causal pathways, and cells of 
origin. Pigment Cell & Melanoma Research, 24(5), pp. 879-897. 
WHITEMAN, D.C., THOMPSON, B.S., THRIFT, A.P., HUGHES, M., 
MURANUSHI, C., NEALE, R.E., GREEN, A.C., OLSEN, C.M. and 
QSKIN STUDY, 2016. A Model to Predict the Risk of Keratinocyte 
Carcinomas. Journal of Investigative Dermatology, 136(6), pp. 1247-1254. 
WIEGELL, S.R., SKODT, V. and WULF, H.C., 2014. Daylight-mediated 
photodynamic therapy of basal cell carcinomas - an explorative study. Journal 
of the European Academy of Dermatology & Venereology, 28(2), pp. 169-175. 
WONG, T.H., MORTON, C.A., COLLIER, N., HAYLETT, A., IBBOTSON, S., 
MCKENNA, K.E., MALLIPEDDI, R., MOSELEY, H., SEUKERAN, 
D.C., RHODES, L.E., WARD, K.A., MOHD MUSTAPA, M.F. and 
EXTON, L.S., 2019. British Association of Dermatologists and British 
Photodermatology Group guidelines for topical photodynamic therapy 2018. 
British Journal of Dermatology, 180(4), pp. 730-739. 
WORK GROUP, INVITED REVIEWERS, KIM, J.Y.S., KOZLOW, J.H., 
MITTAL, B., MOYER, J., OLENCKI, T. and RODGERS, P., 2018. 
Guidelines of care for the management of basal cell carcinoma. Journal of the 
American Academy of Dermatology, 78(3), pp. 540-559. 
WORLD HEALTH ORGANIZATION, 2008. The global burden of disease : 2004 
update. Geneva: World Health Organization||World Health Organization. 
WORLD HEALTH ORGANIZATION and LUCAS, R., MCMICHAEL, T., 
SMITH, W., ARMSTRONG, B., PRÜSS-ÜSTÜN, A., 2006. Solar Ultraviolet 
Radiation: global burden of disease from solar ultraviolet radiation. Geneva: World 
Health Organization||World Health Organization. 
  
 141 
WRIGHT, F.C., SOUTER, L.H., KELLETT, S., EASSON, A., MURRAY, C., 
TOYE, J., MCCREADY, D., NESSIM, C., GHAZARIAN, D., HONG, 
N.J.L., JOHNSON, S., GOLDSTEIN, D.P., PETRELLA, T. and 
MELANOMA DISEASE SITE GROUP, 2019. Primary excision margins, 
sentinel lymph node biopsy, and completion lymph node dissection in 
cutaneous melanoma: a clinical practice guideline. Current Oncology, 26(4), pp. 
e541-e550. 
XIANG, F., LUCAS, R., HALES, S. and NEALE, R., 2014. Incidence of 
nonmelanoma skin cancer in relation to ambient UV radiation in white 
populations, 1978-2012: empirical relationships. JAMA Dermatology, 150(10), 
pp. 1063-1071. 
YELAMOS, O., BRAUN, R.P., LIOPYRIS, K., WOLNER, Z.J., KERL, K., 
GERAMI, P. and MARGHOOB, A.A., 2019. Usefulness of dermoscopy to 
improve the clinical and histopathologic diagnosis of skin cancers. Journal of 
the American Academy of Dermatology, 80(2), pp. 365-377. 
YOULDEN, D.R., YOUL, P.H., SOYER, H.P., AITKEN, J.F. and BAADE, 
P.D., 2014. Distribution of subsequent primary invasive melanomas 
following a first primary invasive or in situ melanoma Queensland, Australia, 
1982-2010. JAMA Dermatology, 150(5), pp. 526-534. 
ZAAR, O., SJOHOLM HYLEN, A., GILLSTEDT, M. and PAOLI, J., 2018. A 
prospective, randomized, within-subject study of ALA-PDT for actinic 
keratoses using different irradiation regimes. Photodermatology, Photoimmunology 
& Photomedicine, 34(5), pp. 338-342. 
ZHOU, W., CHEN, Z., YANG, S. and XING, D., 2017. Optical biopsy approach 
to basal cell carcinoma and melanoma based on all-optically integrated 
photoacoustic and optical coherence tomography. Optics Letters, 42(11), pp. 
2145-2148. 
 
 142 
 
 143 
PUBLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 144 
 
PUBLICATION 
I 
Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma  
 
Neittaanmäki N, Salmivuori M, Pölönen I, Jeskanen L, Ranki A, Saksela O, Snellman E, 
Grönroos M  
 
Br J Dermatol. 177(6):1742-1744, 2017 Dec. 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 
 1 
KMA  8 June 2017 
Research letter 16/924R2 
 
Hyperspectral imaging in detecting dermal invasion in lentigo maligna 
melanoma 
 
Dear Editor, Invasive lentigo maligna melanoma (LMM) and its in situ precursor 
lentigo maligna (LM) are the most common melanoma types on sun-damaged skin.1 
Clinically unsuspected invasion is revealed histologically in 5–52% of LMs.2 Correct 
early diagnoses are crucial for determining accurate resection margins and discussion 
of sentinel lymph node examination.3 
Hyperspectral imaging is based on the detection of spectral differences reflecting a 
tissue’s biological properties.4,5 We determined how accurately a hyperspectral 
imaging system (HIS) detected LMM invasion. A total of 31 patients, with 32 lesions, 
with histologically confirmed LM or LMM, participated in the study. Of the 32 
LM/LMM lesions, 10 were histologically defined as LMMs (eight on the face or 
scalp, two on the trunk) with Breslow thicknesses between 0.4 and 1.6 mm (mean 
0.85 mm). The remaining 22 lesions were histologically LMs (20 on the face or scalp, 
two on the trunk). 
All lesions were evaluated with dermatoscopy (DermLite®, 3Gen Inc., San Juan 
Capistrano, CA, U.S.A.) and photographed (Canon Ixus 115 HS, 12.1 megapixel, 
Canon Inc., Tokyo, Japan). Hyperspectral images were taken in vivo using a HIS 
camera prototype (VTT FPI VIS-VNIR Spectral Camera, VTT Technical Research 
Centre of Finland, Espoo, Finland), based on a Fabry-Perot interferometer. Within 
seconds HIS captures the diffuse reflectance of visible and near-infrared light (500–
900 nm), with a 12 cm2 field of view (spatial resolution 6400 pixels cm-2, pixel = 125 
µm) and imaging depth of approximately 2 mm. In acquired hyperspectral images 
every pixel represents a diffuse reflectance spectrum, formed from mixing of spectra 
from the image’s different materials. With mathematical modelling this spectrum can 
be separated into ‘pure’ or ‘endmember’ spectra. Endmembers can further be used to 
create abundance images showing localization of these spectra in the imaged area. A 
detailed description of the technique has been reported elsewhere.4,5  
 2 
For the first four patients, the lesions were excised with 5-mm margins after imaging. 
In the subsequent cases, punch biopsies were taken from the suspected invasion sites, 
and thereafter excised completely, using a 5-mm margin for LM and a 10-mm margin 
for LMM. Specimens were processed routinely and stained with haematoxylin and 
eosin. 
In abundance images, in situ LMs were seen as homogeneous white areas. In LMMs, 
abundance maps showed a dark hole on the invasion site, while the rest of lesion was 
seen as a homogeneous white area, as in LM. These areas, which represented the 
LMM invasion, were seen as clear white areas in separate abundance maps (Fig. 1). 
This finding was seen in nine of 10 LMMs (true positives). HIS did not detect the 
invasion in one of the 10 LMMs, where the Breslow thickness was 0.5 mm (false 
negative). In 19 of 22 LMs HIS did not indicate any sites of invasion (true negatives), 
but in three of 22 cases did suggest invasion where it was not detected histologically 
(false positives). Thus, HIS achieved a positive predictive value of 75%, a negative 
predictive value of 95%, sensitivity of 90% and specificity of 86.3%. 
Diffuse reflectance records both light absorption and scattering, and thus provides 
information on skin morphology and chromophore content. In this study the 
abundance images showed clear differences between LM and LMM. Most likely, 
absorption of the skin chromophores (like melanin) at different skin levels explains 
most of the differences between spectra. 
Many techniques have been developed for melanoma diagnostics. Of these, 
dermatoscopy and reflectance confocal microscopy (RCM) are widely used.6 Both 
techniques are imprecise in determining melanoma thickness and early invasion. 
Multispectral imaging devices use four to 15 noncontinuous bands of wavelengths 
resulting in discrete spectral images, while HIS uses continuous narrow wavebands 
delivered from a tuneable filter. The HIS method used in this study showed potential 
in guiding practitioners to obtain more targeted diagnostic biopsies of LMM, 
improving early staging of LMM. HIS could also be developed further to measure the 
thickness of LMM noninvasively prior to surgery. 
A limitation in our study was its small sample size. Although the analysis method is 
objective, clinicians still need to interpret the HIS images, albeit this needs less 
expertise than the interpretation of near-histological RCM images. The quality of the 
HIS images may be affected by imaging artefacts. A future goal is to image a large set 
 3 
of various skin tumours for the development of a classification algorithm for 
noninvasive tumour diagnostics based on spectral data. 
In conclusion, HIS is a promising tool to detect basal membrane invasion in LMM, 
and thus to separate in situ and invasive LMs for more accurate presurgical 
diagnostics. 
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Figure legend 
Fig 1. Clinical images, histological images and hyperspectral abundance images 
representing lentigo maligna melanoma (LMM) (true positive). (a) Photograph of 
LMM. (b) Dermatoscopic image of LMM. (c) Hyperspectral abundance map 
representing the healthy skin around the lesion (white). (d) Hyperspectral abundance 
map representing the noninvasive part of the LMM lesion (white). (e) Hyperspectral 
abundance map representing the dermal invasion in LMM seen in a separate 
 5 
abundance map; the red arrow points to the invasion area. (f) Haematoxylin and eosin 
staining of LMM (Breslow thickness 1.6 mm). (g) Immunohistochemistry for 
MART1 in LMM (Breslow thickness 1.6 mm). 
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ABSTRACT 
Background Basal cell carcinoma (BCC) is the most common skin cancer in the 
Caucasian population. Eighty percent of BCCs are located on the head and neck area. 
Clinically ill-defined BCCs often represent histologically aggressive subtypes, and 
they can have subtle subclinical extensions leading to recurrence and the need for re-
excisions. 
 
Objectives The aim of this pilot study was to test the feasibility of a hyperspectral 
imaging system (HIS) in vivo in delineating the preoperatively lateral margins of ill-
defined BCCs on the head and neck area. 
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Methods Ill-defined BCCs were assessed clinically with a dermatoscope, 
photographed, and imaged with HIS. This was followed by surgical procedures where 
the BCCs were excised at the clinical border and the marginal strip separately. HIS, 
with a 12 cm
2
 field of view and fast data processing, records a hyperspectral graph for 
every pixel in the imaged area, thus creating a data cube. With automated 
computational modelling, the spectral data is converted into localisation maps 
showing the tumour borders. Interpretation of these maps was compared to the 
histologically verified tumour borders. 
 
Results Sixteen BCCs were included. Of these cases, 10/16 were the aggressive 
subtype of BCC and 6/16 were nodular, superficial, or a mixed type. HIS delineated 
the lesions more accurately in 12/16 of the BCCs compared to the clinical evaluation 
(4/16 wider and 8/16 smaller by HIS). In 2/16 cases, the HIS-delineated lesion was 
wider without histopathological confirmation. In 2/16 cases, HIS did not detect the 
histopathologically confirmed subclinical extension.  
 
Conclusions HIS has the potential to be an easy and fast aid in the preoperative 
delineation of ill-defined BCCs, but further adjustment and larger studies are 
warranted for an optimal outcome.  
 
INTRODUCTION  
Basal cell carcinoma (BCC) is a locally destructive and rarely metastasising non-
melanoma skin cancer (NMSC), which comprises 40% of all cancers worldwide
1
. 
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Eighty percent of NMSCs are BCCs
2
. The incidence of BCC is as high as the 
incidence of all other cancers combined, and its incidence continues to increase, also 
affecting ever-younger populations
3-5
. BCC is causing a remarkable burden via 
healthcare costs, treatment capacity, and the morbidity of affected individuals
1,2,4
.  
Histologically, BCCs can be classified by their morphological growth pattern into 
indolent (nodular and superficial) or aggressive (micronodular, morpheaform, 
infiltrative, and metatypical – i.e. basosquamous) types6. In 27–43% of cases, a 
combination of different patterns – i.e. a mixed histology – exists6-8. The histological 
subtype affects the clinical choice of treatment and the prognosis
6
. A high risk of 
recurrence is associated most importantly with aggressive growth patterns along with 
location in high-risk anatomic areas (nose, ears, eyes, and periocular areas), clinically 
unclear visualisation of the border, immunosuppression, recurrence, and perineural 
involvement
9
. Clinically, BCCs are classified by visual assessment as either indolent 
(nodular, superficial) or ill-defined (aggressive subtypes)
9
. Roughly one out of five 
BCCs is the histologically verified aggressive subtype
6,10
. However, the proportion 
might be even higher. The accuracy of a punch biopsy in the interpretation of a mixed 
histology is 37%
11
. Moreover, in 39.1% of aggressive BBCs, the punch biopsy fails to 
identify the subtype correctly compared to the following excision, and 11–14.1% of 
any type of BCC shows an unsuspected aggressive component in the excision 
compared to the preceding punch biopsy
8,11
.  
 
The incidence of BCC is highest in the most sun-exposed anatomic locations
12
. Thus 
80% of BCCs – and most of the aggressive types – are located on the head and neck 
area
2,13
, where preserving the anatomy and function plays a major role. Surgery and, if 
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available, Mohs micrographic surgery (MMS) with a 100% margin control is the 
treatment of choice for high-risk BCCs
9
.  
Hyperspectral imaging is based on tissue chromophores (like melanin if present, 
haemoglobin, proteins, and water) affecting the absorption and scattering of emitted 
light, thus causing, together with autofluorescence, a unique spectral graph for 
different biological tissues
14
. A hyperspectral imaging system (HIS) has shown 
potential in the preoperative delineation of lentigo maligna
15
 and the detection of 
field-cancerised skin
16
. In this pilot study, the aim was to test the feasibility of HIS in 
the preoperative delineation of the lateral margins of ill-defined BCCs on the head 
and neck area. 
 
MATERIALS AND METHODS 
We followed the Declaration of Helsinki, and the Ethics Committee of the Tampere 
University Hospital District, Finland, approved our study protocol. All the recruited 
volunteering patients were informed orally and in writing, and they provided their 
written consent.  
 
Patients 
Twenty-three patients with 24 lesions were recruited prospectively between March 
2014 and March 2017 at the Department of Dermatology and Allergology at the 
Päijät-Häme Social and Health Care Group, Lahti, Finland. The inclusion criterion 
was a clinically assessed primary BCC with a visually ill-defined margin on the head 
and neck area, and which was later histologically confirmed to be a BCC. Eight BCCs 
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from seven patients were excluded: six because these were not treated according to 
the study protocol (3 represented only the superficial subtype and were treated with 
cryosurgery, and 3 were operated on without a separate circumferential marginal 
strip). Furthermore, one patient was excluded due to the imaging artefacts and one 
due to discrepancy in the histopathological statement (subclinical extension shown 
only in the preoperative biopsies and not in the separate margin strip).  
Thus, 16 patients (7 female and 9 male) with 16 lesions completed the study. The 
mean age of the patients was 77 years (range 59–91 years). Five patients displayed 
anamnestic skin phototype I, nine patients displayed skin phototype II, and two 
patients displayed skin phototype III. Thirteen patients had a previous history of skin 
malignancy or its precursor, and seven of them had multiple conditions (basal cell 
carcinoma n=12, actinic keratosis n=8, and melanoma n=2). None of the patients had 
received cytostatics or radiotherapy in the study areas or received phototherapy for 
any skin condition. One patient had received immunosuppressive treatments. 
 
Imaging processes 
All the lesions were initially evaluated clinically and with a dermatoscope (Dermlite® 
3GenCA, USA). They were photographed native with a digital camera (Canon Ixus 
115 HS, 12.1 megapixel or Canon Ixus 130, 14.1 megapixel) and with the 
dermatoscope linked to the digital camera. The hyperspectral imaging process was 
performed initially without drawing the clinically assessed tumour border, and then 
after marking the clinical borders on the skin. The prototype of HIS is described more 
detailed elsewhere 
15
. (In short, the VTT FPI VIS-VNIR Spectral Camera uses 
visible-to-near infrared light – i.e. wavelengths 500–900 nm based on a Fabry-Perot 
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interferometer – which enables the use of tuneable waveband selection. It has a large, 
12 cm
2
 field of view (FOV) with a spatial resolution of 6,400 pixels/cm
2
, where one 
pixel is approx. 125 µm, and an imaging depth of approx. 2 mm.)
 15
 The hyperspectral 
imaging took only seconds to capture the hyperspectral data cube, which thereafter 
was analysed computationally in 5–10 minutes.  
Data analysis 
The hyperspectral data cube is a three-dimensional data cube, where the x-axis and y-
axis are the dimensions on the skin surface, and the z-axis is the 70 layered 
hyperspectral images, where every layer is imaged on a narrow waveband. Every 
pixel on the skin’s surface has a unique hyperspectral graph – i.e. an end-member – 
from which the abundance maps are calculated based on mathematical modelling (see 
Fig.1).  
In this pilot study, we used mathematical modelling of linear mixture, as used in our 
previous studies
15,16
. These abundance maps were interpreted on site by the test-
readers (M.S., M.G., I.P. and N.N.). Additionally, we developed three diverse 
enhanced mathematical models to create more sensitive ways to characterise the 
visually ill-defined margins of BCCs. Finally, the mathematical models used for the 
results were 1) an inversion of linear mixture model using iterative Vertex Component 
Analysis – i.e. the linear mixture (the one used on site), 2) an inversion of linear 
mixture model from the estimated single scattering albedo (SSA) using iterative 
Vertex Component Analysis – i.e. the linear mixture with SSA, 3) a closed form 
chromophore-specific approximation for the estimated SSA – i.e. chromophore 
specific with SSA, and 4) a modified standard normal variate correction algorithm – 
i.e. a standard variate. All abundance maps from these four models were interpreted 
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by the same test-readers. A summarised technical and mathematical presentation of 
the imaging system used, the algorithms, and simulated results are presented in the 
supplementary material, S1. 
Each of the mathematical models used has advantages and disadvantages. The 
standard variate model is quite sensitive to all changes in spectra that differ from the 
mean spectra of the imaged area. When there is either a lot of normal skin or an ill-
defined BCC, the standard variate model will distinguish the areas well. The linear 
mixture and linear mixture with SSA both capture changes in the concentration of 
skin chromophores. The chromophore specific with SSA is sensitive to skin scattering 
and absorption. The results from calculations with the linear mixture, the linear 
mixture with SSA, and the chromophore specific with SSA models can be used to 
simulate an imaged spectral cube. The simulated cube is a characterisation of the 
originally acquired image presented in the form of an abundance map for 
interpretation.  
 
Surgical procedures and the histopathological sampling 
After the imaging and analysis processes, and if the patient did not have an 
appointment for an operation on the same day, we took biopsies from the lesions and 
the areas where the HIS imaging indicated the BCC may be spreading. For all cases, 
we used a special operation technique to verify whether a subclinical extension was 
detected by HIS (see Fig.1). This included an initial excision of the tumour from the 
clinically and dermatoscopically detected border followed by a separately operated 2 
mm circumferential marginal strip, both with orientation marks. The circumferential 
strip allowed us to evaluate whether there was a subclinical extension in the marginal 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
area. If a free margin was found in the separately excised tumour specimen, this 
allowed us to evaluate if the BCC was smaller than the clinical evaluation with 
dermatoscopy. All the samples were orientated, fixed in 10% formalin, embedded in 
paraffin, and cut into 3 µm thick slices, which were stained with haematoxylin and 
eosin and, if necessary, with CK-PAN staining for the evaluation of perineural 
involvement. The tumour specimens were sectioned using the normal “bread-loaf” 
technique. The circumferential strips were sectioned closely in vertical slices. The 
histopathological samples were analysed by an experienced dermatopathologist 
blinded to the HIS outcome. If the circumferential marginal strip was BCC-positive, a 
re-excision was performed. 
 
RESULTS 
The histopathological subtypes of the 16 included BCCs are shown in Table 1. 10/16 
BCCs represented the aggressive subtype (infiltrative, infiltrative with perineural 
invasion, morpheaform, or micronodular features) in the final excision. In 6/16 BCCs 
the subtype was nodular, superficial, or a mixed histology of these two in the final 
excision, even though clinically all the included lesions were ill defined.  
In 12/16 cases, HIS was capable of delineating the BCCs more accurately than the 
conventional clinical evaluation by the naked eye and with a dermatoscope. HIS-
delineated lesions were wider in 4/16 of the BCCs (see Fig.2), and in 8/16 BCCs the 
lesions were delineated to be smaller than the clinical evaluation. In 2/16 cases, the 
HIS-delineated lesion was wider but could not be confirmed histopathologically (false 
positives). In 2/16 cases, HIS did not detect the histopathologically confirmed BCC in 
the circumferential strip (false negatives).  
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The results were quite similar in the four different mathematical models. If three out 
of four models showed similar tumour borders, those were regarded as the 
HIS-defined borders (see Table 1). However, it is still unclear which model is best for 
the imaging of BCC. 
 
DISCUSSION 
This study shows that HIS is feasible in detecting the borders of ill-defined BCCs, but 
further development work is needed to determine the optimal model for data 
processing. 
To our knowledge, there are no earlier studies on delineating BCC margins using 
hyperspectral imaging technology.  
Other non-invasive imaging techniques for delineating the lateral margins of BCCs 
include dermatoscopy, reflectance confocal microscopy (RCM), and optical 
coherence tomography (OCT)/high-definition optical coherence tomography (HD-
OCT). In clinical practice, dermatoscopy is the most widely used for the detection of 
lateral margins, although its use preoperatively has not reduced the excision stages in 
MMS, and thus evidence of its accuracy is lacking
17
. It has been previously shown 
that preoperative in vivo use of RCM and OCT can reduce the number of excision 
stages in the MMS of BCCs
17
. 
The advantages of HIS compared to the previously studied imaging techniques in the 
preoperative assessment of the lateral surgical margin are the following: i) adjustable 
FOV up to a maximum of 12 m
2
 in HIS captured and processed in 5–10 min 
compared to 1 cm
2
 (with mosaicking) in RCM captured and processed in 2 min
18
, and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
6x6 mm (0.36 cm
2
) in OCT, where 5x5 mm is captured and processed in 40 s
19
; ii) 
imaging depth of approx. 2 mm for HIS compared to 200 µm for RCM
17
 and 0.2–2.5 
mm for OCT, though one should note that the higher resolution is compromised by 
the penetration depth
19
; and iii) interpretation of HIS images is quick, easy to learn 
with a little experience, and does not require histological knowledge, unlike HD-OCT 
and RCM
17,19
. It seems that the interpretation of HIS images can be straightforward, 
but currently in some cases more combined information is needed from different 
models to conclude the interpretation, and thus further development of HIS is 
warranted.  
Our result for 4/16 BCCs revealed that subclinical extension by HIS is quite similar to 
RCM in the preoperative in vivo assessment of the margins, as in Venturini et al.’s 
study, RCM found subclinical extension in 3/10 cases compared to the 
dermatoscopically assessed margins prior to excision
20
. OCT found the subclinical 
extension of BCC in 11/52 cases compared to clinical evaluation by a Mohs 
surgeon
21
. Wang et al.
 21
 had a 100% evaluation of the margins in MMS excision 
compared to our design with vertical sections, which is clearly a limitation in our 
study. Furthermore, OCT delineated the lateral margins to be smaller by 1.4 +/-1.3 
mm than the clinical evaluation
21
. HIS delineated the lesion as being smaller in 8/16 
cases.  
In addition, high frequency ultrasound (HFUS) and fluorescence diagnosis have 
earlier been studied for the in vivo preoperative delineation of BCC. In lateral margin 
delineation, ultrasound has a low correlation compared to histopathology
22
. The 
subclinical extensions of the infiltrative and micronodular subtypes of BCC in 
particular are less likely to be detected by HFUS
23
. In deep margin assessment, the 
correlation using HFUS is intermediate
22
, and in facial BCCs, there is even a good 
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correlation for the deep margin with histopathology
24
. HFUS has the advantage of 
showing underlying structures like cartilage and bone
24
. In the fluorescence diagnosis 
of facial BCCs, the exogenic fluorescence diagnosis has no benefit in margin 
assessment compared to clinical evaluation in high risk areas (though most of the 
BCCs were nodular in this study)
 25
, but in aggressive types bispectral fluorescence 
imaging (using autogenic and exogenic fluorescence) had some potential in 
delineating the margins of BCC, with a 42% agreement in lateral margin assessment 
compared to the histopathology of MMS26.  
A limitation of HIS is its poorer resolution compared to OCT and RCM. In this study, 
HIS was not used to evaluate the deep margin, which in the future might be possible 
with further developments given the approx. 2 mm penetration depth of HIS. 
However, the assessment of deep margins is also limited with RCM and HD-OCT
17
. 
Artefacts in HIS abundance maps can be caused by an uneven imaging surface – i.e. 
round and sharp forms in the imaging area, and thus one case locating on nose was 
excluded with low quality in the abundance maps for interpretation. With further 
developments of HIS, it might be possible to handle these artefacts better. Additional 
pathological findings (i.e. actinic keratoses, etc.) in the imaging area might also be 
confounding factors in the interpretation of the HIS abundance maps, and thus further 
development work with HIS is needed. The limitations in our pilot study design were 
the small number of the cases, and thus these results are preliminary. This study was 
not performed to distinguish BCCs from other lesions on sun-damaged skin, but 
rather to visualise the borders of the lesions. Thus, larger studies are warranted in the 
future. 
Subclinical extension in aggressive BCCs can consist of cords with a thickness of a 
few cells
6
. Thus, in the future it would be interesting to repeat this study design by 
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assessing 100% of the margin and comparing the results to MMS. At the clinic where 
patients were recruited, MMS is not available, and thus we used the presented 
operation technique. Compared to MMS, in our method the separate circumferential 
strip was not assessed with a 100% margin control. In one true positive case, we were 
able to confirm subclinical extension of the marginal strip after additional histological 
sectioning based on the suspected subclinical extension in the HIS abundance maps. 
However, additional sectioning failed to reveal the subclinical extension in the two 
other false positive cases. It can be speculated that MMS with a 100% margin control 
would have revealed the histological extension in these false positive cases. 
It would be interesting to investigate if HIS could be useful in MMS by reducing the 
number of stages by defining the margins preoperatively more accurately than the 
clinical evaluation, and by being faster than RCM. HIS might be also useful in 
reducing the number of re-excisions by more accurate preoperative assessment in 
intermediate- or low-risk anatomic locations, and also in high-risk areas if MMS is 
not available. After MMS, primary BCCs have a 4.4% recurrence and recurrent BCCs 
have a 3.9% recurrence in the 10-year follow-up; after traditional excision, the 
corresponding rates are 12.2% and 13.5%
27
. In traditional excision, the recurrence 
rates varies according to the width of the surgical margin, where a 2, 3, 4 or 5 mm 
announced negative margin has a recurrence rate of 3.96, 2.56, 1.62 and 0.39% 
respectively; if a positive margin is announced, the overall recurrence is 27%
28
. In the 
future with HIS, it might be possible to save tissues in cosmetically sensitive areas. 
With the increasing incidence of BCCs, there is a need for new technologies to make 
the treatment of BCC less time-consuming and more cost-effective. With preliminary 
results of 12/16 more precisely delineated lesions and 4/16 revealed subclinical 
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extensions, the HIS has the potential to be a clinical aid in treatment of ill-defined 
BCCs in the cosmetically sensitive areas of the head and neck region. 
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FIGURES AND LEGENDS 
 
 
Fig. 1 A) Hyperspectral imaging process and B) operation technique to verify the 
subclinical extension detected by HIS. 
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Fig. 2 Example patient with BCC delineated wider by HIS. Histologically, there was a 
nodular, superficial, micronodular, and infiltrative BCC, with perineural invasion, 
which showed subclinical micronodular growth in the marginal strip shown by HIS 
(arrows). A) Clinical picture, B) final excision with our operation technique, C) 
dermatoscopy image, D1) histological image from the main tumour area with the 
different aggressive growth patterns D2–D3) histological image, where the subclinical 
extension of BCC was detected in the separate marginal strip (D2 lower arrow and D3 
upper arrow). HIS abundance maps marking the clinically and dermatoscopically 
assessed tumour border on the skin (arrows pointing the subclinical extension 
detected by HIS): E) linear mixture F) linear mixture with single scattering albedo 
(SSA), G) chromophore specific with SSA H) standard variate. 
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TABLES  
Table 1. Histopathological analyses of the BCCs, anatomic location of the lesion, interpretation of the mathematical models, and the HIS 
outcome compared to clinical evaluation. 
esion 
Anatomic 
location of 
the lesion 
BCC subtype in 
the biopsies BCC subtype in the final excision 
BCC subtype in 
the separate 
circumferential 
strip 
Additional 
histopathological 
findings 
Linear 
mixture 
model 
Enhanced 
linear 
mixture 
model 
Chromo-
phore 
specific 
model 
Mean 
value 
model 
HIS outcome compared to the 
clinical assessment, and 
confirmed histologically 
1 right cheek  superficial, nodular, micronodular sun damaged skin + + + + false pos.* 
2 tip of nose  superficial, nodular sun damaged skin - - - 0 smaller** 
3 preaurically 
on right 
cheek 
nodulocystic superficial, nodular, micronodular superficial solar lentigo + + + + wider*** 
4 tip of nose  superficial, nodular, micronodular,  
infiltrative, basosquamous 
sun damaged skin - - - 0 smaller 
5 lateral to 
nasolabial 
fold on right 
cheek 
nodular nodular  sun damaged skin - - - - smaller 
6 left cheek nodular, 
micronodular 
nodular, micronodular sun damaged skin - - - - smaller 
7 forehead nodular, 
micronodular 
superficial, nodular, micronodular, 
infiltrative with perineural invasion 
micronodular actinic keratoses + + + + wider 
8 left auricle superficial, 
nodular 
superficial, nodular sun damaged skin - - - 0 smaller 
9 right temple nodular, 
micronodular, 
sclerotic 
nodular, micronodular, infiltrative 
with perineural invasion 
micronodular solar lentigo + + + 0 wider 
10 left auricle superficial, 
nodular 
nodular, micronodular, infiltrative micronodular sun damaged skin = = = 0 false neg. **** 
11 neck, behind left ear nodular  actinic kertoses,  
solar lentigo 
- - - - smaller 
12 left cheek nodular superficial, nodular sun damaged skin, solar 
lentigo 
+ + + + false pos. 
13 left cheek nodular cicatrix  eczema - - - - smaller 
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14 right ala of 
nose 
nodular nodular, micronodular nodular, 
micronodular 
actinic keratoses = = = = false neg. 
15 right temple superficial superficial, nodular, micronodular,  
infiltrative with perineural invasion 
sun damaged skin, ulcer - - - -  smaller 
16 forehead nodular, 
infiltrative 
nodular, micronodular nodular, 
micronodular 
sun damaged skin 0 + + + wider 
(+) interpret wider in the abundance maps 
        
(-) interpret smaller in the abundance maps 
       
(0) too much of artefact for interpretation 
        
(=) interpreted as same borders as than visually assessed (the margins announced in the tumor specimen were from 0 to 0,9 mm) 
  
* HIS delineated the lesion wider than clinical assessment, but this wasn't supported by histopathology 
    
** HIS delineated the lesion smaller than clinical assessment, and histopathology supported this 
    
*** HIS delineated the lesion wider than the clinical assessment, and the histopathology supported this 
    
**** HIS showed no suspicious for subclinical extension, but in the histopathology there was BCC in the circumferential strip 
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ABSTRACT
Background In the photodynamic therapy (PDT) of non-aggressive basal cell carcinomas 
(BCCs), 5-aminolevulinic acid nanoemulsion (BF-200ALA) has shown non-inferior efficacy 
when compared with methyl aminolevulinate (MAL), a widely used photosensitizer. Hexyl 
aminolevulinate (HAL) is an interesting alternative photosensitizer. To our knowledge, this is the 
first study using HAL-PDT in the treatment of BCCs. 
Objectives To compare the histological clearance, tolerability (pain and post-treatment reaction), 
and cosmetic outcome of MAL, BF-200 ALA, and low-concentration HAL in the PDT of non-
aggressive BCCs. 
Methods Ninety-eight histologically verified non-aggressive BCCs met the inclusion criteria, and 
54 patients with 95 lesions completed the study. The lesions were randomized to receive LED-A
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PDT in two repeated treatments with MAL, BF-200 ALA, or HAL. Efficacy was assessed both 
clinically and confirmed histologically at three months by blinded observers. Furthermore, 
cosmetic outcome, pain, post-treatment reactions fluorescence, and photobleaching were 
evaluated.
Results According to intention-to-treat analyses, the histologically confirmed lesion clearance was 
93.8% (95% confidence interval [CI] = 79.9–98.3) for MAL, 90.9% (95% CI = 76.4–96.9) for BF-
200 ALA, and 87.9% (95% CI = 72.7–95.2) for HAL, with no differences between the arms 
(p=0.84). There were no differences between the arms as regards pain, post-treatment reactions, or 
cosmetic outcome. 
Conclusions PDT with low-concentration HAL and BF-200 ALA have a similar efficacy, 
tolerability, and cosmetic outcome compared to MAL. HAL is an interesting new option in 
dermatological PDT, since good efficacy is achieved with a low concentration.
Registration numbers: EudraCT with 2014-002746-50 and clinicaltrial.gov with NCT02367547.
INTRODUCTION
The incidence of basal cell carcinoma (BCC), especially the superficial subtype (sBCC) is 
rising1,2. BCC is as common as all other malignancies combined, and thus causes remarkable 
health care costs3,4. The sBCC and the thin nodular BCC (nBCC) are often classified as low-risk 
tumours, and they can be treated with non-surgical options5, i.e. photodynamic therapy (PDT), 
imiquimod or 5-fluorourasil (5-FU), where imiquimod has superior efficacy 6-7. The advantages of 
PDT include a superior cosmetic outcome and short application and down times8,9.
PDT uses a combination of light, a photosensitizing agent (an exogenous source for 
photoactive protoporphyrin IX, PpIX), and oxygen to generate a radical oxygen species that cause 
cell apoptosis and necrosis10,11. Of these factors, PpIX production in particular seems to be related 
to cell death12. Thus, changing the prodrug of PpIX could be an effective way to enhance the 
reaction. 
The PpIX produced can be measured as the fluorescence of a photosensitizer13. 
Fluorescence and especially photobleaching (i.e. the difference in fluorescence measured before 
and after illumination) correlate with the accumulation of PpIX and with efficacy14,15.
5-aminolevulinic acid (5-ALA) was the first photosensitizer in PDT of skin malignancies 
with selectivity in the tumour tissue10. The esters of 5-ALA like methyl aminolevulinate (MAL) 
are more lipophilic, and a shorter incubation time is needed, when compared to 5-ALA11. With A
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nanoemulsion of 5-ALA (BF-200 ALA) at a 10% concentration a greater fluorescence was 
detected after incubation time, when compared to 20% 5-ALA16. In addition, BF-200 ALA was 
shown to penetrate deeper in an ex vivo skin model, when compared to MAL17. The efficacy of 
BF-200 ALA is shown to be non-inferior compared to MAL in PDT of non-aggressive BCCs18. 
Hexyl aminolevulinate (HAL) is a long-chain lipophilic 5-ALA ester, capable to produce 
significantly higher fluorescence intensities in the human epidermis and superficial dermis, when 
compared to MAL – though in the mid and deep dermis the intensity is only slightly higher19. An 
equal fluorescence intensity is achieved in the rat skin using HAL2% and MAL20%20. HAL, BF-
200 ALA and MAL seem to be equally tolerated when applied on normal human skin21.
This prospective trial aims to compare the efficacy and tolerability (i.e. pain and post-
treatment-reaction) of MAL, BF-200 ALA, and low-concentration HAL in the PDT of non-
aggressive BCCs.
Materials and methods 
The protocol complied with the Declaration of Helsinki and was approved by the Ethics 
Committee of Tampere University Hospital and by the Finnish Medicines Agency. Written 
informed consent was obtained from all participants. Patients were recruited from those referred to 
the Department of Dermatology and Allergology at Päijät-Häme Social and Health Care Group, 
Lahti, Finland, between March 2015 and September 2018.
The three parallel arms were MAL16% (Metvix®, Galderma Norcid AB), and BF-200 
ALA7.8% (Ameluz®, Biofrontera), and HAL2% (mixture of Hexvix® powder, Photocure ASA, 
and unguentum M cream, Allmirall Hermal GmbH) with allocation ratio of 1:1:1. Of these, MAL 
and BF-200 ALA are approved for the PDT of non-aggressive BCCs, and HAL is approved for the 
photodynamic diagnosis of uroepithelial cancer and the treatment of cervical dysplasia by the 
European Medicines Agency.
Inclusion and exclusion criteria
Patients over 18 years old presenting with a superficial BCC clinically were enrolled. Exclusion 
criteria included pregnancy, lactation, allergy/intolerance to the photosensitizers used, porphyria, 
and photosensitivity. 
The target lesions had to be located on the trunk or extremities. Lesions located on the face 
or head were not eligible. In the case of multiple BCCs in the same patient, we included only A
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lesions located at least 10 cm apart from each other to minimize mixing up the photosensitizers22. 
The target BCCs were included according to clinical inspection with a dermatoscope, and 
randomized to one of the three arms at the recruitment visit. However, a diagnostic biopsy was 
taken from all included lesions prior to treatment. Lesions with some other histopathology than 
BCC were excluded from the analyses. Only lesions confirmed to be non-aggressive, i.e. a 
superficial or thin nodular – defined as growing into the epidermal-dermal junction or the most 
upper third of the dermis – could be included for analyses. 
Outcomes
The primary outcome was histologically verified clearance at three months. The secondary 
outcomes were pain during the illumination with the use of a long-acting local anaesthetic prior to 
pre-handling, post-treatment reaction, cosmetic outcome, and fluorescence/photobleaching. 
Power calculations, randomization and treatment allocation
In the power calculations (alpha=0.05, power=0.85, delta=0.30), it was assumed that BF-200 
ALA/HAL would be superior to MAL, as MAL has an efficacy of 72.8% at twelve months9, 
although the efficacy might be even lower in a group aged over 60 years23. Thus the efficacy of 
MAL was assumed to be 65%. Same delta-value was used both for BF-200 ALA and HAL. Thus, 
the needed sample size was 31 lesions/arm. The initial set (93 lesions) was randomized using a 
web-based validated program, Research randomizer.org®. As the trial proceeded, we noticed of 
the other histology than BCC being notable, and performed another set of randomization (24 
lesions) with closed envelopes (at the moment troubles using Research randomizer®). In total, 117 
lesions (39/arm) were randomized, Figure 1. 
Protocol
Prior to treatment (performed by M.S. and J.R.), the lesions were assessed with a dermatoscope 
(Dermlite® DL3 or DL3N, 3GenCA, USA, or Heine Delta 20T®). Treatment areas including the 
lesion, a 5 mm margin, and a biopsy site were marked on plastic sheets with scaling (1x1mm 
squares). A diagnostic 3 mm punch biopsy was taken prior to curettage at the first session (PDT I), 
and local anaesthetics (1:1 mixture of lidocaine 10mg/ml cum epinephrine 10 μg/ml to ropivacaine 
7.5mg/ml) were infiltrated prior to any procedures at both sessions. Curettage i.e. removing 
crusts/scabs and handling the whole treatment area was used for all of the lesions. If needed A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
aluminium chloride was used for haemostasis, and in PDT I the biopsy site was closed with a 
transparent stitch (Monocryl 4-0). Thereafter a 1 mm thick layer of photosensitizer (treatment area 
calculated from plastic sheets in mm2, photosensitizer scaled with 1 mg/mm2 dosing) was applied 
to the treatment area followed by three hours occlusion with a light-impermeable cover before 
illumination (Aktilite, CL128, Galderma, 37 J/cm2 per session). All lesions were illuminated with 
the same total time of 7 min and 24 seconds, but recording of pain and illuminating together took 
approximately 8 minutes of time. The second session (PDT II) followed 8–14 days after PDT I. 
Figure 2 represents an example case.
Assessment of efficacy
At the three-month follow-up visit an experienced dermatologist (M.G.), blinded for treatment, 
evaluated all lesions with inspection and with a dermatoscope, and took 3 mm control punch 
biopsies near the diagnostic biopsy site using the marked plastic sheets as guidance. Additional 3 
mm punch biopsies were taken from clinically suspicious sites if needed. Non-responsive lesions 
were completely excised as a second line treatment, which allowed us to evaluate if a mixed 
histology with aggressive features would exist. An experienced pathologist (T.T.), blinded for 
treatment, assessed all histopathological specimens.
Assessment of the treatment tolerability and cosmetic outcome
Pain was assessed by patients, blinded for photosensitizer, using a visual analogue scale (VAS)24 
at the beginning, in the middle, and in the end of each illumination. No other pain management 
was used. For our analyses we named the difference of VAS in the middle and at the beginning as 
4 min, and the difference of VAS in the end and at the beginning as 8 min. Thus we acknowledged 
that the pain experienced by the patient at the beginning of the illumination could be something 
else than zero. 
Post-treatment reactions (oedema, erythema, erosion, and crust formation) were 
photographed 8–14 days after PDT I and assessed afterwards on a five-point scale 
(none/minimal/mild/moderate/severe) by the blinded observer (M.G.). The cosmetic outcome was 
assessed on a four-point-scale (excellent/good/fair/poor) at the three-month follow-up visit by the 
blinded observer (M.G.).
Fluorescence measurementA
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Fluorescence images were taken at the beginning and end of illumination using a digital camera 
(Canon Ixus 130, 14.1 megapixel with the set-up ISO800, FW 2.8, no zoom), a Wood’s light 
(Philips Burton®, Somerset, USA, kept hand-held at a distance of about 8 cm) and a yellow filter 
lens (Hoya HMC, yellow-green xo, attached to the top of the Wood’s light), as used by 
Neittaanmäki-Perttu et al.21 The photosensitizer was removed with saline solution before imaging. 
Statistical analyses and calculations of fluorescence
Statistical analyses were conducted with a professional statistician using SPSS 23.0 (IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.), or a mathematician (I.P.) with 
Python 3.6 using Numpy and Scipy libraries. 
As statistical methods, Fisher’s exact test was used to compare the efficacy, post-treatment 
reactions, and the cosmetic outcome. As regards pain, the comparison between the arms was 
performed with the Kruskall–Wallis test, and the comparison between the sessions in each arm 
with the Wilcoxon Signed Rank Test. For fluorescence and photobleaching, the ANOVA test was 
used to compare the treatment arms, and to calculate the correlation between the histological 
clearance and the fluorescence/photobleaching, the Chi-squared was used.
Fluorescence images were processed semi-automatically using affine transformation and 
manually selected matching points by a mathematician (L.A.) with Python 3.6. The intensity was 
extracted in the red light channel to achieve arbitrary units (A.U.) for fluorescence and 
photobleaching (as the absolute difference of the mean fluorescence before and after illuminating).
Results
Altogether 98 histologically verified non-aggressive BCC (in 57 patients) were included to the 
study, but there were three dropouts. Thus 54 patients completed the study with 95 non-aggressive 
BCCs (Figure 1). Table 1 represents the patients and lesion characteristics. In total, six residual 
lesions were found at three months follow-up (1/31 in MAL, 3/33 in BF-200 ALA, and 2/31 in 
HAL). In the final excision of non-responsive lesions, there were no aggressive subtypes. 
Lesion clearance with intention-to-treat analyses
Among the 98 non-aggressive BCCs, i.e. including the dropouts, the histologically verified 
efficacy was 93.8% (95% CI = 79.9–98.3) for MAL, 90.9% (95% CI = 76.4–96.9) for BF-200 A
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ALA, and 87.9% (95% CI = 72.7–95.2) for HAL (in the comparison of the arms; p=0.84). Thus, 
there were no differences between the arms in terms of efficacy.
Tolerability and cosmetic outcome
Pain results for the 95 BCCs of the 54 patients who completed the study are reported in Figure 3A. 
No differences were found in pain between the arms during illumination (MAL vs BF-200 ALA 
vs HAL; PDT I 4 min p=0.21, 8 min p=0.18; PDT II 4 min p=0.47, 8 min p=0.87). In the HAL 
group, the second session was more painful than the first session (PDT I vs PDT II; 4 min 
p=0.006, 8 min p=0.005). There was no difference in pain between the sessions in the other arms 
(PDT I vs PDT II; MAL 4 min p=0.17, 8 min p=0.79; BF-200 ALA 4 min p=0.45, 8 min p=0.43). 
Among the 95 BCCs, no differences were either found in the post-treatment reactions 
(p=0.49; Figure 3B, and Figure 2E). There was one treatment-related withdrawal from the trial, as 
one patient from the MAL group experienced remarkable swelling, oedema, erythema, and 
haematoma in the treatment area after PDT I, and refused to attend PDT II. 
Among the 95 BCCs, the cosmetic outcome was regarded as good/excellent in 77.4% of 
the lesions in the MAL group, 75.7% in the BF-200 ALA group, and 61.3% in the HAL group, 
with no differences between the arms (p=0.61; Figure 3C, and Figure 2F).
Fluorescence and photobleaching
In total, fluorescence images were available from 84 lesions in 49 patients from PDT I, and 
respectively from 91 lesions in 51 patients from PDT II. At the beginning of the illumination, 
fluorescence was lower in HAL2% compared to MAL16% and BF-200 ALA7.8% (PDT I p=0.043 
and PDT II p=0.043). However, there was no statistical significant difference in photobleaching 
between the arms (PDT I p=0.09 and PDT II p=0.42). We found no correlation between the 
histological clearance and the photobleaching (PDT I p=0.40, PDT II p=0.77) or fluorescence 
(PDT I p=0.77, PDT II p=0.55). Fluorescence and photobleaching showed a wide variation. 
Discussion
To our knowledge, this is the first trial using HAL-PDT for non-aggressive BCCs. Morrow et al. 
have earlier suggested that HAL is more effective in equimolar doses compared to MAL and 5-
ALA25. Dögnitz et al. reported that HAL could be used in smaller concentrations to achieve a 
similar distribution of PpIX in the BCC tissue compared to 5-ALA26. Our results support the idea. A
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Kiesslich et al. demonstrated for 5-ALA, MAL, and HAL in vitro that after a certain threshold 
limit, the intracellular PpIX concentration doesn’t rise by increasing the concentration of the 
prodrug, but under this threshold the concentration matters, also the incubation time of the 
prodrug27. There are many variables in PDT, and thus the protocol used can affect the efficacy28,29. 
Consequently, the optimal concentration and protocol for HAL-PDT of non-aggressive BCCs is 
still unexplored.
In a recent multi-centre trial, Morton et al. reported a three-month clinical clearance of 
91.8% for MAL and 93.4% for BF-200 ALA in the PDT of non-aggressive BCCs18. In another 
multi-centre trial, Arits et al. reported clinical clearance of 84.2% at three months for MAL-PDT9. 
We and Morton et al. used curettage, but Arits et al. reported ‘a non-traumatic surface 
preparation’. In our experience, some small trauma can occur in curettage, and physical pre-
treatment in PDT enhances the PpIX uptake30,31. 
Morton et al. have shown the similar tolerability of BF-200 ALA and MAL18. 
Interestingly, HAL seems to have a more precise effect on the site of application compared to 5-
ALA on mice skin, and this could be beneficial in terms of post-treatment reactions32. 
Neittaanmäki-Perttu et al. reported that on healthy human skin, HAL2% caused a similar erythema 
as BF-200 ALA7.8% and MAL16%, and in terms of pain, there was a significant difference in the 
respective comparison21. In our results, for BCC we did not found any differences between the 
arms in terms of adverse events. 
As regarding pain, Lindeburg et al. have reported that PDT II is more painful than PDT I 
when treating actinic keratosis and sBCC with MAL-PDT33. Perhaps due to the small sample size, 
this difference was found only for HAL in our results. Our mean and median VAS score was 2.3 
at its highest. Interestingly, Morton et al. had a highest mean pain score (on a 1–10 scale) of 4.5 
without analgesia, despite the use of a BF-RhodoLED (Biofrontera) light source with reduced pain 
levels compared to Aklite (Galderma)34. Thus, it seems that a long-acting local anaesthetics prior 
to pre-handling could be effective in pain management – though this differs from the European 
PDT guidelines35. Previously, nerve blocking has been shown to be an effective option, whereas 
topical analgesia has not36. Our method should be studied more closely in a prospective and 
randomized setting, including in carcinomas in situ and head locations, where pain can be a major 
obstacle37. 
In PDT, the use of local analgesia can have a potential impact on efficacy through 
vasoconstriction, pH, and oxygen availability 37. The use of epinephrine in particular could lead to A
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this. Infiltration of local anaesthetics has earlier been used during illumination with 
lidocaine/prilocaine cum ropivacaine, and also cum epinephrine, with good treatment success38,39. 
However, our pain management protocol didn’t affect the results.
We found a good/excellent cosmetic outcome in 71.6% of all the lesions at three months. 
We did not achieve the results of Jansen et al.8 (the same trial as by Arits et al.), who reported a 
good/excellent cosmetic outcome in MAL-PDT for 89.5% of patients at five years. However, the 
cosmetic outcome tends to improve over time18. 
Non-surgical options provide a cost-effective alternative to surgery in the treatment of non-
aggressive BCCs40, and patients with multiple lesions or facial lesions are willing to risk the 
recurrence rate for a better cosmetic outcome41. The advantages of PDT include the cosmetic 
outcome8, the shorter application and down times, and the mode of delivery9, but the major 
disadvantage is the lower efficacy compared to imiquimod6. However, the topical creams demand 
good patient compliance and correct patient selections, as the creams are applied by the patient at 
home for a number of weeks. Regarding the economic aspect of low-concentration HAL, there 
could be benefits in the manufacture of the cream, as only a low concentration is demanded. 
Interestingly in the daylight PDT of thin actinic keratosis, a similar efficacy was achieved with 
HAL0.2% as compared to MAL16%42.
The strengths of our study are the investigator-initiated double-blinded design, 
histopathological confirmation in addition to the clinical evaluation, and the complete excision of 
the non-responsive lesions to examine the possible underlying mixed histologies as the cause for 
treatment failure. We assumed our patients would be over 60 years, and this corresponded to our 
material quite accurately; only 6/54 of the analysed patients were under 60 years.
The limitations of our study design are a limited sample size and optimistic assumptions in 
the power calculations. The taking of diagnostic biopsies at the first treatment session should also 
be considered a limitation, since these could potentially lead to lesion resolution due to 
inflammation induced by the biopsy. A limitation of the pain analyses was the absence of a control 
group for local anaesthetics. Furthermore, the summation of pain may have occurred in patients 
with multiple lesions, but in our protocol lesions (not patients) were randomized, and thus the 
possible effect should be quite equal for all arms. A major limitation in the 
fluorescence/photobleaching analyses was the lack of a validated imaging system. 
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In conclusion, HAL is an interesting new option for dermatological PDT. The efficacy and 
tolerability of low-concentration HAL was comparable with BF-200 ALA and MAL. Dose-
finding studies and larger trials are warranted in the future for HAL.
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Figure legends
Figure 1. Flow-chart of the trial.
117 randomized lesion 
(in 60 patients) at the enrollment 
95 BCC (in 54 patients) completed the study
3 BCC (in 3 patients) excluded, protocol
 not followed
BF-200 ALA 33 BCC:
8 patients with single
18 patients with multiple
All patients attended 3 months follow-up
19 excluded lesion (in 12 patients):
Not BCC in histopathology
HAL 31 BCC:
5 patients single
19 patients with multiple
MAL 31 BCC:
14 patients with single
13 patients with multiple
BF-200 ALA
 30/33 responded BCC
HAL
29/ 31 responded BCC
MAL 
30/31 responded BCC
2 BCC from HAL group:
 Not receiving enough of HAL for PDT II (MAL was used for the 
second treatment)
1 BCC from MAL group:
Patient refused from PDT II due to local reaction from PDT I
98 BCC (in 57 patients) met 
inclusion criteria
1 non-
responded
3 non-
responded
2 non-
responded
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Figure 2. Example lesion with images from all phases of the protocol. The example lesion was 
randomized to the HAL group: A) Clinical image of an sBCC; B) Dermatoscopic image at 
baseline; C) Marking the lesion, treatment area, and diagnostic biopsy site (copied on plastic 
sheets with scaling); D) Histology presenting an sBCC in the diagnostic biopsy; E) Post-treatment 
reaction after PDT I, assessed as strong; F) Clinical image at thee months’ follow-up; cosmetic 
outcome assessed as fair; G) Dermatoscopic image at three months; H) Biopsy site of the control 
biopsy at three months; and I) Histology of the responsive lesion with reactive changes at three 
months.
Figure 3. A) Results for pain during the illumination of the PDT for different photosensitizers. In 
the analyses we named the difference of the recorded VAS in the middle and at the beginning as 4 
min (4 min= VAS of the middle – VAS at the beginning), and the difference of recorded VAS in 
the end and at the beginning was named as 8 min (8 min= VAS of the end – VAS at the 
beginning); B) severity of post-treatment reactions (visually assessed on scale 
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none/minimal/mild/moderate/severe); and C) cosmetic outcomes (visually assessed on scale 
excellent/good/fair/poor).
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Tables
Table 1. Patient and lesion characteristics.
 MAL BF-200 ALA HAL
Patient Characteristics Patients 27 26 24with single lesion 14 8 5with multiple lesions 13 18 19Female 10 5 12Male 17 21 12Average age in years (range) 71 (47–91) 74 (51–91) 74 (57–91) Anamnestic skin phototype   Phototype I 6 4 7Phototype II 10 13 8Phototype III 11 9 9Phototype IV 0 0 0Immunosuppression or previous radiotherapy 2 1 2Previous history of skin cancer (AK, MB, MM, SCC, BCC) 19 20 19Previous history of BCC 13 19 16
Lesion characteristics   Lesions 31 33 31Location on trunk 25 26 25Location on extremities 6 7 6Average treatment area in mm2 (range) 439 (150–1100) 377 (130–850) 376 (160–750)New 30 30 29Recurrent 1 3 2
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